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Abstract 
Plasma contains small, non-protein coding RNA species, microRNAs (miRNAs). 
Circulating miRNAs originate from tissues throughout the body and circulate in the 
blood bound to proteins or encapsulated in extracellular vesicles (EVs). The pattern 
of circulating miRNAs changes in different pathological states, leading to the 
hypothesis that they could act as biomarkers or mediators of inter-organ signalling. 
Acute kidney injury (AKI) is associated with high morbidity worldwide. Recent work 
has highlighted a potential role for EV signalling in the delivery of functional 
exogenous miRNA into kidney cells, which may contribute to the pathogenesis of 
AKI. The studies described in this thesis investigate the effects of circulating 
miRNAs on renal proximal tubular (PT) cells.  
 
Utilising next generation sequencing technology, circulating miRNA profiles were 
demonstrated to change significantly following myocardial injury. These findings 
were translated from humans into a mouse model of myocardial injury. Investigation 
of EV cell signalling, using flow cytometry and nanoparticle tracking analysis, 
demonstrated that PT cell EV uptake was not affected by known physiological 
agonists. By contrast, EV release from PT cells was regulated by purinergic P2Y1 
and dopamine D1 receptors. Toxic cisplatin injury of PT cells resulted in increased 
EV release and reduced EV uptake in a dose-dependent manner. Cisplatin toxicity 
in PT cells was unaffected by EVs from mice with myocardial injury, but toxicity was 
reduced by EVs from mice with drug-induced liver injury (DILI). Circulating EVs from 
mice with DILI transferred the liver specific miRNA, miR-122, into PT cells in both in 
vivo and in vitro models. The consequence of miR-122 transfer was modulation of 
downstream target genes including Foxo3 which has been implicated in cell injury 
by apoptosis. 
 
These findings therefore show that circulatory miRNA profiles change in different 
models of organ injury and suggest miRNAs can be transferred to PT cells in vivo 
and in vitro. The improved viability of injured PT cells following co-incubation with 
DILI EVs, and subsequent transcriptomic work, suggests this may be as a 
consequence of miRNA transfer. In conclusion, circulatory miRNAs may act as 
mediators of inter-organ signalling and could play a crucial role in the propagation of 
systemic illness.   
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1.1. EXTRACELLULAR MIRNA 
MicroRNA (miRNA) are small (~22 nucleotides), non-coding RNA species 
expressed in all eukaryotic cell types[1]. Since their discovery in 2001[2], they have 
emerged as key regulators of post-transcriptional gene expression, by base-pairing 
with messenger RNA. Wielding this influence over protein translation, miRNAs are 
critical in a wide range of physiological and pathophysiological processes, and have 
been implicated in a wide range of diseases.  
 
MiRNA have been described in all biological fluids; including plasma, urine, 
cerebrospinal fluid, saliva, breast milk [3], yet the total miRNA concentration and 
relative concentration of specific miRNAs vary substantially across different fluid 
types. In the extracellular space, miRNAs are protected from RNase degradation by 
extracellular vesicles (EVs) [4] and RNA binding protein complexes [5]. While the 
precise mechanism of release of miRNA from cells into the extracellular 
environment is subject to speculation, it is clear that the extracellular miRNA 
signature exhibits a specific pattern in different pathological states [6-8]. This 
dynamic miRNA signature change has underpinned the two main threads of miRNA 
research; biomarker discovery and cell to cell signalling.  
1.1.1. MiRNA biogenesis 
In order to critically investigate extracellular miRNAs, researchers must consider 
miRNA biogenesis [9] (Figure 1.1). 
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Figure 1.1: Biogenesis of microRNA. Modified from [10] 
All miRNAs originate in the cell nucleus, initially as long primary 5′ capped and 3′ 
polyadenylated miRNA primary transcripts (pri-miRNA). This initial transcription is 
mainly regulated by RNA polymerase II, although RNA polymerase III may be 
responsible for the generation of specific transcripts[11, 12]. Pri-miRNA is then 
cleaved by a microprocessing complex, comprising of type III RNAse Drosha and 
RNA-binding protein DGCR8, to form a stem-loop structure referred to as precursor 
miRNA (pre-miRNA) [13]. This pre-miRNA is shuttled into the cytoplasm via an 
Exportin 5 complex [14], where is it further processed by the enzyme Dicer into a 
duplex miRNA/miRNA* (the duplex refers to a passenger strand and a mature 
strand, in which *denotes which is the passenger in published literature) [15]. When 
the duplex in unwound, the mature miRNA becomes incorporated into an RNA-
induced silencing complex (RISC), ultimately targeting messenger RNA 
(mRNA)[16].  
RISC represses protein expression either by mRNA degradation or translation 
repression, a process dictated by the degree of complimentary binding between the 
miRNA and the 3'untranslated region of the target mRNA [17]. Recently, miRNAs 
have been described to affect downstream signalling pathways, by directly binding 
with toll-like receptors (TLR) [18].   
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1.1.2. Cellular Release and Stability of Extracellular miRNAs 
Exogenous miRNAs are quickly degraded by the high level of ribonuclease activity 
in plasma [19]. Endogenous extracellular miRNA is, however, relatively stable within 
the plasma. This is hypothesised to be due to their incorporation in RNA-binding 
proteins (such as argonaute-2 (Ago)2 [5]) and lipoprotein complexes [20]); or 
association with EVs [21].  
1.1.3. MiRNAs Associated With Protein Complexes  
Utilising size discrimination, Arroyo et al. isolated a vesicle- and non-vesicle 
population of circulating miRNAs, concluding the latter population existed by forming 
a miRNA-protein complex. More than 90% of plasma miRNAs are reported to be 
bound to proteins [5, 22]. Interestingly, the population of protein bound miRNAs is 
not the same as that of the circulating EVs [5]; suggesting these two cohorts have 
different mechanisms of cellular release or cell source. This research has been 
further extended by in vitro observations in which the miRNA population in the EV 
and non-vesicle fractions was different from that of the cell line of origin, supporting 
the hypothesis that the populations had different export systems [23]. Mature 
miRNAs are protein bound within the cell cytoplasm [9], and the picture is emerging 
that the majority of circulating miRNAs is associated with Ago2 [5, 22], one of the 
major components of RISC complex. Nucleophosmin-1 is also associated with 
miRNA biogenesis, shuttling the pre-miRNA from the nucleus into the cytoplasm, 
but at present this miRNA-protein complex has not been described in the circulation. 
How protein bound miRNAs are transported from a cell into the extracellular 
environment has yet to be elucidated. It has been hypothesised that this may be a 
non-specific passive process as a result of cell lysis[24]. The proposed non-
selective process of protein bound miRNA release would be consistent with the 
close correlation in circulating miRNA and cell death reported in toxicity and cell 
injury studies[25-27]. 
1.1.4. Circulating miRNAs associated with HDL  
Studies which demonstrated the transfer of small interfering RNA (siRNA) via the 
reconstituted functional protein of HDL[28] opened up the field to miRNA association 
with lipoproteins. The seminal work in the field was published 2 years later, in which 
both high-density lipoprotein (HDL) and low-density lipoprotein (LDL) were found to 
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associate with miRNA in human plasma[20], and the HDL quotient was able to 
affect the transcriptome of hepatocytes in vitro. MiRNA-HDL complexes have since 
been demonstrated to affect the transcriptome and function of endothelial cells, 
suggesting they may have wider cell-cell signalling implications[29]. In additional to 
their proposed functional capability, miRNA-lipoprotein complexes have also been 
interrogated as a biomarker reservoir. MiRNAs associated with HDL, miR-486 and 
miR-92a, have been proposed as biomarkers for stable coronary artery disease[30] 
1.1.5. Plasma miRNAs in EVs  
EVs is an umbrella term for the array of vesicles found in the extracellular space. 
Proteins, pre-miRNA, mature miRNA, retrotransposon RNA transcripts, single-
stranded DNA (ssDNA), double-stranded DNA (dsDNA) and mitochondrial DNA 
have all been in identified within EVs (Figure 1.2)[31-34]. Rigorous characterisation 
of EVs has identified protein and RNA content specific to their cell of origin, 
identifying both molecules unique to the originator cell and identifying products of 
genes associated with multiple disease processes [35, 36]. First described as a cell 
signalling pathway in 2011[21], accumulating evidence suggests that EVs can 
function as inter-cellular transmitters to convey their contents, in particular miRNA, 
from one cell to another. The composition, biogenesis, targeting and physiological 
role of EVs will be discussed extensively from Section 1.4.  
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Figure 1.2: EV biogenesis and interaction with recipient cells. Published in 
[37].  
EVs broadly consist of exosomes and microvesicles. Exosomes are generally 
considered a homogenous population of vesicles, derived from the endosomal 
pathway. This process commences with the invagination of the plasma membrane 
and terminates when the mature MVB fuses with the limiting aspect of the plasma 
membrane. The contents of the MVB are liberated into the extracellular 
environment, releasing exosomes. Microvesicles are formed by the budding of the 
plasma membrane, releasing a heterogeneous population of larger vesicles. Due to 
their biogenesis, EVs (yellow) act as vectors for mRNA, miRNA, protein, dsDNA, 
mitoDNA and antigens. This parcel of biological information can be interrogated as a 
biomarker reservoir or propagate a signal to a recipient cell. EV interaction with a 
recipient cell has been described through a number of modalities, ultimately 
influencing a recipient cell’s proteome and function. The contents can be delivered 
directly to the cytosol by fusion with the recipient cell membrane or through 
phagocytosis, macropinocytosis or clathrin-mediated endocytosis. Alternatively, the 
vesicles can signal by directly activating cell surface receptors via ligands or present 
antigen and MHC. 
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1.2. CIRCULATING MIRNAS AS BIOMARKERS  
As discussed, miRNAs can form intriguing expression profiles within the plasma, 
providing detailed feedback on the fine function of the tissue of interest. 
Unsurprisingly, circulating miRNAs have therefore emerged as potential biomarkers 
for diagnosis of illness and disease prognostication [7, 38]. The plasma biomarker 
reservoir has been interrogated in a broad array of fields including, but not exclusive 
to: cardiology[39], oncology[40], hepatology[41] and nephrology[42]. For the 
purposes of this thesis, an overview of miRNA biomarkers in myocardial infarction 
and drug-induced liver injury (DILI) will be considered.  
1.2.1. Circulatory miRNAs as biomarkers of myocardial infarction  
Myocardial infarction is a leading cause of morbidity and mortality in the developed 
world[43]. Timely intervention is critical to its clinical management[44] and 
consequently it is a rich area for biomarker research. To date, the gold standard 
biomarker is high-sensitivity troponin I (hsTnI), a highly sensitive but poorly specific 
marker for myocardial infarction [45]. HsTnI is used in clinical care to diagnose 
myocardial ischaemia, an umbrella term encompassing myocardial infarction 
(related to coronary artery disease) and myocardial injury. Patient outcome has 
improved in myocardial infarction following the introduction of lower diagnostic TnI 
thresholds [46], yet the number of patients with myocardial injury undergoing 
additional investigation has doubled with no change in patient outcome 
[47].Consequently, novel biomarker research within the field of myocardial 
ischaemia focuses upon improving the specificity of cardiac biomarkers for 
myocardial infarction; improving time to definitive intervention in myocardial 
infarction, and avoiding unnecessary additional tests for those with myocardial 
ischaemia.  
 
The investigation of miRNAs as cardiac biomarkers has been extensively reviewed 
in the literature [39, 48], and specific patterns of miRNA have been described in 
both the trans-coronary and peripheral circulations correlating to the degree of 
myocardial injury[7]. Specifically, several miRNAs have been described as 
promising early biomarkers of myocardial ischaemia. Concentrations of miR-1[49, 
50], miR-499[49, 51] miR-208a/b[52, 53] and miR-133a[54, 55] have been 
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consistently demonstrated to increase in the circulation post-myocardial insult and 
translate across species. Significantly, circulatory miRNA-499 has been positively 
correlated to cardiac infarct size[7, 56-58].  
 
Despite these observations, head-to-head comparisons with hsTnI, have reported 
that measurement of these miRNAs did not improve diagnostic accuracy [59]. 
Furthermore, with the exception of miR-208a, all other identified cardiac miRNAs 
are enriched in skeletal muscle[60]; limiting specificity for the diagnosis of 
myocardial injury. Investigation of biomarker panels, incorporating known protein 
and miRNA biomarkers, has been investigated for improved positive predictive 
power for myocardial infarction in comparison to hsTnI alone. The combination of 
miR-1, miR-499 and miR-21 may improve the diagnostic accuracy of troponin for 
myocardial ischaemia when used in combination[25]. However, other studies 
investigating miRNA/TnI biomarker panels have failed to describe added diagnostic 
value [61]. 
 
1.2.2. Circulatory miRNAs as biomarkers of DILI 
DILI is defined as the development of abnormal liver tests or liver dysfunction 
following the use of drugs, both prescription and over-the-counter, with the 
reasonable exclusion of other aetiologies[62]. DILI is implicated in negative 
outcomes across the spectrum of translational medicine: limiting early-phase drug 
development [63] and contributing to morbidity and mortality in clinical practice [64]. 
It is, therefore, important that DILI-biomarkers can translate across species, 
sensitively diagnose early liver injury and predict development of severe or life-
threatening DILI. Conventional liver-injury biomarkers, such as alanine 
transaminase(ALT), relate to reduced hepatocyte integrity and lacks both sensitivity 
and specificity for liver injury when measured early in the onset of illness[65]. 
 
Within the field of DILI, management of paracetamol poisoning is of paramount 
importance. Paracetamol is a safe analgesic, when taken at the recommended 
dose. Taken in overdose, paracetamol is hepatotoxic and is the most common 
cause of DILI in the UK and the US. The decision to commence treatment is based 
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on a binary ‘stop-go’ approach based on ALT and the paracetamol serum 
concentration normogram, plotted 4 hours following overdose[66]. The clinical 
decision is further complicated in staggered overdose, when the normogram can no 
longer be applied. A stratified approach to identify patients who will develop severe 
DILI is therefore ideal and a growing body of evidence suggests novel biomarkers, 
including miRNAs could be of clinical utility[67]. 
 
MiR-122, miR-192, miR-194, miR-483 and miR-210 have been identified as liver-
enriched miRNAs with potential as biomarkers in paracetamol DILI [6]. 
MiR-122 and miR-192, have been demonstrated to have high sensitivity for DILI and 
exhibit dose- and temporal-dependent changes[26], outperforming ALT in a murine 
model of paracetamol poisoning. These findings have been subsequently 
reproduced in humans[68]. MiR-122 accounts for 72% of an hepatocytes total 
miRNA [69], a finding translated across several species[70-72]. It plays an important 
role in modulation of several critical pathways including fatty acid metabolism, stress 
response and gluconeogenesis [73]. MiR-122 increases 100-fold in the circulation of 
patients with paracetamol-induced DILI and exhibits a greater sensitivity and 
specificity than the current biomarker ALT [74]. Recently, miR-122, in addition to 
other novel biomarkers, has been shown to be effective in identifying patients 
progressing to severe liver injury, despite current best clinical care[75]. 
1.3. A POSSIBLE ROLE FOR MIRNAS IN CELL COMMUNICATION  
The mounting evidence of a dynamic population of transcription regulators in the 
circulation has given rise to the concept they may mediate paracrine signalling or 
even distal signalling via the blood steam. Protein bound miRNA, presumably 
released as a process of cell lysis[9], remains stable in the circulation for prolonged 
periods, providing a rich source of biomarker information regarding their cell of 
origin. However, there is no evidence in the literature of their selective release or 
subsequent uptake by recipient cells; suggesting they have no role in cell-cell 
communication. Conversely, since the first description by Valadi et al. in 2007[21], 
EVs have been repeatedly demonstrated to transfer miRNA to recipient cells to alter 
the cell’s transcriptome, and ultimately modulate cellular function [76-78]. 
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Consequently, the rest of this introduction shall be dedicated to discussion of the 
biogenesis and functional capability of EVs. 
1.4. COMPOSITION AND BIOGENESIS OF EVS 
EVs encompass a vast heterogeneous and dynamic population of membrane bound 
vesicles; their content and membrane composition is dictated by their cellular source 
and is sensitive to both cellular stress and environmental changes. Historically, 
naming of EVs was dependent upon their cell of origin e.g. cardiosomes 
(cardiomyocyte origin), prosatosomes (seminal fluid). Current nomenclature, 
however, largely distinguishes vesicles by their biogenesis. Criteria for EV 
classification have been proposed based on their origin, function or biogenesis; yet 
there is still no consensus about their nomenclature. Subpopulation categories 
range from 3-6 in number in most reviews and have been extensively discussed 
elsewhere [79, 80]. These categories are often difficult to use in practice, which 
results in confusing overlapping nomenclature. For the purposes of this review, we 
will consider three distinct subtypes with characteristics related to their origin, size 
and identifying markers. 
1.4.1. Exosomes 
Exosomes are derived from the endosomal pathway. Transmembrane proteins are 
trafficked to early endosomes by endocytosis. These early endosomes undergo 
sorting to late endosomes, which in turn become multivesicular bodies (MVBs). 
Formation of MVBs is directed by the recruitment of proteins and budding of 
intraluminal vesicles (ILVs), via the endosomal sorting complex required for 
transport (ESCRT). ILVs are released as exosomes upon fusion of MVBs with the 
plasma membrane (Figure 1.3). Alternatively, MVBs can fuse with lysosomes, 
resulting in degradation of their contents.  
 
Intriguingly, the relative abundance of cellular RNA and protein does not closely 
correlate with that of the exosome, suggesting a selective process of entry into 
vesicles [21]. This cargo sorting may allow the cell to generate exosomes of 
precisely defined biochemical composition. ESCRT, tetraspanins and lipid-
dependent mechanisms have all been implicated in the selective loading of 
proteins[81]. A specific pattern of protein post-translational modifications (PTMs) 
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has been noted in exosomes and a potential role in exosome sorting has been 
suggested [82]. The most commonly described PTM, ubiquitination, involves the 
addition of ubiquitin to a target protein (Figure 1.3). In MVBs, a ubiquitinated protein 
is sorted into ILVs by the ESCRT and the downstream fate of the MVB is dependent 
upon the type of ubiquitin modification on a specific substrate. Ubiquitin may be 
cleaved from its cargo protein during incorporation to the ILV but a recent in vivo 
study reported that 15% of proteins in EVs are ubiquitinated, suggesting a 
significant proportion are sequestered into ILVs without deubiquitination [83, 84]. 
Others PTMs that have been described include phosphorylation and 
glycosylation[82].  
 
The sorting of RNA into exosomes is less well understood; specific small ubiquitin-
related modifier (SUMO) proteins are hypothesized to interact with cis-acting 
elements within RNA, such as hnRNPA2B1, to selectively load vesicles [85]. MiRNA 
sorting to exosomes may be modulated by the dynamic transcriptomic changes 
seen in cell activation, differentially engaging miRNAs at P bodies or MVBs [86].  
 
As a result of the above processes, exosomes represent a parcel of protein, DNA 
and various RNA species [78, 87]. The majority of RNA species isolated from 
exosomes are small RNAs including microRNAs (miRNAs) [88]. Exosomes are 
identified by their lipid bilayer membrane, 20–120 nm size and density of 1.15–1.19 
g/ml in continuous sucrose gradient [89]. Their often cited cup-shaped morphology 
is likely artificial, attributed to collapse during drying [90]. An exosome’s lipid bilayer 
outwardly displays the apical surface of the membrane from which the vesicle was 
formed, therefore displaying the same extracellular surface markers as the cell of 
origin (Figure 1.3)[79]. This membrane orientation has lead to the postulation of 
inward budding, from the limiting membrane of endosomes, as the mechanism of 
exosome biogenesis. Exosomal protein markers mainly relate to intra-cellular 
vesicle trafficking and exosome biogenesis i.e. ESCRT components, tetraspanins 
and flotillin. Although there are signature protein profiles for exosomes from defined 
tissue, there is no single unifying marker. Specific to the urinary exosome 
population, CD24 has been postulated as a suitable biomarker [91, 92].  
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Figure 1.3: EV biogenesis and role of ubiquitination. Modified from [93] 
Exosome biogenesis is depicted on the right. Transmembrane proteins are 
internalized from the cell surface via endocytosis and their cytosolic domains 
ubiquinated. ESCRT 0 recognises the ubiquitinated protein and segregates these 
proteins into microdomains. ESCRT I and II are subsequently recruited, by ESCRT 
I, and initiate the reverse budding of intraluminal vesicles (ILVs). At this stage, a 
same amount of cytosol, and therefore cytosolic proteins and RNA, have access to 
the interior of the ILV. The ILV is cleaved from the bud, following recruitment of 
ESCRT III, by ESCRT II and ALIX. The mature multivesicular body (MVB) formed 
can either follow a degradation pathway, or proceed to fusion with the plasma 
membrane. The pathway for each MVB is likely determined by its contents. For 
example, ubiquitinated LMP2A has been shown to follow the secretory pathway, 
while MVBs containing ubiquitinated EGFR are degraded. The degradation pathway 
consists of fusion of the mature MVB with a lysosome. In the secretory pathway 
MVBs fuse with the plasma membrane mediated by a Rab27A-dependent pathway, 
releasing the ILVs, now termed exosomes, into the extracellular environment. 
Please note, not all proteins require ubiquitination to be targeted to ILVs. Other post-
translation modifications can result in recruitment to ILVs and have been reviewed in 
[82].  
 
Microvesicle assembly is illustrated on the left. Transmembrane proteins cluster in 
membrane lipid microdomains during nucleation at the plasma membrane. 
Myristoylated protein contributes to membrane curvature, lipid distribution is 
randomized by calcium dependent scramblases and, concurrently, the cytoskeleton 
loosens. A member of the ESCRT-I complex, TSG101, recruits ESCRT III to the 
plasma membrane, which promotes the assembly of a spiral, ultimately 
disassembled by ATPase VPS4. This process results in cleavage of the bud and 
release of a heterogeneous population of microvesicles.   
University of Edinburgh  EE Morrison 
 
  14 
 
1.4.2. Microvesicles 
Microvesicles are shed directly from the plasma membrane via detachment of small 
cytoplasmic protrusions[94] in response to cell stress. This process is dependent on 
calcium influx, calpain, and cytoskeleton reorganization (Figure 1.3)[95]. As a result 
of this outward budding, microvesicles contain a small volume of cytoplasm and are 
enriched with membrane markers from their cell of origin including proteins 
associated with membrane lipid rafts [96]. Microvesicles are characteristically 50 - 
1000nm in size and specific markers proposed for their identification are ADP-
ribosylation factor 6 (ARF6; implicated in endocytosis of protein) and vesicle-
associated membrane protein 3 (VAMP3)[97].  
 
Consideration can also be given to demonstrating the absence of non-EV protein 
markers when screening exosome and microvesicle populations. For example 
transferrin receptors are enriched in the exosomes but are absent in the 
microvesicle population from the same tissue [98].  
1.4.3. Apoptotic bodies 
Apoptotic bodies are blebs containing cytoplasm and densely packed organelles. 
They are extensively liberated from the plasma membrane in the later stages of 
apoptosis. Although apoptotic bodies are generally considered to be larger in size 
than other vesicles (500-4000nm), a smaller subpopulation has been proposed, 50-
500nm [79, 99]. The translocation of phosphatidylserine onto the outer cell 
membrane during apoptosis has been previously described and it is unsurprising 
that apoptotic bodies are enriched for this phospholipid. Binding of annexin V to 
phosphatidylserines therefore can be used as a protein marker for apoptotic bodies. 
Phosphatidylserines are also exposed by microvesicles and, to a lesser extent, 
exosomes. Increased binding sites for thrombospondin and C3b allow these 
proteins to be used as markers [100]. Given the circumscribed pathophysiological 
role of apoptotic bodies and their efficient local clearance by phagocytosis in vivo, 
apoptotic bodies will not be discussed in further detail. 
 
Pisitkun et al. first described the presence of urinary EVs, identifying these as 
exosomes due to their small size and biogenesis, and describing the proteome of 
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these vesicles [35]. Since this seminal work was published, the presence of different 
vesicle subtypes has also been described [101]. Over recent years, a wealth of 
studies have gone on to describe both the proteome and transcriptome of the 
urinary EV population [36, 102], culminating in the development of public access 
online databases (http://www.exocarta.org, 
https://hpcwebapps.cit.nih.gov/ESBL/Database/Exosome/). 
 
Isolation of a pure vesicle sub-population is notoriously difficult, in part because of 
the size overlap between the vesicle sub-populations, and other vesicles are often 
co-purified along with the specific type of interest. Due to inconsistency in EV 
isolation protocols and often-incomplete vesicle characterization, there is an 
inherent difficultly in differentiating between the subpopulations in published work. 
For clarity, in this thesis, vesicle like structures that are not rigorously defined will be 
referred to as EVs unless clearly stated.  
1.5. EV CONCENTRATION AND QUANTIFICATION 
 
Technical standardisation of sample processing is an area of controversy in EV 
research, although the influence of varying practice on downstream outputs remains 
unclear. Variability exists in storage, handling and characterisation of EVs between 
published works; fortunately, guidance is now available through position papers of 
best practice and consensus statements on EV isolation and minimal 
experimentation requirements for EV definition [103, 104]. 
1.5.1. Storage and handling of EVs 
Fresh serum or urine samples are preferable for isolation of EVs, although for 
practicality frozen samples may need to be used with like-for-like being compared 
(i.e. fresh-to-fresh, frozen-to-frozen). EVs are relatively insensitive to freeze/thaw 
cycles and may even resist bursting in a hypotonic environment [104]. Storage of 
samples at -80°C is appropriate and EVs have been concentrated from samples 
after 7 months in storage [92, 105]. Use of protease inhibitors to preserve samples 
has been described, but opinion remains inconsistent regarding their use [92, 105]. 
Calcium oxalate and amorphous calcium crystal precipitates can be present after 
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thawing, macroscopically forming a cloudy sample. Vigorous vortexing can re-
dissolve these salts [106].  
1.5.1.1. Ultracentrifugation  
Differential ultracentrifugation, with or without a size exclusion technique, remains 
the most accepted method of exosome isolation from biological fluids [107, 108]. 
Following cell depletion of a biological fluid by slow speed centrifugation, 10,000 to 
20,000 x g is used to pellet larger EVs. Subsequently, smaller EVs, including 
exosomes, are pelleted from this supernatant using an ultracentrifuge (100,000 to 
200,000 x g). The limitations of this technique are that ultracentrifugation introduces 
variability, has a low through put, and is heavily operator and rotor dependent [109]. 
Importantly, not all exosomes are recovered following ultracentrifugation; 40% 
remain in the supernatant although it is unknown if this subpopulation contains 
unique features of biological/clinical relevance [110]. Size exclusion chromatography 
can be used in conjunction with ultracentrifugation to remove protein contaminants 
and is considered the gold standard for isolation of a highly purified population of 
morphologically intact exosomes [101, 111].  
 
Alternatively, filtration through a nano-membrane, using slow centrifugation or 
gravity, can further aid size exclusion and theoretically improve purity of the vesicle 
subpopulation. Limitations of this technique include a lower EV recovery, vesicle 
fragmentation and contamination with proteins, with further protein retention on the 
membrane[104, 112]. Addition of a sucrose gradient can further improve purity and 
isolate subpopulations, but this process is lengthy and associated with a very low 
EV yield (<1% of the initial crude pellet)[113]. Interestingly, sucrose gradient 
ultracentrifugation has been used to elucidate 2 different subtypes of exosome 
population within melanoma cell supernatant. The populations were distinct in their 
proteome, transcriptome and effect on recipient cell gene expression; raising the 
possibility of heterogeneous exosome population capable of exerting different 
effects on downstream cell physiology[114].  
1.5.1.2. Other concentration techniques 
A number of commercial platforms support rapid EV precipitation. These proprietary 
polymers pellet EVs, with the aid of a slow centrifugation step, and have been used 
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for a wide variety of downstream applications. This approach is attractive due to the 
rapid aggregation, low user variability and relative simplicity [115, 116]. However, 
caution must be exercised as these techniques also concentrate larger vesicles and 
protein aggregates, forming an impure pellet [117]. Immunoaffinity precipitation has 
been used in a number of studies to concentrate purified subpopulations of EVs, 
utilising magnetic beads coated with antibody against proteins of interest [118, 119]. 
Similar peptide-based isolation techniques have also been described [120]. 
Although these techniques have the capability to achieve an adaptable, rapid 
platform for EV isolation, they do, inherently, introduce population bias due to 
targeting only vesicles that express a certain protein marker [121].  
 
Novel microfluidic devices utilise a variety of techniques; namely, immunoaffinity, 
sieving (through nanoporous membranes) and trapping of vesicle structures, to 
identify a highly purified EV population [122-124]. Although in its infancy, this 
technique could be used in point-of-care rapid exosome isolation [124]. There 
remain a number of hurdles to employment of this technique, mainly low recovery of 
exosomes, sheer stress to structures, and requirement for prior sample preparation.  
 
1.5.2. Normalisation 
Total EV number can be ascertained by nanotracking analysis (NTA) without or with 
fluorophores to known protein targets, with the additional benefit of using 
unprocessed urine samples [92]. This methodology could be used to sample 2 
populations (the subpopulations of interest and a control) or even dichromatous 
populations [125]. Alternatively, manipulation of pore size of a stretchable nanopore 
membrane, utilised in resistive pulse sensing, can allow for measurement size 
distribution and concentration but this approach is limited by the inability to provide 
phenotypic information[124]. The primary issue with NTA and nanopore 
technologies include lengthy processing and inter-assay variability. Until recently 
conventional flow cytometry could only phenotype EVs down to ∼500nm in size, 
restricting its use to the study of larger vesicle populations. The advent of newer 
instruments has raised the exciting possibility of discriminating between particles as 
small as 100 nm in diameter [104]. The impact of different refractive indices 
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between biological, silica and polystyrene microparticles, and the resultant 
possibility of confounding results, remains debatable [104, 126]. This issue is further 
complicated in the study of urinary EVs, as calcium-phosphate microprecipitates 
have been shown to overlap the EV population on the flow cytometry signal[127]. 
 
Given the limitations of describing a total EV population, alternative normalisation 
methods across samples are needed to allow valid analysis of proteomic and 
transcriptomic changes. This has previously been described ‘the holy grail’ of EV 
study, with a number of well described limitations [128]. Theoretically, protein-
normalization (normalizing to a target housekeeping protein) can also be used. 
Example proteins include: CD9, CD63, CD81, TSG-101, and ALIX[117, 129]. This 
approach assumes the normalising protein expression does not change in different 
disease states and there is no biological/clinical relevance to a change in the 
number of vesicles within the sample.  
1.6. EVS AND THE KIDNEY 
The kidney is the one of the most important regulators of the body’s physiological 
state, manipulating filtration and reabsorption of solutes in order to maintain an 
optimal environment for health. The kidney is vulnerable to a plethora of injury 
modalities. High oxygen demand and low tissue oxygen tensions in the renal 
parenchyma sensitise tubular cells to hypoxia and can lead to acute and chronic 
kidney injury, disease processes which are associated with substantial morbidity 
and mortality. Furthermore, tubular cells are vulnerable to the toxic effects of drugs. 
Increasing intra-tubular drug concentrations as the filtrate moves along the nephron 
combined with reuptake mechanisms for solutes result in potentially toxic 
intracellular drug concentrations. As a result of the high morbidity associated with 
renal disease, and the limiting role of nephrotoxicity in translation of drug 
development to clinical practice, improving our understanding of the underlying 
molecular signalling would be of value to prevent toxicity and treat kidney injury 
[130].  
 
Urine, the excreted filtrate of the kidney, is unique in providing a non-invasive 
snapshot of the kidney’s function. This filtrate is composed of ions, inorganic and 
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organic compounds (including proteins, hormones and metabolites) suspended in 
water. Investigation of the protein fraction of urine has demonstrated the presence 
of integral membrane proteins within small EVs [131]. Rigorous characterisation of 
the urinary EV’s protein and RNA content has been conducted, identifying 
molecules unique to all regions of the nephron and identifying products of genes 
associated with multiple disease processes [35, 36]. Several subtypes of vesicles 
have been identified in urine, including exosomes and microvesicles, the 
characteristics of which are described below [35, 101].  
 
Inter-cellular communication depends upon an EV’s ability to influence a recipient 
cell, either by receptor-mediated interaction, endocytosis of the EV or fusion of the 
vesicle membrane to the plasma membrane. This latter signalling mechanism 
results in delivery of an EV’s contents directly into the cytoplasm; including 
transcription factors, miRNA, mature RNA and infective particles [21, 95, 132, 133]  
1.6.1. Physiology 
Along the nephron, EV-mediated intercellular signalling has been postulated to 
explain why proximal tubule proteins are present in downstream nephron segments 
[134-136], but this has not yet been conclusively demonstrated in vivo [135]. EVs 
are released into urine from all regions of the nephron and can be readily identified 
by transcriptomic and proteomic markers specific to the cell of origin [35, 117]. 
Hypothetically, via EV release and downstream reuptake, EV contents could affect 
the function of a downstream recipient cell [137]. Notably, the exosomal fraction of 
aquaporin-2 (AQP2) increases in response to desmopressin and transfer of EVs 
from desmopressin-treated cells to untreated cells results in an increase of 
functional AQP2 expression in the recipient cell [129, 138]. Cortical collecting duct 
cells stimulated with vasopressin take up ECVs, in vitro and in vivo. This process 
can be manipulated to deliver miRNA to collecting duct cells resulting in 
downregulation of target transcripts [139]. This study demonstrated that EV 
signalling is a physiologically regulated process, which can be manipulated to 
deliver miRNA. Interaction of EVs with recipient cells may involve specific interaction 
with primary cilia, as reported with polycystic disease-positive vesicles using 
transmission electron microscopy images [140, 141]. This observation is supported 
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by data from a biliary model that demonstrate exosome signalling affects ERK 
signalling, miRNA expression and cell proliferation, with abolishment of this signal 
following removal of cilia [142]. This work, in conjunction with the observation of 
multiple protein products of genes known to be responsible for renal and systemic 
diseases in normal urine, raises interesting questions about the role of EV signalling 
in health and disease [35]. 
 
1.6.2. Pathophysiology 
EV signalling has been implicated in the pathogenesis of acute kidney injury (AKI): 
exosomes from injured tubular cells transfer TGF-b1 mRNA into fibroblasts, 
resulting in cell activation [143]. In vitro, vesicles appear to be important in mediating 
vascular smooth muscle cell calcification, a potential mechanism for accelerated 
vascular calcification in end stage renal disease[144]. Interestingly, the paracrine 
effect of liver stem cells has been shown to aid regeneration of renal tubular injury 
via release of EVs, highlighting the possible beneficial role of exosome signalling in 
systemic illness[145]. 
 
Mesenchymal stem cells (MSC) accelerate recovery and repair tissue following AKI; 
an effect demonstrated using diverse injury modalities [146-150]. Whether this 
reflects direct cell engraftment and differentiation, or is mediated through release of 
paracrine factors is unclear. Interestingly, MSC supernatant conferred the same 
effect as the cells themselves, giving rise to the hypothesis of EV signalling [151]. 
Several groups have since confirmed EV signalling in this circumstance, likely 
exerting their effect through RNA interference [152-156]. Recent work suggests EV 
miRNA has a significant role in this MSC effect on kidney cell injury [157]. Notably, 
miRNAs associated with EV endothelial progenitor cells reduced apoptosis and 
promoted cell regeneration in ischemia reperfusion injury [153, 158, 159]. This 
possible role of EV signalling in the delivery of functional miRNA and pathogenesis 
of AKI highlights their potential as a therapeutic intervention. Abnormal levels of 
miRNA could be one of the mechanisms explaining dysregulated protein expression 
during kidney disease progression and interference with this process represents a 
potential therapeutic target [160].  
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In addition, EVs may also act as antibacterial immune effectors within the urine, 
mediating the host response to urinary tract infection by inhibiting growth of 
pathogenic and commensal Escherichia coli and inducing bacterial lysis [161]. This 
highlights the multimodality capacity of EVs in therapeutics, specifically their 
potential as novel antibiotics for urinary tract infections, a common illness affecting 
150 million patients annually[162]. Furthermore, renal brush border-derived 
exosomes can induce calcium oxalate crystallization in nephrolithiasis and may 
have a role in renal stone disease although this mechanism is yet to be 
demonstrated in vivo [163]. 
1.6.3. Vectors for drug delivery 
The contribution of EV signalling in health and disease highlights their potential as 
attractive therapeutic targets and there are a number of on-going phase I and II 
clinical trials harnessing EV-based therapeutics. Although we remain in the early 
phase of such studies, theoretical clinical utility could be mediated by interfering with 
EV biogenesis or the manipulation of EVs as therapeutics vectors. 
 
EVs are candidate drug delivery systems; they are stable vehicles with a wide 
biodistribution. At least in theory they can be selectively loaded and can deliver 
functional RNA into cells. The integrity of RNA isolated from vesicles is similar to 
that of tissue and far higher than RNA in whole urine, as the membrane protects the 
RNA cargo from RNase degradation [36, 88]. Interestingly, EVs have natural 
targeting capacity, presumably by receptor-ligand binding [164-166]. In oncology, 
intergrins displayed on the EV surface may direct tissue specific uptake [167], 
manipulation of which may reduce EV uptake and impede metastatic spread of 
cancer. This ability to predict the metastatic course of cancer raises the exciting 
possibility of prediction and redirection of tumour progression. A similar mechanism 
could also be responsible for EV signalling along the kidney and the in vitro transfer 
proximal tubular specific proteins in distal tubule cells[168]. EV signal manipulation 
in vivo, to target exogenous vesicles to the tissue of interest through delivery of 
miRNA and siRNA, has already been demonstrated, ultimately affecting 
downstream gene expression [169, 170]. Furthermore, bioengineered nanoparticles 
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can serve as exosome mimics, recreating these functions and delivering targeted 
chemotherapeutics [171]. 
1.6.4. Inhibiting EV biogenesis and uptake 
The circulating concentration of exosomes has been correlated to cancer 
progression and overall survival, which suggests that reducing exosome numbers 
may be a potential therapeutic approach. Proof-of-concept using amiloride (an 
antihypertensive agent) to attenuate endocytic vesicle recycling increased the effect 
of chemotherapy agents in a murine model, speculatively as a result of reduced EV 
numbers in the circulation [172]. Although precise regulation of exosome release 
remains unclear, a number of possible therapeutic targets have been identified. 
Rab27b interference inhibits exosome release and can reduce tumour progression 
[173-175]. Other therapeutic targets of interest include P53 and GTPases, 
implicated in the cytoskeleton dependent mechanism underpinning exosome 
exocytosis [164, 176, 177]. Inhibition of EV uptake into cells is also possible by 
blocking surface phosphatidylserine, however due to lack of specificity this 
mechanism it is unlikely to translate into a therapeutic intervention. Regardless of 
the therapeutic strategy employed, there are a large number of limitations to 
targeting exosome biogenesis and uptake; in particular, currently elucidated 
mechanisms are not tissue-specific and affect a number of complex, core functions 
in diseased and healthy tissue. For a future drug, this may manifest in a large 
number of off-target effects, greatly affecting this approach as a therapeutic 
strategy. 
1.7. URINARY EVS AND BIOMARKER DISCOVERY 
In both acute and chronic kidney disease current biomarkers, such as creatinine, 
focus on the recognition of established disease rather than early detection of 
imminent renal dysfunction. These investigations provide little information about the 
underlying pathophysiology and renal biopsy is considered the gold-standard 
investigation. Renal biopsy is an invasive technique with a number of adverse 
events such as infection and haemorrhage. Also biopsy cannot be performed 
serially (daily) and is prone to sampling error. There is hope that harnessing the 
proteomic and transcriptomic changes of urinary EVs in varying disease states will 
present a non-invasive alternative to biopsy. As discussed, urinary EVs are released 
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into urine from all regions of the nephron and are readily identified by proteins 
specific to the cell of origin, potentially providing a non-invasive snapshot of the 
physiological state of nephron [35, 117]. Urinary EVs represent a remarkably stable, 
easily accessible, biomarker reservoir, which protects its cargo from the harsh extra 
vesicular environment. EVs are promising biomarker candidates, with potential to 
predict disease, define mechanisms and prognosticate. Intriguingly, EV biomarkers 
for systemic disease have been identified in the urine, adding further evidence to the 
debate surrounding passage of EVs across the glomerulus (Table 1.1). 
 
Three fundamental biomarker development stages have been described; biomarker 
discovery, validation of the markers predictive value within the population and 
implementation of a clinically approved assay [178, 179]. In relation to urinary EVs, 
biomarker discovery in well-defined populations has identified a number of targets. 
Table 1.1 summarises the candidate EV biomarkers to date, distinguishing 
biomarkers of interest by disease process. In models of kidney injury, the proteins in 
the exosomal fraction have been reported to change prior to elevation in the ‘free’ 
fraction in urine and, importantly, prior to traditional biochemical and histological 
diagnostic tests [180, 181]. Lower EV recovery rates in patients with heavy 
proteinuria and the outlined difficulties in normalisation have led investigators to 
pursue qualitative targets i.e. the presence or absence of the target defines disease 
or health. Ultimately, quantitative measurements would be desirable, allowing the 
ability to track deterioration or improvement in the clinical condition. The validation 
phase of study, and the challenges to further progress, perhaps best reflect the 
current situation. Large population studies are required, outwith the population of 
interest, to identify both the positive and negative predictive value of the EV-based 
biomarker. Several studies have investigated the selectivity of EVs but few have 
interrogated the specificity. The practicality and cost of the necessary large-scale 
clinical studies limits further progress, as sample processing and quantification are 
not currently translatable to hundreds or thousands of samples. 
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Disorder 
Potential urinary EV biomarker 
Protein miRNA/mRNA 
Acute Kidney injury     
   AKI Fetuin -A*, Activating transcription factor-3*, 
Na+/H+ exchanger type 3* 
 CD2AP*† 
   Ischaemic  
   reperfusion injury 
 
Aquaporin-1*, Activating transcription 
factor-3* 
  
Glomerular injury     
   Diabetic 
   nephropathy 
Dipeptidydl peptidase IV†, Podocalyxin*, 
Wilm's tumour-1*, Histone-lysine N-
methyltransferase* Voltage-dependent 





   Focal segmental  
   glomerular  
   sclerosis 
Wilm's tumour 1†‡, Podocalyxin*   
   Autoimmune     
   glomerulonephritis  
  miR-26a† 
   Lupus nephritis  A disintegrin and metalloprotease 10* miR-29c*†, miR-26a*, 
miR-146a* 
   Glomerular disease     
   (mixed population) 
A disintegrin and metalloprotease 10*   
   IgA nephropathy α1 antitrypsin*, Aminopeptidase N*, Vasorin 
precursor*, Ceruloplasmin*,  
 
   Glomerular fibrosis  CD2AP*† 
Other disorders     
   Polycystic Kidney  
   Disease 
Polycyctin-1*†, Polycyctin-2*†, Polyductin*, 
Transmembrane protein 2*† 
  
   Primary aldosteronism Phosphorlyated NCC*, Prostasin*   
   Obstructive  
   Nephropathy 
Transforming growth factor β*   
   Bartter syndrome Na+, K+, Cl- cotransporter type 2*   
   Gitelman syndrome Phosphorlyated NCC*   
   Renal fibrosis   miR-29c*, miR-200* 
   Chronic Kidney Disease Neutrophil gelatinase-associated lipocalin* 
 
   Transplant Neutrophil gelatinase-associated lipocalin†,   mRNA Il-18† 
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Cancer     
   Prostate cancer  Integrin β1*, Integrin α3*, Prostate specific 
antigen*‡, Prostate specific membrane 
antigen* 
 miR-34a‡ 
   Bladder cancer EGF-Like Repeats And Discoidin I-Like  
 
Domains 3*, Tumor-associated calcium-
signal transducer 2*, Mucin 4, Epidermal 
Growth Factor Receptor Pathway Substrate 
8-Related Protein 2* 
 LASS2*, GALNT1* 
   Renal Cell carcinoma Matrix metalloproteinase 9*, 
Ceruloplasmin*,  
Podocalyxin*, Dickkopf related protein 4*, 
Carbonic Anhydrase IX*, Aquaporin-1*, 
Extracellular Matrix Metalloproteinase 
Inducer*, Neprilysin*, Dipeptidase 1*, 
Syntenin-1* 
  
Systemic illness     
   Acute myocardial     
   infarction  
  miR-1*, miR-208*  
   Parkinsons Disease Protein deglycase DJ-1†   
   Ovarian serous  
   adenocarcinoma  
  miR-30a-59*  
   Lupus erythematosus    miR-146a*  
   Autoimmune  
   encephalomyelitis  
  miR-155-5p*‡ 
   Type 2 diabetes    miR-143*  
   NSCLC Leucine-rich α-2-glycoprotein*   
Table 1.1: Examples of urinary EV biomarkers and proposed clinical usage 
*diagnostic †prognostic ‡response to treatment   
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Functional, circulatory miRNAs are transferred from injured distant organs to the 
renal proximal tubule (PT) via EVs. 
1.9. RESEARCH AIMS 
• Describe the circulatory miRNA concentration changes following myocardial 
injury in human and mouse models of illness. 
• Develop a PT model of EV uptake and release, and identify physiological 
and pathophysiological regulators.  
• In the PT model, compare the effect of circulating EVs containing miRNA 
from injured heart and liver. 
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Chapter 2: Circulatory miRNA concentration changes in a 
human model of myocardial ischaemia 
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Circulating miRNAs represent a potentially rich reservoir of biological information as 
they provide insights into the fine regulatory function of the tissue of origin[1]. 
MiRNA’s negative interference with post-transcriptional gene expression, and their 
subsequent role in cellular function, provide potential for these molecules to be both 
biomarkers of illness and therapeutic agents. 
 
Despite recent advances, coronary artery disease is a major contributor to 
worldwide morbidity and mortality[182, 183]. Post-infarct miRNA expression 
changes are an active area of research and several miRNAs have been described 
as early biomarkers of myocardial ischaemia, potentially reducing time from start of 
symptoms to diagnosis (or exclusion of cardiac injury) [53]. Concentrations of miR-
208a/b[52, 53] and miR-133a[54, 55] have been demonstrated to increase 
significantly in the circulation post-myocardial insult, and circulatory miRNA-499 has 
been positively correlated to cardiac infarct size[7, 56-58]. However, head-to-head 
comparisons with established biomarkers, such as high-sensitivity troponins, have 
reported that measurement of these miRNAs did not improve diagnostic accuracy 
[59]. Furthermore, with the exception of miR-208a, all other previously described 
cardiac miRNAs are enriched in skeletal muscle[60]; limiting specificity for the 
diagnosis of myocardial injury. Measurement of circulating high-sensitive troponin 
concentration at presentation to hospital can accurately identify patients at low risk 
of myocardial infarction [184]. At present, it remains unclear if and how miRNAs as 
biomarkers can contribute to this clinical scenario. 
 
Research into the potential role of miRNA in cell signalling within the myocardium is 
still in its infancy. MiRNAs have been implicated in multiple disease processes, 
including; heart failure[185], myocardial infarction[7], cardiac remodelling[186], 
arrhythmias[187] and ischaemic heart disease[188]. Exosomal miRNA transfer 
between cells has been implicated as a paracrine signalling process within the 
myocardium. For example, cross-talk between cardiac fibroblasts and cardiac 
myocytes may be underpinned by exosomal transport of miR-21. This microRNA 
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transfer significantly impacts upon cardiac function via repression of the SH3 
domain containing 2 (SORB2) and PDZ and LIM domain 5 (PDLIM5) target 
genes[189]. Exosomes from cardiac progenitor cells may aid in cardiac remodelling 
after myocardial infarction by inhibiting apoptosis in cardiac myocytes[190]. 
Although these results are promising, the relevance of miRNA signalling within the 
myocardium is not fully understood, much less the potential biological role changing 
circulatory miRNA patterns may exert on a distant organ.  
 
The experiments described in this chapter aimed to define the change in circulatory 
miRNA expression following myocardial injury in humans, with a line of sight on 
determining the impact of these changes on the kidney in subsequent chapters. 
 
To elucidate circulating miRNA expression changes small RNA sequencing was 
conducted on plasma samples from patients prior to and following myocardial injury. 
The study design focused on interrogating the changing miRNA signature at early 
time points. Elective coronary artery bypass graft (CABG) is a predictable model of 
ischaemic myocardial injury[191], ideal for miRNA biomarker discovery and was 
therefore selected as our group of interest. Patients undergoing elective hip 
arthroplasty were recruited as a control group because they experienced bone and 
skeletal muscle injury without cardiac damage.  
2.1.2. Objectives 
To describe the changes in circulatory miRNA expression associated with 
myocardial ischaemia at 2 and 6 hours following start of cardiac injury in humans. 
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2.2. METHODS 
2.2.1. Study design 
2.2.1.1. Research governance and ethics 
Studies were approved by a local Research Ethics Committee and were performed 
in accordance with the Declaration of Helsinki of the World Medical Association and 
approved by the Medical Ethics Committee of NHS Lothian. Written informed 
consent was obtained from all subjects.  
 
CABG patient blood sampling was conducted during the Elafin Myocardial 
Protection from Ischaemia RepErfusion injury (EMPIRE; EudraCT number: 2010-
019527-58) trial. This trial was conducted between September 2011 and August 
2013. Age- and sex-matched blood samples required for the control group were 
collected in the Stratification of heart disease using miRNA biomarker discovery 
study (EMPIRE miRNA study; REC reference number 15/LO/0727) between July 
and September 2015. Both studies had comparable protocols which are described 
as follows. 
2.2.1.2. Subjects 
Potentially suitable subjects were identified from patients awaiting elective coronary 
artery bypass graft surgery (EMPIRE study) or elective hip arthroplasty (EMPIRE 
miRNA study), attending clinics in the Royal Infirmary of Edinburgh. 
2.2.1.2.1. Inclusion criteria 
• Male. 
• Adults (aged 16-75 inclusive).  
• Patients undergoing elective CABG or hip arthroplasty involving general 
anaesthetic. 
• Adults within the CABG group administered placebo 
2.2.1.2.2. Exclusion criteria 
• Female. 
• Adults unable to provide informed consent.  
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• Recent troponin positive event (a recorded troponin higher than the normal 
range indicated for the assay < 1 month of surgery). 
• Severe left ventricular dysfunction (ejection fraction less than 30%).  
• Chronic renal failure (preoperative estimated glomerular filtration rate 
(eGFR) <60 ml/minute/1.73m3) 
• Adults undergoing emergency surgery. 
• Adults undergoing re-intervention surgery. 
• Adults within the CABG group administered Elafin (the elastase-specific 
protease inhibitor used as the pharmacological intervention within the 
EMPIRE study) 
2.2.1.3. Study protocol 
Blood samples were taken at baseline (defined as up to 4 hours before the first skin 
incision, T0) and at 2-(T2), 6-(T6) and 24- (T24) hours after first skin incision (CABG 
or hip arthroplasty). These blood samples were taken on the ward by either the 
named researcher or clinical research nurse. Blood samples required to be taken 
intra-operatively, were obtained by the theatre staff and collected by the clinical 
research nurse or named researcher. Samples taken at T0, T2 and T6 represented 
additional blood sampling to the routine care of the patient.  
2.2.1.3.1. Sample handling 
Blood samples were taken from patients for measurement of serum urea, creatinine, 
sodium, potassium and troponin I. A sensitive cardiac troponin I assay 
(ARCHITECTstat troponin I assay; Abbott Laboratories, IL, USA) was used because it 
was the highest standard of care at the time of blood sampling. These samples were 
analysed by the clinical laboratories at the Royal Infirmary of Edinburgh, ensuring 
robust analysis. Notably, the limit of detection for the troponin assay was 10 ng/L 
and the upper reference limit (99th centile) of a normal reference population was 28 
ng/L [46]. The inter-assay coefficient of variation was less than 10 % at 50 ng/L 
under local laboratory conditions and this concentration was used as the diagnostic 
threshold.  
 
Concomitant blood samples were taken for isolation of RNA. After blood collection, 
1 serum gel (S-Monovette® Z-Gel, Sarstedt, Nümbrecht, Germany) and 2 
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ethylenediaminetetraacetic acid (EDTA; S-Monovette® 1.6 ml K3EDTA, Sarstedt, 
Nümbrecht, Germany) were centrifuged at 1000 x g for 10 minutes, and the 
subsequent supernatant isolated and stored as 500µL aliquots. Samples were 
immediately stored at -80°C until RNA extraction. 
2.2.1.3.2. Patient followup 
The following adverse event information was collected up to 24 hours post 
procedure. Patients encountering any of these events were excluded from 
downstream analysis.  
• Any cardiac arrhythmia, including atrial fibrillation (sustained for more than 5 
minutes).  
• Deterioration in renal function as defined by a serum creatinine rise from 
baseline by ≥ 26µmol/L within 24 hours (AKI Stage 1 for acute kidney injury).  
• Low cardiac output syndrome and inotrope requirement.  
• Red blood cell transfusion.  
• Re-operation for bleeding.  
• Orthopaedic group only: Increase in Troponin I from baseline (T0) 
concentration (defined as >10% troponin rise at any time point in comparison 
to T0) 
2.2.2. Second generation sequencing  
2.2.2.1. Study design 
132 plasma samples were transported to BGITech, Hong Kong, for small RNAseq 
analysis. This represented 22 patients in the CABG and control group, respectively, 
with bloods samples corresponding to T0, T2 and T6 time points. 
 
Total RNA was extracted from 200µL of each sample using the miRNeasy 
Serum/Plasma kit and Qiazol (Qiagen, MD, United States) according to the 
manufacturer’s instructions. Small RNA sequencing libraries were prepared using 
the TruSeq Small RNA Library Prep Kit (Illumina, CA, United States). RNA quality 
and quantity was assessed using the Agilent 2100 (Agilent technologies, CA, United 
States) and 106 samples were confirmed to contain >4ngµL and and RNA integrity 
number (RIN) >2. These 106 samples contained complete temporal profiles (T0, T2 
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and T6) of 14 patients in CABG group and 14 in the orthopaedic group and were 
subsequently taken forward to sequencing. 
 
8 samples were pooled by lane and underwent single-end sequencing using the 
HiSeq4000 (Illumina, CA, United States). Sequence data (raw fastq format) for the 
84 samples was transferred by hard disk for bioinformatics analysis.  
 
2.2.2.2. Analyses performed 
Raw sequences, provided as 18-44 base long single-end reads in gzipped fastq 
format were quality assessed using FASTQC (Babraham Institute, Cambridge, 
United Kingdom). Based on the output of the FASTQC analysis, the raw fastq 
sequences required further pre-processing to remove contaminating primers. This 
was done using Cutadapt software (Massachusetts Institute of Technology, MA, 
United States). Cleaned sequences were collapsed within each sample to generate 
a non-redundant set of fasta sequences. Singletons were excluded.  
 
Using miRDEEP2 software[192], the hg19 human genome (obtained from NCBI, 
chromosomes and unmapped sequences, 68 in total) was the reference sequence 
used to identify miRNAs. Alignments (end-to-end, -very-sensitive settings) to the 
reference were performed using Bowtie (John Hopkins University, MD, United 
States). No mismatches were allowed. Raw "tag counts" (i.e. sequences aligning) 
per sample were normalised, within each of the two groups, to the sample with the 
lowest number of miRNA alignments, and counts converted to log2.  
 
Pairwise comparisons of sample groups (e.g. T2 relative to T0, T6 relative to T0, T6 
relative to T2) were performed within groups. Analyses were also conducted 
between groups but given the group-group variation in number of reads obtained, 
these data were largely uninterpretable and were not pursued further. Only patients 
that had all three time points were included (84 of the 106 initial samples). A series 
of 6 group-wise comparisons was undertaken to identify differences (fold changes) 
between the normalised tag counts, using linear modelling including vertical P value 
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adjustment (Bioconductor limma package)[193]. All data are presented as a log2 
fold change, a log2 fold change of 1.5 represents a fold change of 2.8. 
2.2.3. PCR validation of sequencing results 
2.2.3.1. RNA extraction 
Total RNA was extracted from 200µL of each sample using the miRNeasy 
Serum/Plasma kit (Qiagen, MD, United States) according to the manufacturer’s 
instructions. Caenorhabditis elegans miRNA mimic (cel-miR-39; Qiagen, MD, United 
States) was used for the spiked-in control. 
2.2.3.2. Heparinase treatment  
Patients undergoing CABG receive intravenous heparin intraoperatively. To remove 
possible heparin contamination of the plasma samples, 6 µl of heparin RNA was 
added to a master mix consisting of 2 µl of 10x reaction buffer (New England 
Biolabs, Ipswich, United Kingdom), 10.75 µl of RNA free H2O, 0.25 µl of Heparinase 
I (New England Biolabs, Ipswich, United Kingdom) and 1 µl of RNase inhibitor 
(Promega, WI, United States). Samples were incubated for 1 hour at 30°C followed 
by 1 minute at 99°C. Samples were stored at -80°C. 
 
To validate our heparin decontamination methodology, paired blood samples were 
taken from healthy volunteers; 1 serum gel collection tube (S-Monovette® Z-Gel, 
Sarstedt, Nümbrecht, Germany) and 1 lithium-heparin collection tube (S-Monovette® 
LH, Sarstedt, Nümbrecht, Germany). Samples were centrifuged at 1000 x g for 10 
minutes, and the subsequent supernatant isolated and stored as 500µL aliquots. 
Samples were immediately stored at -80°C until RNA extraction. In this study miR-
122 was chosen as a high abundance miRNA target to assess DNA polymerase 
inhibition.  
2.2.3.3. Reverse transcription reaction setup 
To generate cDNA the miScript II Reverse Transcription Kit (Qiagen, MD, United 
States) was used according to manufacturer instructions. 6 µl of treated RNA was 
added to a master mix consisting of 4 µl of 5x HiSpec buffer, 2 µl of 10x Nucleics 
mix, 6 µl RNA free H2O and 2 µl of reverse transcriptase mix. Samples were 
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incubated for 1 hour at 37 °C followed by 5 minutes at 95 °C. All cDNA syntheses 
were diluted 10-fold and stored at -80°C. 
2.2.3.4. Quantitative real time analysis  
Real-time quantification to measure miRNAs was performed by using the SYBR 
green miRNA kit (Qiagen, MD, United States) with Lightcycler 480 (Roche 
Diagnostics, IN, United States). For quantification, 1µl of cDNA was added to a 
master mix consisting of 5 µl SYBR green PCR mix, 1 µl of miScript universal 
primer, miScript primer assay and 2 µl of RNA free H2O. MiRNA-specific miScript 
primer sets were obtained from Qiagen. Melting curve analyses showed specific 
amplification with no primer dimer or non-specific products. The data were analysed 
with automatic setting for assigning baseline; the Ct is defined as the fractional cycle 
number at which the fluorescence exceeds the given threshold. The Ct values from 
real-time PCR assays greater than 40 were treated as 40. All samples were 
processed in triplicate and Ct values were normalized by using the mean Ct 
obtained from the spiked-in or internal controls. The data obtained by real-time PCR 
were translated by the 2ΔCt method [194].  
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2.2.3.5. Primer details 
The following pre-designed MiScript Primer Assays were purchased from Qiagen 








Hs_let-7e_3 hsa-let-7e-5p MS00031227 5'UGAGGUAGGAGGUUGUAUAGUU 
Hs_miR-125b-2*_1 hsa-miR-125b-2-3p MS00008568 5'UCACAAGUCAGGCUCUUGGGAC 
Hs_miR-133a_2 hsa-miR-133a-3p MS00031423 5'UUUGGUCCCCUUCAACCAGCUG 
Hs_miR-140-3p_1 hsa-miR-140-3p MS00008673 5'UACCACAGGGUAGAACCACGG 
Hs_miR-145_1 hsa-miR-145-5p MS00003528 5'GUCCAGUUUUCCCAGGAAUCCCU 
Hs_miR-199a-3p_1 hsa-miR-199a-3p MS00007602 5'ACAGUAGUCUGCACAUUGGUUA 
Hs_miR-208_1 hsa-miR-208a-3p MS00003794 5'AUAAGACGAGCAAAAAGCUUGU 
Hs_miR-23a_2 hsa-miR-23a-3p MS00031633 5'AUCACAUUGCCAGGGAUUUCC 
Hs_miR-378g_1 hsa-miR-378g-5p MS00037618 5'ACUGGGCUUGGAGUCAGAAG 
Hs_miR-769-5p_1 hsa-miR-769-5p MS00007210 5'UGAGACCUCUGGGUUCUGAGCU 
Hs_miR-99a_2 hsa-miR-99a-5p MS00032158 5'AACCCGUAGAUCCGAUCUUGUG 
Hs_miR-22_1 hsa-miR-22-3p MS00003220 5'AAGCUGCCAGUUGAAGAACUGU 
Hs_miR-1_2 hsa-miR-1-3p MS00008358 5'UGGAAUGUAAAGAAGUAUGUAU 
Hs_miR-499_1 hsa-miR-499a-5p MS00004375 5'UUAAGACUUGCAGUGAUGUUU 
Hs_miR-30a-5p_1 hsa-miR-30a-5p MS00007350 5'UGUAAACAUCCUCGACUGGAAG 
Hs_miR-30d_2 hsa-miR-30d-5p MS00009387 5'UGUAAACAUCCCCGACUGGAAG 
Hs_miR-99b_2 hsa-miR-99b-5p MS00032165 5'CACCCGUAGAACCGACCUUGCG 
Hs_miR-100_2 hsa-miR-100-5p MS00031234  5'AACCCGUAGAUCCGAACUUGUG 
Hs_miR-486_1 hsa-miR-486-5p MS00004284 5'UCCUGUACUGAGCUGCCCCGAG 
Ce_miR-39_1 cel-miR-39-3p MS00019789 5'UCACCGGGUGUAAAUCAGCUUG 
 
Table 2.1: MiScript Primer Assays used during real-time PCR validation of 
miRNA expression changes in human model of myocardial injury 
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2.2.3.6. Data evaluation and statistical analysis of PCR data 
 
Where possible data were presented as Tukey box plots. Tukey box plots consist of 
4 parameters; box ends at the quartiles Q1 and Q3, median as a horizontal line in 
the box, ‘whiskers’ to the farthest points that are not outliers (i.e. within 3/2 times 
the interquartile range of Q1 and Q3) and dot plot of outliers. Data were analysed 
using a one-way ANOVA with Dunnett’s post-hoc test. The software used was 
GraphPad PRISM (version 6.03 for Windows, GraphPad Software, San Diego, 
USA). A P-value < 0.05 was considered statistically significant.  
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Male subjects were recruited to the CABG group (n=22) and the orthopaedic control 
(n=22). There was no difference in the mean age or BMI between the 2 groups but 
significant differences were seen in baseline co-morbidity and medications (Table 
2.2). Increased incidence of hypertension and hyperlipidaemia, and subsequent 
statin prescription, was present in the CABG cohort. 
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Age (mean±SD) 62.45 ± 7.92 67.82 ± 10.72 0.070 
BMI 29.67±3.86 29.18±5.42 0.755 
Smoker, n (%) 7 (31.8) 2 (9.1) 0.132 




IHD 22 (100) 3 (13.6) <0.001 
Hypertension 16 (72.7) 6 (27.3) 0.006 
Hyperlipidaemia 13 (59.1) 3 (13.6) 0.004 
Diabetes 3 (13.6) 1 (4.5) 0.607 
Medication 
n (%) 
Aspirin 22 (100) 3 (13.6) <0.001 
Clopidogrel 9 (40.9) 2 (9.1) 0.034 
Statin 21 (95.5) 2 (9.1) <0.001 
 
Table 2.2: Baseline characteristics of the subjects  
Significance of numerical data between groups was ascertained using 2-tailed t-test. 
Analysis of nominal data was calculated using 2-tailed Fishers exact test.  
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2.3.2. Second generation sequencing results 
2.3.2.1. Summary of raw data 
333 mature miRNAs were identified within the CABG group. Circulatory miRNAs 
within the CABG group showed reduced variance in their temporal fold change 
following myocardial injury (Figure 2.1, Group 1, panels A-C) in comparison to the 
orthopaedic control group (Figure 2.1, Group 2, panels D-F). This likely was as a 
consequence of the difference in storage times between the 2 cohorts. The study 
was technically challenging in that the input samples were generally small, leading, 
in some cases, to poor RNA yields for sequencing purposes. CABG blood samples 
were stored for 4-6 years at -80°C, while the orthopaedic control group were stored 
at the same temperature for 2-3 months. Consequently, there was significantly 
reduced variance in the miRNA temporal fold change following myocardial injury 
(Figure 2.3, Group 1, panels A-C) in comparison to the orthopaedic control group 
(Group 2, panels D-F)(Table 2.3). 
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CABG (Group 1) Orthopaedic (Group 2) 
F test P value 
 
Mean± SD Mean± SD 
T2-T0 0.0881 ± 0.4634 0.1006 ± 1.1080 5.721 < 0.0001 
T6-T0 0.0403 ± 0.4597 0.1577 ± 0.7486 2.651 < 0.0001 
T6-T2 -0.0479 ± 0.3769 0.0577 ± 0.9331 6.128 < 0.0001 
 
Table 2.3: Comparison of variance between groups of miRNA concentration 
mean log fold change 
Comparison of mean log fold change of circulating miRNAs in CABG and 
orthopaedic cohorts. F test conducted to ascertain variance between log fold 
changes between group 1 and group 2 (group 2 exhibited the largest variance and 
was consequently used in the numerator). 
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2.3.2.2. Temporal expression of miRNA within groups 
The following comparisons were undertaken: CABG group, T2 relative to T0, T6 
relative to T0 and T6 relative to T0, and; orthopaedic group T2 relative to T0, T6 
relative to T0 and T6 relative to T0.  
 
The 10 miRNAs exhibiting the largest differential temporal expression changes in 
the CABG group and orthopaedic group are shown in Table 2.5. Within the CABG 
cohort, several miRNAs have previous been identified as biomarkers of myocardial 
injury, significantly more than in the orthopaedic group (8 and 2 miRNAs 
respectively, 2-tailed Fishers exact test, P <0.05; Table 2.4 and Table 2.5). 
 
 




Figure 2.1: Volcano plots of group comparisons 
Panels A-F show volcano plots (-log(10) raw P value versus log(2) fold change) for all comparisons. Red lines transecting x- and y-axis’ 
demonstrate ± 1 fold change and P-value 0.05 respectively. CABG group mature miRNA (Group 1; panels A-C) demonstrate reduced 
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2.3.2.3. 66 miRNAs exhibited a 1.5 fold log change within the 
CABG cohort 
Across all 3 time-point comparisons, 66 miRNAs were found to be up-or down-
regulated 1.5 log2 fold within the CABG group (Table 2.6). Of these 66, 42 have 
previously been identified in the myocardium. 12 out of the 66 miRNA species 
identified to have changed in the CABG have previously been described as potential 
cardiac biomarkers.  
 
15 miRNAs of interest were selected for further study. Selection criteria were based 
on their previous identification in the myocardium, degree of expression change and 
stability in comparison to control (Figure 2.2). The 15 miRNAs were: hsa-let-7e-5p, 
hsa-miR-100-5p, hsa-mir-125b-2-3p, hsa-miR-133a-3p, hsa-miR-140-3p, hsa-miR-
145-5p, hsa-miR-199a-3p, hsa-miR-22-3p, hsa-miR-23a-3p, hsa-miR-30a-5p, hsa-
miR-30d-5p, hsa-miR-378g, hsa-miR-769-5p, hsa-miR-99a-5p and hsa-miR-99b-5p.  
2.3.2.4. miR-486-5p is a potential internal normaliser  
Within the CABG cohort, expression levels were considered for each miRNA for 
each time point. Mir-486-5p varied the least across the 3 considered time points 
(19.2957 ± 0.0001729; mean normalised read count ± SD) and therefore taken 
forward as a potential internal normalizer in this experimental design. 
2.3.3. rtPCR validation of miRNAs of interest 
The process of miRNA validation was undertaken using rtPCR. The 15 miRNAs of 
interest identified from the second generation sequencing document study were 
interrogated, as were 3 additional miRNAs proposed in the literature as biomarkers 
of myocardial injury (miR-1, miR-208 and miR-499). Plasma samples interrogated in 
the rtPCR verification phase were collected from patients using the same EMPIRE 
and EMPIRE miRNA study protocol as the second generation sequencing 
biomarker discovery phase. Notably, the scarcity of samples resulted in the same 
study patients not being available for both experiments. Plasma samples from T0, 
T2 and T6 time points were analysed from both CABG (n=10) and Orthopaedic 
cohorts (n=10). T24 samples were included for the CABG cohort alone, as samples 
were not collected for this time point in the orthopaedic control group.  
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Mature miRNA Log fold change Raw P value 
T2-T0 hsa-miR-22-3p 1.9 0.006 
hsa-miR-451a 1.87 0.018 
hsa-miR-99a-5p 1.51 0.089 
hsa-miR-769-5p 1.51 0.039 
hsa-miR-30a-5p* 1.47 0.087 
hsa-let-7f-5p -1.83 0.027 
hsa-let-7f-5p -1.79 0.041 
hsa-let-7e-5p* -1.74 0.016 
hsa-let-7a-5p -1.53 0.039 
hsa-let-7a-5p -1.49 0.043 
T6-T0 hsa-miR-22-3p 1.58 0.023 
hsa-miR-451a* 1.46 0.064 
hsa-miR-145-5p* 1.42 0.024 
hsa-miR-186-5p 1.41 0.094 
hsa-miR-27b-3p* 1.36 0.068 
hsa-miR-150-5p -1.71 0.073 
hsa-miR-21-5p* -1.45 0.14 
hsa-miR-146b-5p* -1.34 0.14 
hsa-miR-148a-3p -1.26 0.13 
hsa-let-7f-5p -1.23 0.13 
T6-T2 hsa-miR-203a-3p 1.35 0.039 
hsa-miR-26b-5p* 1.23 0.128 
hsa-miR-145-5p 1.18 0.059 
hsa-miR-92b-3p 1.17 0.174 
hsa-miR-181a-3p* 1.15 0.100 
hsa-miR-146b-5p -2 0.016 
hsa-miR-150-5p -1.66 0.081 
hsa-miR-140-3p -1.29 0.065 
hsa-miR-320a -1.28 0.243 
hsa-miR-769-5p -1.2 0.102 
Table 2.4: Circulatory miRNAs exhibiting the largest differential expression 
(fold change) in the CABG cohort 
The 10 miRNAs demonstrating the greatest differential expression (five up-
regulated, five down-regulated) for each comparison are shown with accompanying 
statistical significance details. Fold change data shown at Log2.*Previously 
described as biomarker of cardiac injury. MiRNAs highlighted in bold have 
previously been described in the myocardium  
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Mature miRNA Log fold change Raw P value 
T2-T0 
 
 hsa-miR-101-3p  3.92  0.008 
 hsa-miR-101-3p  3.92  0.008 
 hsa-miR-99a-5p  3.89  0.006 
 hsa-miR-19a-3p  3.71  <0.001 
 hsa-miR-30a-5p*  3.64  0.008 
 hsa-miR-423-5p*  -5.76  <0.001 
 hsa-miR-423-3p  -4.48  0.002 
 hsa-miR-22-3p  -3.36  0.003 
 hsa-miR-409-3p  -3.14  0.013 
 hsa-miR-320b  -2.99  0.028 
T6-T0  hsa-miR-24-3p  3.73  0.001 
 hsa-miR-24-3p  3.73  0.001 
 hsa-miR-125a-5p  3.38  0.013 
 hsa-miR-99a-5p  2.87  0.042 
 hsa-miR-21-3p  2.79  0.007 
 hsa-miR-877-5p  -2.74  <0.001 
 hsa-miR-423-5p*  -2.38  0.152 
 hsa-miR-409-3p  -2.06  0.100 
 hsa-let-7f-5p  -1.91  0.143 
 hsa-let-7f-5p  -1.9  0.169 
T6-T2  hsa-miR-24-3p  4.85  <0.001 
 hsa-miR-24-3p  4.33  <0.001 
 hsa-miR-125a-5p  3.38  0.0427 
 hsa-miR-99a-5p  3.16  0.010 
 hsa-miR-21-3p  2.81  0.084 
 hsa-miR-877-5p  -3.87  <0.001 
 hsa-miR-423-5p*  -3.37  0.034 
 hsa-miR-409-3p  -3.02  <0.001 
 hsa-let-7f-5p  -2.52  0.083 
 hsa-let-7f-5p  -2.51  0.103 
Table 2.5: Circulatory miRNAs exhibiting the largest differential expression 
(fold change) in the orthopaedic cohort 
The 10 miRNAs demonstrating the greatest differential expression (five up-
regulated, five down-regulated) for each comparison are shown with accompanying 
statistical significance details. Fold change data shown at Log2. *Previously 
described as biomarker of cardiac injury. MiRNAs highlighted in bold have 
previously been described in the myocardium  
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hsa-let-7a-5p* -1.5 0.039 -0.68 0.35  0.85 0.25 
hsa-let-7b-5p 0.92 0.29 -0.12 0.89  -1 0.23 
hsa-let-7c-5p -0.3 0.74 -1 0.26  -0.72 0.42 
hsa-let-7e-5p*† -1.7 0.016 -0.92 0.2  0.83 0.25 
hsa-let-7f-5p* -1.8 0.028 -1.2 0.13  0.6 0.46 
hsa-let-7g-5p -1.1 0.25 -0.48 0.62  0.65 0.51 
hsa-miR-100-5p* 0.25 0.81 -0.52 0.62  -0.76 0.46 
hsa-miR-101-3p* 0.8 0.41 1.3 0.19  0.63 0.49 
hsa-miR-103a-3p*† 0.39 0.59 1.3 0.087  0.87 0.24 
hsa-miR-106b-3p 1.3 0.12 1.3 0.12  0.0007 1 
hsa-miR-107 0.5 0.5 1.1 0.14  0.62 0.41 
hsa-miR-125b-5p* 0.37 0.5 -0.073 0.89  -0.44 0.42 
hsa-mir-125b-2-3p* 0.88 0.011 -0.073 0.89  -0.93 0.007 
hsa-miR-127-3p -0.34 0.42 -0.55 0.19  -0.21 0.61 
hsa-miR-133a-3p* 0.44 0.32 0.4 0.36  -0.036 0.93 
hsa-miR-140-3p* 1.1 0.13 -0.24 0.73  -1.3 0.065 
hsa-miR-142-3p 0.12 0.84 1 0.093  0.9 0.14 
hsa-miR-143-3p* 0.69 0.2 0.4 0.6  -1.3 0.065 
hsa-miR-144-5p 0.38 0.58 -0.29 0.68  -0.29 0.59 
hsa-miR-145-5p* 0.24 0.7 1.4 0.024  1.2 0.06 
hsa-miR-146a-5p 1.1 0.25 0.25 0.79  -0.86 0.37 
hsa-miR-146b-5p 0.67 0.41 -1.3 0.1  -2 0.016 
hsa-miR-148a-3p* -1.2 0.16 -1.3 0.13  -0.094 0.91 
hsa-miR-150-5p -0.24 0.78 -1.7 0.073  -1.7 0.082 
hsa-miR-151a-5p*† 0.46 0.45 1 0.097  0.56 0.36 
hsa-miR-151a-3p* 1.3 0.13 0.27 0.75  -0.99 0.24 
hsa-miR-155-5p -0.62 0.32 -0.74 0.23  -0.12 0.85 
hsa-miR-16-5p -0.22 0.69 0.73 0.38  0.96 0.24 
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hsa-miR-181a-3p*† 0.13 0.85 1.3 0.069  1.2 0.1 
hsa-miR-181a-2-3p*† 0.31 0.6 -0.6 0.31  -0.77 0.13 
hsa-miR-181c-5p* 0.45 0.35 -0.23 0.64  -0.68 0.16 
hsa-miR-182-5p 0.77 0.31 0.46 0.54  -0.3 0.69 
hsa-miR-186-5p*† 1.1 0.18 1.4 0.095  0.29 0.79 
hsa-miR-191-5p -0.093 0.69 -0.99 0.15  -0.9 0.19 
hsa-miR-192-5p 0.37 0.61 1 0.16  0.64 0.68 
hsa-miR-199a-3p*† 0.8 0.14 0.58 0.29  -0.23 0.68 
hsa-miR-19b-3p* 1.4 0.11 0.38 0.37  -1 0.25 
hsa-miR-203a-3p -0.21 0.74 1.1 0.082  1.4 0.039 
hsa-miR-21-5p*† -1 0.27 -1.5 0.11  -0.69 0.62 
hsa-miR-215-5p -0.68 0.15 -0.52 0.26  0.16 0.73 
hsa-miR-22-3p* 1.9 0.006 1.6 0.024  -0.33 0.63 
hsa-miR-223-3p -0.68 0.46 -0.17 0.85  0.51 0.58 
hsa-miR-23a-3p* 0.84 0.057 0.21 0.63  -0.63 0.15 
hsa-miR-25-3p 0.77 0.39 0.96 0.28  0.19 0.83 
hsa-miR-26a-5p*† -0.81 0.31 -0.98 0.21  -0.17 0.83 
hsa-miR-26b-5p*† -0.4 0.62 0.83 0.3  1.2 0.13 
hsa-miR-27a-3p -1.1 0.22 -0.82 0.34  0.23 0.69 
hsa-miR-27b-3p*† 0.76 0.31 1.4 0.068  0.6 0.41 
hsa-miR-28-3p* -0.48 0.57 -1 0.22  -0.57 0.5 
hsa-miR-30a-5p* 1.5 0.087 1.3 0.12  -0.15 0.86 
hsa-miR-30d-5p* 0.35 0.6 0.86 0.2  0.51 0.44 
hsa-miR-30e-3p* 1.3 0.072 0.72 0.3  -0.53 0.44 
hsa-miR-32-5p* -0.59 0.32 -0.76 0.21  -0.16 0.79 
hsa-miR-320a 1.1 0.33 -0.21 0.5  -1.3 0.24 
hsa-miR-340-5p -1 0.29 -1.1 0.27  -0.057 0.95 
hsa-miR-342-3p* 0.9 0.46 -0.31 0.43  -0.61 0.12 
hsa-miR-3615 0.71 0.099 0.46 0.28  -0.25 0.56 
hsa-miR-363-3p 0.93 0.15 0.53 0.41  -0.41 0.53 
hsa-miR-378c* -0.57 0.32 -0.75 0.19  -0.18 0.75 
hsa-miR-378d* -0.71 0.12 -0.84 0.063  -0.13 0.77 
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hsa-miR-378f* -0.87 0.033 -0.79 0.054  0.086 0.83 
hsa-miR-378g* -0.84 0.039 -0.83 0.04  0.0071 0.99 
hsa-miR-421 -0.55 0.53 -1 0.24  -0.49 0.58 
hsa-miR-423-3p* 1.3 0.13 1.2 0.18  -0.15 0.86 
hsa-miR-425-5p* 1.2 0.069 0.35 0.57  -0.8 0.21 
hsa-miR-451a*†‡ 1.9 0.019 1.5 0.064  -0.41 0.6 
hsa-miR-501-3p 0.9 0.15 0.21 0.73  -0.69 0.27 
hsa-miR-532-5p 1.1 0.12 1.3 0.086  0.1 0.88 
hsa-miR-660-5p -0.12 0.79 0.61 0.2  0.74 0.12 
hsa-miR-769-5p* 1.5 0.04 0.31 0.66  -1.2 0.1 
hsa-miR-9-5p -0.24 0.78 -0.7 0.4  -0.46 0.58 
hsa-miR-92b-3p -1 0.24 0.15 0.86  1.2 0.17 
hsa-miR-93-5p 1.2 0.087 1 0.15  -0.2 0.78 
hsa-miR-99a-5p*† 1.5 0.09 1.3 0.14  -0.22 0.81 
hsa-miR-99b-5p* 0.45 0.72 0.05 0.97  -0.4 0.75 
 
Table 2.6: Temporal miRNA changes within the CABG cohort. 
miRNAs exhibiting a greater than 1.5 fold change in expression in any time point 
comparison are shown above.  
*Previously identified in the myocardium, †Previous described as a biomarker of 
myocardial injury, ‡Haemolysis marker, miRNAs highlighted in bold were taken 









Figure 2.2: Temporal expression changes of miRNAs of interest  
X axis represents the 42 miRNAs identified in the CABG cohort, which demonstrated a >1.5 log2 fold change from baseline and have 
been previously identified in the myocardium. Y-axis represents temporal and cohort comparison between the CABG cohort (group1) and 
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2.3.3.1. Heparinase treatment prior to reverse transcription 
effectively removes heparin 
Before PCR replication of the sequencing data, it was essential to remove the 
inhibitory effect of heparin. Within our healthy volunteer cohort (n=5), it was evident 
contamination with heparin significantly reduced the absolute Ct levels of detectable 
miR-122 in comparison to serum control; with similar results seen with spike in 
C.elegans miR-39 (LH only vs serum only; Figure 2.3 a & b respectively). 
Interestingly, when miR-122 was normalised to the external control miR-39, relative 
expression of miR-122 appeared to be higher in the LH contaminated samples in 
comparison to serum only (LH only vs serum only; Figure 2.3 c). 
 
Following treatment with heparinase, samples contaminated with LH had 
significantly lower absolute miR-122 and miR-39 content in comparison to serum 
control (LH+heparinase vs serum only; Figure 2.3 a & b). When miR-122 is 
normalised to the external control miR-39, there was no significant difference in the 
relative miR-122 content of LH samples treated with heparinase when compared to 
either serum or serum treated with heparinase (LH+heparinase vs serum only and 
serum+heparinase, respectively; Figure 2.3 c). 
 
2.3.3.2. miR-486-5p is not an approriate internal normaliser within 
the CABG cohort  
Initial analysis of the raw Ct miR-486-5p values demonstrated that this varied 
significantly by time within the CABG group at T2 in comparison to T0 (T0 28.867 ± 
2.022, T2 27.721 ± 1.973; mean expression level ± SD; 2-tailed paired t-test, p = 
0.0341). Consequently, this miRNA was not used as the internal control and the 
external control C. elegans miR-39 was used for all further analyses. 
2.3.3.3. Temporal expression profile of miRNA within groups 
The temporal miRNA expression changes within the CABG cohort are described in 
Appendix 1. Plasma expression of miR-30a significantly increased at T2 in 
comparison to baseline. MiR-499a, miR-1 and miR-30a significantly increased at 6 
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hours in comparison to baseline. In the control group (hip arthroplasty), none of the 
selected miRNAs showed a significant change from baseline 2- or 6-h after 
myocardial injury (Appendix 2). The data from Appendix 1 and Appendix 2 has been 
converted using the 2Ct method and demonstrated in Figure 2.4 to allow for 
easier visual comparison. In light of variation in mean miRNA expression in the 
second generation sequencing biomarker study phase (Table 2.3), no direct 
comparison was made between the CABG and Orthopaedic cohort.   
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Figure 2.3: rtPCR analysis of heparinised serum samples. 
Matched lithium-heparin (LH) and serum blood samples from healthy volunteers 
were treated with heparinise and the miRNA content quantified using rtPCR (n=5). 
Figure 2.3 a & b demonstrate absolute Ct value of miRNA of interest, miR-122 and 
miR-39 respectively and Figure 2.3 c shows miR-122 normalised to external control 
miR-39. Statistically significant differences were established using 1-way ANOVA 
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Figure 2.4: Plasma rtPCR results of miRNA expression changes from baseline. 
Tukey boxplot analyses of miRNA expression changes in comparison to baseline 
using 2ΔΔCt method (normalising miRNA of interest to first to miR-39 and 
subsequently to baseline expression). Blue boxplot corresponds to CABG cohort for 
indicated time point; red corresponds to orthopaedic cohort. Comparison to baseline 
expression was conducted using paired 1-way ANOVA and Dunnet’s multiple 
comparison; statistically significant differences from baseline are indicated by 
symbol ascribed to each group.   
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Figure 2.4 (cont.) 
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Figure 2.4 (cont.) 
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2.3.3.4. ComparIson of second generation sequencing and rtPCR 
methodology 
Consistency of fold change of miRNA of interest across the 2 platforms; second 
generation sequencing and rtPCR was interrogated. Comparison between 
methodologies was done across time points (i.e. T2-T0, T6-T0) for both the CABG 
and orthopaedic cohorts (Figure 2.5) 
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Figure 2.5: Comparison of miRNA temporal expression changes using rtPCR 
and second-generation sequencing. 
Mean fold change in miRNA of interest using second-generation sequencing (x-axis) 
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2.4.1. Main findings 
The main findings of this chapter were:  
• Circulating miR-30a significantly increases 2 hours following myocardial 
injury in humans. 
• 6 hours following myocardial injury, miR-499a, miR-1 and miR-30a 
significantly increased within human serum. 
• Heparinase effectively removes heparin contamination from serum samples.  
2.4.2. CABG affects the circulating miRNA signature in humans 
The main objective of the present study was to identify miRNAs that change with 
cardiac injury within a human model of cardiac injury. Figure 2.3 and Table 2.6 
reveal the breadth of the changing miRNA signature in both the cardiac and control 
cohort.  
 
In comparison to published literature, the presented study design is novel, 
particularly with regard to control cohort. Previous studies using cardiac surgery as 
a model of myocardial injury typically include healthy volunteers as the control 
cohort [195], if a control cohort is used at all [57, 196, 197]. In the presented study, it 
was felt to be vital to control for injury unrelated to the myocardium. While miRNA 
profile changes following CABG have been correlated to changes seen in IRI injury 
[197], circulating miRNA expression changes have been described as a 
consequence on anaesthesia , bone injury [198] and muscle turnover [199]. 
Critically, miR-1 and -133a, typically cited as cardiac biomarkers, have both been 
described as biomarkers of skeletal muscle injury [199]. Consequently, both miRNA 
species have been described to be upregulated in the circulation following sham 
cardiac procedures in mice [53]. Negating for these predictable insults was critical in 
the present study and consequently, orthopaedic patients undergoing an elective 
procedure were included as an appropriate control population. Using second 
generation sequencing, the circulating miRNA signature was shown to vary 
following myocardial injury. Significantly more of the fluctuating miRNAs identified 
within the CABG cohort have been previously described as biomarkers of 
myocardial injury in comparison to the orthopaedic cohort, adding credence to our 
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study design. Notably, many of the miRNAs in both groups have been previously 
identified in human myocardial tissue, likely reflecting the ubiquitous nature of the 
majority of miRNAs.  
 
Validation of sequencing data is required by many journals for publication and 
remains the gold standard for second generation technologies [200]; yet the 
requirements for technical validation are controversial. The correlation between 
sequencing results and rt-PCR is reassuring and has cast doubt on the utility of the 
time-and resource- consuming technical validation process; fold changes estimated 
from RNA-seq have been shown to have a high correlation with that from the qRT-
PCR [201]. Current best practice guides recommend validation and have clear 
guidelines on methodology [202]. This study used different biological replicates from 
the same population, validating both the sequencing technology but also the 
biological conclusion of the second-generation sequencing experiment. PCR 
validation of sequencing data using the same RNA samples only validates the 
sequencing methodology. 
 
Of the miRNAs taken forward to rtPCR validation, the only significant temporal 
relationships identified were miR-30a increasing at T2 in comparison to baseline, 
and miR-499a, miR-1 and miR-30a significantly increasing at 6 hours in comparison 
to baseline (Figure 2.4). There were no significant temporal changes noted in the 
orthopaedic group. All three of these miRNAs have been described as biomarkers of 
myocardial injury in humans previously [7, 57, 203] but miR-30a has not been noted 
significantly increase at a 2h time point, suggesting it has potential as an early 
biomarker of myocardial injury. 
 
Mir-499-5p is an intronic miRNA encoded within MyH7p, a myosin gene and 
subsequently enriched within the myocardium [7, 204]. Its expression is regulated 
by other myosin genes, as well as miR-208a. miR-499 kinetics have previously been 
described, with peak circulation concentration at 12 hours post-injury, returning to 
baseline 72 hours following injury onset [205]. Other groups have concluded it may 
remain elevated within the serum up to 7 days post-injury [206]. It has been noted to 
accurately predict myocardial damage within 6 hours of onset of symptoms [25]. 
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With regard to its performance against the current gold standard biomarker, it is 
likely to have similar diagnostic accuracy an TnI and may outperform miR-208a 
[207], despite close biological association.  
 
MiR-1-1/133a-2 and miR-1-2/133a-1 are two bicistronic miRNA clusters identified in 
both myocardial and skeletal muscle [208, 209], explaining the necessity to exclude 
or negate for skeletal muscle injury and avoid confounding cardiac biomarker data 
[53, 210]. MiR-1 has been proposed to be an earlier biomarker of cardiac damage in 
comparison to miR-499, becoming significantly elevated in the circulation 2 hours 
following injury [49]. Similarly, miR-1 has also been proposed to correlated to 
plasma TnI and predict degree of myocardial damage [59]. MiR-30a is enriched in 
many more tissues and has been reported to be an effective biomarker of cardiac 
injury [7], predicting myocardial damage as early as 4 hours following myocardial 
ischaemia [203]. 
 
Despite promising studies, no biomarker study has concluded that a cardiac miRNA 
biomarker is more effective than TnI. What may be of clinical utility is a panel of 
dynamic proteomic and transcriptomic biomarkers, to provide detailed information 
regarding the temporal course of, and extent of, myocardial injury. Elevated high 
sensitivity TnI, in a clinical setting, predominantly reflects myocardial injury rather 
myocardial infarction [45] and a panel of candidate biomarkers may improve the 
positive predictive value for myocardial infarction. The combination of miR-1, miR-
499 and miR-21 may improve the diagnostic accuracy of troponin when used in 
combination [25]. However, other studies investigating miRNA/TnI biomarker panels 
have failed to describe added diagnostic value when combined with cTnT [61]. 
2.4.3. Heparin can be effectively removed from RNA extract 
All the miRNAs taken forward to the rtPCR validation phase were identified within 
the circulating serum of both the CABG and orthopaedic cohorts. Removal of 
contaminating heparin from samples was necessary due to the inhibition of DNA 
polymerase by heparin, an enzyme critical in the synthesis of complementary DNA. 
Heparin is an anticoagulant, commonly administered to hospital patients to prevent 
thrombosis and has been previously shown to reduce the perceived concentration of 
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circulating miRNA due to interference in reverse transcription [211, 212]. Chemical 
digestion was not necessary for second generation sequencing as the gel 
electrophoresis stage of small RNA sequencing preparation effectively removes 
contaminants. These data suggest that heparin can be effectively removed by 
heparinise, but only when the miRNA of interest is normalised using the DCt method 
(Figure 2.3). This highlights a potential difficulty in absolute miRNA quantification of 
heparin-contaminated samples, an observation not previously reported [213]. 
 
2.4.4. Limitations 
There was variation in sample storage times across both groups; orthopaedic serum 
samples were stored for 2-3 months and CABG samples were stored for 4-6 years. 
This probably affected the number of samples that were passed through quality 
control for the sequencing study. Of the original 132 samples, 106 passed on dual 
measures of RNA quantity and quality (RIN). To ensure balanced patient numbers 
across cohorts 84 samples were ultimately sequenced, lowering the power of the 
study. The prolonged storage of the CABG samples likely caused the reduced 
variance seen in RNA fold changes in the CABG cohort in comparison to the 
orthopaedic cohort (Figure 2.1 and Table 2.3). This difference complicated head-to-
head comparison between the CABG and orthopaedic groups and limited the ability 
to demonstrate a statistically significant effect of temporal miRNA profile change 
within the CABG cohort. Consequently, raw P values were reported to ascertain 
statistical significance and all identified miRNAs were taken forward to verification in 
another species (Chapter 3). Current opinion regarding the recommended storage 
time for miRNAs appears to vary. Analysis of frozen serum samples in long-term 
storage (>10years) suggests it is possible to isolate enough RNA for analysis [214], 
but how expression changes over time has yet to be fully understood. RNA quantity 
has been demonstrated to drop by >50% following 4 years in storage[215] and each 
circulating miRNA may not affected at a similar rate, leading to possible confounding 
over time [216]. 
 
Another source of potential confounding could be the difference in concomitant 
medications across cohorts. Cell-free circulating miRNAs have huge potential as 
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biomarkers of illness yet a number of studies have recently highlighted the effect of 
medication alone on the miRNA pool. In the present study, greater use of statin and 
antiplatelet agents was noted within the CABG cohort (Table 2.2). This is 
unsurprising, given these medications are recommended for secondary prevention 
of IHD, but both drug categories have been implicated in changing the miRNA 
signature and represent possible confounding factors [217, 218]. Of the miRNAs 
identified, only miR-140-3p has previously been implicated in statin-induced 
changes to the circulating miRNA profiles [218], and longstanding drug therapy 
would not account for acute changes in the miRNA profile described in the present 
study. Despite this, differences in baseline medication must be considered in case-
control studies relating plasma miRNAs to cardiovascular disease. 
 
2.4.5. Summary 
The circulating miRNA profile significantly changes in human subjects following 
myocardial injury. Some of the identified miRNA biomarkers may have potential as 
early biomarkers of myocardial injury. In the next chapter these microRNA 
biomarkers are back translated into a mouse model with a view to subsequently 
investigating whether changes in circulating microRNA may have an impact on 
distant organs.   
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Circulating miRNAs are a rich source of clinical biomarkers and have therapeutic 
potential in identifying severity of myocardial injury and prognostication at point of 
clinical care. Three fundamental biomarker development stages have previously 
been described; biomarker discovery, validation of a markers predictive value within 
the population and implementation of a clinically approved assay [178, 179]. Within 
the discovery phase, candidate biomarkers are identified within a well-defined 
human study clinical population and these finding are translated across species. 
Ensuring effective translation across species remains an ideal characteristic of 
clinical biomarkers for 2 main reasons. Firstly, the connection of a certain biomarker 
signature with a disease usually emerges from experimental studies using small 
sets of patient samples. Even with optimal study design and analysis, confounding 
issues inherent to the population of interest, for example with concomitant illness or 
medication use, may limit the discovery process and therefore require verification in 
an alternative model [217, 218]. Secondly, pre-clinical studies are dependent on 
non-human experimental modelling and an ideal biomarker should translate across 
species; facilitating appropriate interpretation of biological experiments which model 
human disease and informing pre-clinical safety evaluations [219].  
 
This chapter aims to provide vital information to correlate with the human myocardial 
injury studies described in Chapter 2. The temporal changes in miRNA profiles of 
the human samples were investigated using RNAseq and verified using rtPCR. miR-
1, miR-100, miR-133a, miR-140, miR-145, miR-22, miR-23a, miR-30a, miR-30d, 
miR-499, miR-99b were interrogated based on their validation using rtPCR against 
the control cohort (Figure 2.4). In the present chapter, these targets were translated 
into a murine model of myocardial injury and described in both tissue and serum.  
3.1.2. Objectives 
• To describe the changes in circulatory miRNA associated with myocardial 
ischaemia at 2 and 6 hours following cardiac injury in mice. 
• To ascertain the presence of miRNA of interest within mouse myocardial 
tissue. 
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• To correlate circulating miRNA concentration to TnI, the gold-standard 
cardiac biomarker in current clinical care. 
  
University of Edinburgh  EE Morrison 
 





3.2.1.1. Breeding and maintenance of mice 
Mouse studies were in accordance with the Animals (Scientific Procedures) Act 
1986 and approved by the local Animal Ethics Committee. A total of 25 male, 10-14 
week old C57BL/6NCrl mice were used for this study (purchased from Charles River 
Laboratory, Wilmington, MA). Animals were housed in standard sterile conditions 
with free access to chow and water. No adverse effects were encountered.  
3.2.2. Study protocol 
3.2.2.1. Surgical technique 
Mice were randomly assigned to 3 groups: baseline (B, n=5) coronary artery ligation 
(CAL, n=10) or sham (S, n=10). All mice underwent tail blood sampling at baseline. 
Mice in group B were culled using cervical dislocation following baseline blood 
sampling. Ten mice underwent coronary artery ligation for induction of myocardial 
infarction. A further 10 mice underwent sham surgery without coronary artery 
ligation (S). 
 
CAL was performed as described previously [220, 221]. The CAL and S mice were 
weighed, given fluid and subcutaneous analgesia just prior to surgery. Analgesia 
was 0.05 mg/kg of s.c. vetergesic (buprenorphine) in a 50 μl volume of saline and 
0.5-1 ml sterile saline (0.9%, s.c.) to aid recovery. Mice were intubated via the 
mouth for mechanical ventilation (120 strokes/minute, 200μl stroke volume). An 
incision was made in the lower thorax and the chest opened at the fourth intercostal 
space and held open using retractors. The left anterior descending coronary artery 
was ligated in mice randomised to the CAL group, at the level below the left atrium 
using an 8-0 Ethilon suture. After ligation, the chest was closed using a 5-0 silk 
suture. The skin was closed using 9mm stainless steel autoclips. For mice 
undergoing sham surgery (S), thoracotomy alone was performed; ligation of the left 
anterior descending coronary artery was not conducted. Following surgery, mice are 
returned to their cages, and observed until they had fully recovered. The cages were 
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left on a 37 °C heat pad. Mice were observed post-operatively until moving about 
their cage.  
 
Five mice from both the CAL and S groups had blood taken 2 hours (T2) following 
surgery and were then culled for tissue. The remaining 5 mice from each group had 
blood taken 6 hours following surgery (T6) and were then culled for tissue. 
3.2.2.2. Blood and tissue sampling 
Blood sampling at T2 and T6 was conducted by mandibular bleed. Blood was mixed 
at 1:6 ratio with 0.109 mM buffered sodium citrate before isolation of plasma. 
Samples were centrifuged at 1000 x g for 10 minutes, and the subsequent 
supernatant isolated and stored at −80 °C. The mice then underwent a schedule 1 
procedure (cervical dislocation) and tissue was collected for further sample 
processing. Tissue samples for RNA interrogation were immediately placed in 
RNAlater (Sigma Aldrich, Dorset, UK) and stored at −80 °C.  
3.2.3. Troponin quantification 
An ultra-sensitive mouse cardiac troponin-I ELISA (Life Diagnostics, Stoke on Trent, 
UK) was used as per the manufacturer’s instructions. As sample volume was limited 
all samples were diluted to a volume of 100 µl with cardiac troponin-I (cTnl) diluent.  
3.2.4. PCR validation  
3.2.4.1. RNA extraction  
3.2.4.1.1. Blood  
Total RNA was extracted from 20µL of each plasma sample using the miRNeasy 
Serum/Plasma kit (Qiagen, MD, United States) according to the manufacturer’s 
instructions. Caenorhabditis elegans miRNA mimic (cel-miR-39; Qiagen, MD, United 
States) was used for the spiked-in control. 
3.2.4.1.2. Tissues 
Murine tissue was macroscopically dissected, as necessary, using anatomical 
landmarks. Total RNA from tissue samples was isolated by using the miRNeasy 
mini kit (Qiagen, Germantown, MD) according to the instructions from the 
manufacturer. No more than 25 mg of tissue was used.  
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Following extraction, RNA quantity was measured with the Nanodrop instrument 
(Thermo Scientific, Perth, UK). Samples were further diluted to an RNA 
concentration of 250 ng/µl with a total volume of 6 µl.  
3.2.4.2. Reverse transcription reaction setup and quantitative real 
time analysis. 
Reverse transcription and rtPCR analysis was conducted as previous described 
(section 2.2.3.3 & 2.2.3.4). Ct values were normalized in plasma samples by using 
the mean Ct obtained from the spiked-in external control (cel-miR-39). U6 was used 
as the internal control for tissue samples and validated in our cohorts (data not 
shown). 
3.2.4.3. Primer details  
The following pre-designed MiScript Primer Assays were purchased from Qiagen 
(MD, United States)(Table 3.1). Where relevant, the human primer sequence was 
clarified to function in the corresponding murine target. 
3.2.5. MiRNA target prediction and function annotation 
To predict miRNA targets in tissues, miRDB was used as the online open source 
database for miRNA target prediction and functional annotations in human tissue 
[222]. MiRDB predicts targets using a bioinformatics tool, MirTarget, which 
catalogues miRNA-target interactions from high-throughput sequencing 
experiments. Additionally, miRDB includes a prediction program based on support 
vector machines (SVMs; machine learning procedures based on statistical learning 
theory) and high-throughput training datasets. High predicted target scores 
(reported between 50-100) have increased confidence in prediction. As per the 
developer’s guidelines, scores below 60 should have supporting evidence presented 
and consequently have not been reported in this work. Additionally, functional 
prediction of miRNA effect was ascertained using miRpath v.3[223]. miRPath can 
utilize predicted miRNA targets provided by the DIANA-microT-CDS algorithm 
and/or experimentally validated miRNA interactions derived from DIANA-TarBase 
v6.0; p-value selected as <0.05 and micro-T threshold 0.8 for prediction of affect 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. 
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3.2.6. Data evaluation and statistical analysis 
Where possible data were presented as Tukey box plots. Tukey box plots consist of 
4 parameters; box ends at the quartiles Q1 and Q3, median as a horizontal line in 
the box, ‘whiskers’ to the farthest points that are not outliers (i.e. within 3/2 times 
the interquartile range of Q1 and Q3) and dot plot of outliers. Data were analysed 
using GraphPad PRISM (version 6.03 for Windows, GraphPad Software, San 
Diego, USA) and a P-value < 0.05 was considered statistically significant. Statistical 
significance was ascertained as follows: t-tests to test for difference in means 
between two datasets (temporal miRNA /troponin concentration changes); 
Pearson’s correlation coefficients to correlate TnI and miRNA of interest, and 
receiver operator characteristic (ROC) was calculated to illustrate the diagnostic 
ability of the miRNAs of interest. 
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Hs_miR-1_2 mmu-miR-1a-3p MS00008358 5'UGGAAUGUAAAGAAGUAUGUAU 
Hs_miR-100_2 mmu-miR-100-5p MS00031234  5'AACCCGUAGAUCCGAACUUGUG 
Hs_miR-133a_2 mmu-miR-133a-3p MS00031423 5'UUUGGUCCCCUUCAACCAGCUG 
Hs_miR-140-3p_1 mmu-miR-140-3p MS00008673 5'UACCACAGGGUAGAACCACGG 
Hs_miR-145_1 mmu-miR-145a-5p MS00003528 5'GUCCAGUUUUCCCAGGAAUCCCU 
Hs_miR-22_1 mmu-miR-22-3p MS00003220 5'AAGCUGCCAGUUGAAGAACUGU 
Hs_miR-23a_2 mmu-miR-23a-3p MS00031633 5'AUCACAUUGCCAGGGAUUUCC 
Hs_miR-30a-5p_1 mmu-miR-30a-5p MS00007350 5'UGUAAACAUCCUCGACUGGAAG 
Hs_miR-30d_2 mmu-miR-30d-5p MS00009387 5'UGUAAACAUCCCCGACUGGAAG 
Hs_miR-499_1 mmu-miR-499-5p MS00004375 5'UUAAGACUUGCAGUGAUGUUU 
Hs_miR-99b_2 mmu-miR-99b-5p MS00032165 5'CACCCGUAGAACCGACCUUGCG 
Ce_miR-39_1 cel-miR-39-3p MS00019789 5'UCACCGGGUGUAAAUCAGCUUG 










Table 3.1: MiScript Primer Assays used during real-time PCR validation of 
miRNA expression changes in murine model of myocardial injury 
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3.3.1. Circulating MiRNA profile changes following ischemic injury in 
mice 
Plasma samples from mice undergoing CAL were interrogated for the 11 miRNAs 
exhibiting the largest fold changes in the human myocardial injury study (Chapter 2). 
Baseline and ‘time point of interest’ samples were taken from the same animal and 
miRNA profile changes were investigated using paired two-tailed t-test (n=5). Table 
3.2 describes the temporal miRNA profile changes within the CAL group. MiR-11, -
100, -133a, -145, -22, -30a, -499 and -99b all significantly increased from their 
baseline circulating concentration, 2 hours following CAL. 6 hours following injury, 
significant increases from baseline remained for miR-1, -133a, -145, -30a, -499 and 
-99b and changes in expression of miR-23a and -30d could now be detected. 
 
MiRNA profile changes within the circulation of mice undergoing the sham 
procedure are described in Table 3.3. Increased expression of miR-1, -133a, -145, -
23a, -30d, and -99b were all seen 2 hours following sham procedure; at 6 hours only 
miR-1, -100, -23a, -499 and -99b were significantly altered from baseline. 
 
Head-to-head comparison of temporal miRNA fold changes was undertaken 
between groups (Table 3.4). 2 hours following procedure, miR-499 was significantly 
increased in the CAL cohort compared to the sham group. Of the miRNAs 
interrogated, only miR-1, -30d and -499 significantly increased in comparison to the 
sham procedure 6 hours post-operation. These fold change data have been visually 
represented with corresponding significance to baseline miRNA expression in 
Figure 3.1. As miR-499, miR-1 and miR-30d all demonstrated significant changes 
within the circulation, their downstream targets were predicted and demonstrated in 







interest Time point 




difference  95% CI of diff. Mean SD  P-value 
miR-1 T0 (T2 Baseline) 0.0117 0.0031          
T2  8.4100 3.7340  T2 baseline vs. 
T2 
8.399 ± 1.670 4.548 to 12.25 0.001 
T0 (T6 baseline) 0.0098 0.0074  
    
T6  14.340 13.570  T6 baseline vs. 
T6  
14.330 ± 6.070 0.331 to 28.330 <0.05 
miR-100 T0 (T2 Baseline) 0.0725 0.0254          
T2  0.1263 0.09151  T2 baseline vs. 
T2 
0.054 ± 0.042 -0.0440 to 0.152 ns 
T0 (T6 baseline) 0.1289 0.0792  
    
T6  0.2829 0.1263  T6 baseline vs. 
T6  
0.154 ± 0.067 0.0002 to 0.308 <0.05 
miR-133a T0 (T2 Baseline) 0.0032 0.0013          
T2  0.1936 0.1105  T2 baseline vs. 
T2 
0.190 ± 0.049 0.076 to 0.304 <0.01 
T0 (T6 baseline) 0.0024 0.0023  
    
T6  0.4366 0.3311  T6 baseline vs. 
T6  
0.434 ± 0.148 0.093 to 0.776 <0.05 
miR-140 T0 (T2 Baseline) 0.4319 0.1533          
T2  0.4591 0.1651  T2 baseline vs. 
T2 





T0 (T6 baseline) 0.3093 0.1080  
    
T6  0.5605 0.4020  T6 baseline vs. 
T6  
0.251 ± 0.186 -0.178 to 0.681 ns 
miR-145 T0 (T2 Baseline) 0.2969 0.2533          
T2  1.8940 2.6870  T2 baseline vs. 
T2 
1.598 ± 0.421 0.627 to 2.568 <0.01 
T0 (T6 baseline) 0.1957 0.2152  
    
T6  1.3800 0.6649  T6 baseline vs. 
T6  
1.184 ± 0.476 0.087 to 2.281 <0.05 
miR-22 T0 (T2 Baseline) 0.6969 0.4282          
T2  7.9260 4.9650  T2 baseline vs. 
T2 
7.229 ± 2.229 2.090 to 12.370 <0.05 
T0 (T6 baseline) 0.5449 0.1464  
    
T6  3.9210 3.7450  T6 baseline vs. 
T6  
3.376 ± 1.676 -0.489 to 7.241 ns 
miR-23a T0 (T2 Baseline) 4.1500 1.6410          
T2  9.1040 5.1350  T2 baseline vs. 
T2 
4.954 ± 2.411 -0.606 to 10.510 ns 
T0 (T6 baseline) 4.1640 1.5530  
    
T6  12.3600 7.7700  T6 baseline vs. 
T6  
8.193 ± 3.543 0.022 to 16.360 <0.05 
miR-30a T0 (T2 Baseline) 1.4630 0.6537          
T2  6.2050 3.5270  T2 baseline vs. 
T2 
4.741 ± 1.604 1.042 to 8.441 <0.05 
T0 (T6 baseline) 1.1170 0.3007  





T6  2.5820 1.2140  T6 baseline vs. 
T6  
1.465 ± 0.559 0.175 to 2.755 <0.05 
miR-30d T0 (T2 Baseline) 0.0809 0.0427          
T2  0.2943 0.2100  T2 baseline vs. 
T2 
0.213 ± 0.096 -0.008 to 0.434 ns 
T0 (T6 baseline) 0.0959 0.0298  
    
T6  0.5825 0.2397  T6 baseline vs. 
T6  
0.487± 0.108 0.237 to 0.736 <0.01 
miR-499 T0 (T2 Baseline) 0.0009 0.0002          
T2  0.0961 0.0784  T2 baseline vs. 
T2 
0.095 ± 0.035 0.014 to 0.176 <0.05 
T0 (T6 baseline) 0.0012 0.0015  
    
T6  0.2421 0.1682  T6 baseline vs. 
T6  
0.241 ± 0.075 0.067 to 0.414 <0.05 
miR-99b T0 (T2 Baseline) 0.0076 0.0028          
T2  0.0223 0.0133  T2 baseline vs. 
T2 
0.015 ± 0.006 0.001 to 0.029 <0.05 
T0 (T6 baseline) 0.0065 0.0009  
    
T6  0.0420 0.0168  T6 baseline vs. 
T6  
0.035 ± 0.008 0.018 to 0.053 <0.01 
 
Table 3.2: Temporal circulatory miRNA changes following murine coronary artery ligation (CAL) procedure.  
Mice randomised to the CAL underwent blood sampling at baseline and either 2- or 6-hours post-procedure (n=5 in both cohorts). Plasma 
samples were analysed for miRNA of interest and normalised to external control ce-miR-39 using the ΔCt method. Statistical significance 






interest Time point 




difference  95% CI of diff. Mean SD  P-value 
miR-1 T0 (T2 Baseline) 0.0207 0.0144          
T2  9.2500 4.6370  T2 baseline vs. 
T2 
9.229 ± 2.074 4.447 to 14.010 <0.01 
T0 (T6 baseline) 0.0101 0.0073  
    
T6  1.576 0.8848  T6 baseline vs. 
T6  
1.566 ± 0.396 0.653 to 2.480 <0.01 
miR-100 T0 (T2 Baseline) 0.1302 0.0724          
T2  0.3202 0.1887  T2 baseline vs. 
T2 
0.190 ± 0.090 -0.0189 to 0.398 ns 
T0 (T6 baseline) 0.1097 0.0166  
    
T6  0.2297 0.1039  T6 baseline vs. 
T6  
0.120 ± 0.047 0.012 to 0.229 <0.01 
miR-133a T0 (T2 Baseline) 0.0012 0.0007          
T2  0.3156 0.1706  T2 baseline vs. 
T2 
0.314 ± 0.076 0.138 to 0.490 <0.01 
T0 (T6 baseline) 0.0010 0.0007  
    
T6  0.1233 0.1289  T6 baseline vs. 
T6  
0.122 ± 0.058 -0.012 to 0.255 ns 
miR-140 T0 (T2 Baseline) 0.4471 0.1089          
T2  0.6123 0.4573  T2 baseline vs. 
T2 
0.165 ± 0.210 -0.320 to 0.650 ns 
T0 (T6 baseline) 0.3306 0.0855  





T6  0.2734 0.1599  T6 baseline vs. 
T6  
-0.057 ± 0.081 -0.244 to 0.130 ns 
miR-145 T0 (T2 Baseline) 0.2533 0.0844          
T2  2.6870 1.4650  T2 baseline vs. 
T2 
2.433 ± 0.656 0.920 to 3.946 <0.01 
T0 (T6 baseline) 0.2152 0.0458  
    
T6  0.6649 0.4809  T6 baseline vs. 
T6  
0.450 ± 0.216 -0.048 to 0.948 ns 
miR-22 T0 (T2 Baseline) 0.8825 0.3731          
T2  10.9900 13.0500  T2 baseline vs. 
T2 
10.110 ± 5.840 -3.355 to 23.580 ns 
T0 (T6 baseline) 0.6236 0.0895  
    
T6  1.8440 1.9540  T6 baseline vs. 
T6  
1.221 ± 0.875 -0.797 to 3.238 ns 
miR-23a T0 (T2 Baseline) 5.9900 2.6460          
T2  14.1100 7.11300  T2 baseline vs. 
T2 
8.123 ± 3.394 0.296 to 15.950 <0.05 
T0 (T6 baseline) 4.5050 1.4550  
    
T6  7.3190 2.1780  T6 baseline vs. 
T6  
2.814 ± 1.171 0.112 to 5.515 <0.05 
miR-30a T0 (T2 Baseline) 2.0610 1.1660          
T2  6.2509 4.7270  T2 baseline vs. 
T2 
4.199 ± 2.177 -0.822 to 9.219 ns 
T0 (T6 baseline) 1.0700 0.1590  





T6  1.6370 0.8536  T6 baseline vs. 
T6  
0.568 ± 0.388 -0.328 to 1.463 ns 
miR-30d T0 (T2 Baseline) 0.1200 0.0644          
T2  0.6228 0.2902  T2 baseline vs. 
T2 
0.503 ± 0.133 0.196 to 0.809 <0.01 
T0 (T6 baseline) 0.0999 0.0165  
    
T6  0.3688 0.2808  T6 baseline vs. 
T6  
0.269 ± 0.126 -0.021 to 0.559 ns 
miR-499 T0 (T2 Baseline) 0.0010 0.0004          
T2  0.0061 0.0059  T2 baseline vs. 
T2 
0.005 ± 0.003 -0.001 to 0.011 ns 
T0 (T6 baseline) 0.0006 0.0002  
    
T6  0.0019 0.0009  T6 baseline vs. 
T6  
0.001 ± 0.0004 0.0003 to 0.002 <0.05 
miR-99b T0 (T2 Baseline) 0.0111 0.0075          
T2  0.0588 0.0357  T2 baseline vs. 
T2 
0.048 ± 0.016 0.010 to 0.085 <0.05 
T0 (T6 baseline) 0.0071 0.0011  
    
T6  0.0360 0.0216  T6 baseline vs. 
T6  
0.029 ± 0.009 0.007 to 0.051 <0.05 
 
Table 3.3: Temporal circulatory miRNA changes following murine sham (S) procedure. 
Mice randomised to the sham cohort underwent blood sampling at baseline and either 2- or 6-hours post-procedure (n=5 in both cohorts). 
Plasma samples were analysed for miRNA of interest and normalised to external control ce-miR-39 using the ΔCt method. Statistical 









log ΔΔCt  
 
Comparison  Mean difference  95% CI of diff. Mean SD  P-value 
miR-1 T2 sham 506.3 207.2          
T2 CAL 715.5 190.6  T2 sham vs. T2 CAL 209.2 ± 125.9 -81.11 to 499.5 ns 
T6 sham 274.6 348.6  
    
 T6 CAL 2730.0 3132.0  T6 sham vs. T6 CAL 2456 ± 1409 -793.8 to 5706.0 <0.05 
miR-100 T2 sham 3.5 3.6          
T2 CAL 1.7 1.1  T2 sham vs. T2 CAL -1.9 ± 1.7 -5.7 to 1.9 ns 
T6 sham 2.1 0.8  
    
 T6 CAL 2.4 0.7  T6 sham vs. T6 CAL 0.3 ± 0.5 -0.8to 1.4 ns 
miR-133a T2 sham 399.6 451.4          
T2 CAL 86.8 81.3  T2 sham vs. T2 CAL -312.8 ± 205.1 -785.8 to 160.2 ns 
T6 sham 185.9 155.0  
    
 T6 CAL 368.7 528.1  T6 sham vs. T6 CAL 182.7 ± 246.1 -384.8 to 750.3 ns 
miR-140 T2 sham 1.6 1.4          
T2 CAL 1.2 0.6  T2 sham vs. T2 CAL -0.4 ± 0.7 -2.0 to 1.2 ns 
T6 sham 0.9 0.6  
    
 T6 CAL 2.5 2.4  T6 sham vs. T6 CAL 1.6 ± 1.1 -0.9 to 4.1 ns 
miR-145 T2 sham 11.8 7.2          





T6 sham 3.0 1.9  
    
 T6 CAL 8.7 8.1  T6 sham vs. T6 CAL 5.7 ± 3.7 -2.9 to 14.4 ns 
miR-22 T2 sham 11.8 10.9          
T2 CAL 15.3 9.5  T2 sham vs. T2 CAL 3.6 ± 6.5 -11.3 to 18.5 ns 
T6 sham 3.2 3.6  
    
 T6 CAL 7.8 9.0  T6 sham vs. T6 CAL 4.6 ± 4.3 -5.4 to 14.6 ns 
miR-23a T2 sham 2.7 1.5          
T2 CAL 2.1 0.8  T2 sham vs. T2 CAL -0.6 ± 0.8 -2.3 to 1.2 ns 
T6 sham 2.0 1.4  
    
 T6 CAL 3.8 3.3  T6 sham vs. T6 CAL 1.9 ± 1.6 -1.8to 5.6 ns 
miR-30a T2 sham 3.3 2.3          
T2 CAL 4.1 0.9  T2 sham vs. T2 CAL 0.7 ± 1.2 -2.0 to 3.5 ns 
T6 sham 1.6 1.4  
    
 T6 CAL 2.7 2.0  T6 sham vs. T6 CAL 1.2 ± 1.0 -1.1 to 3.4 ns 
miR-30d T2 sham 6.8 4.9          
T2 CAL 4.4 3.4  T2 sham vs. T2 CAL -2.4 ± 2.7 -8.6 to 3.7 ns 
T6 sham 3.6 2.1  
    
 T6 CAL 5.9 2.1  T6 sham vs. T6 CAL 2.4 ± 1.3 -0.7 to 5.4 <0.05 
miR-499 T2 sham 6.8 5.3          





T6 sham 3.3 1.3  
    
 T6 CAL 403.9 455.1  T6 sham vs. T6 CAL 400.6 ± 203.5 -68.68 to 870.0 <0.05 
miR-99b T2 sham 9.3 10.5          
T2 CAL 3.3 3.0  T2 sham vs. T2 CAL -5.9 ± 4.9 -17.2 to 5.4 ns 
T6 sham 5.2 3.0  
    
 T6 CAL 6.3 2.5  T6 sham vs. T6 CAL 1.2 ± 1.7 -2.8 to 5.2 ns 
 
Table 3.4: Comparison of miRNA fold changes following coronary artery ligation and sham procedure. 
Mice were randomised to CAL or sham procedure (n=10 each cohort). They underwent blood sampling at baseline and either 2- or 6-
hours post-procedure (n=5 each time point). Plasma samples were analysed for miRNA of interest, normalised to external control ce-miR-
39 and transformed to fold change from baseline using the ΔΔCt method. Statistical significance was ascertained using unpaired 2 tailed 
t-test 
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Figure 3.1: MiRNA of interest fold changes following coronary artery ligation 
(CAL) and sham (S) procedure 
Mice were randomised to CAL (blue) or sham (pink) procedure, undergoing blood 
sampling at baseline and either 2- or 6-hours post-procedure (n=5 each group). 
Plasma samples were analysed for miRNA of interest, normalised to external control 
ce-miR-39 and transformed to fold change from baseline using the ΔΔCt method. 
Data shown as Tukey boxplot (n=5 each group). Statistical significance was 
ascertained using paired 2 tailed t-test comparing time point of interest to baseline.  
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3.3.2. Circulating miRNAs correlate to troponin in a mouse model of 
myocardial injury 
Firstly, the temporal changes of TnI were investigated following both the CAL and 
sham procedure. As predicted, TnI significantly increased 2- and 6-hours post-CAL 
but TnI also increased in the sham cohort 6 hours post procedure (Figure 3.2). 
Despite this increase within the control population, a significant difference in TnI 
concentration was seen between both cohorts at both time points of interest.  
 
To ascertain the utility of miRNA targets as biomarkers of myocardial injury, miRNAs 
of interest were correlated to circulating TnI concentration (Figure 3.3). Of the 11 
interrogated miRNA biomarkers, only miR-499 correlated to TnI levels 2 hours post 
procedure (Figure 3.3a). At 6 hours, both miR-499, -1, -133a all correlated to TnI 
concentration at that time (Figure 3.3b). 
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Figure 3.2: Circulating troponin concentration increases following sham and 
CAL procedure.  
Statistically significant differences were seen between CAL (blue) and S (red) group 
2- and 6- hours (P = 0.04 and <0.00001 respectively). Notably within the sham 
group, troponin concentration at 6- hours was statistically higher than baseline 
(P=0.0014), but at 2- hours it was not (p>0.05). Both 2- and 6- hour values in the 
CAL group were statistically higher than baseline (p = 0.034 and p<0.00001, 
respectively). The plotted values represent mean troponin concentration and SEM 
for each group, statistically significance was ascertained using unpaired t-tests (n=5) 
 






















Figure 3.3: Expression of circulating miRNA correlates to plasma troponin. 
Mice were randomised to CAL or sham procedure and underwent blood samples at either 2- or 6-hours post-procedure (n=5 each group). 
Plasma samples were analysed for TnI and miRNA of interest (normalised to external control ce-miR-39 using the ΔCt method) and 
correlated. Figure 3.3a shows miR-499 (blue) correlates with TnI 2 hours following procedure (r=0.7157, p=0.0302). Figure 3.3b 
demonstrates miR-499 (blue), miR-1 (red), miR-133a (yellow) all significantly correlated with plasma TnI (r = 0.80, p<0.01; r = 0.72, 
p<0.05; r = 0.76 p <0.01 respectively). Only miRNA/troponin correlations with a P value of <0.05 have been shown. 
 














































a) 2 hours post-CAL b) 6 hours post-CAL





3.3.3. Cardiac miRNAs have potential as biomarkers of myocardial 
injury 
miRNAs identified in the human cohort and described in the murine model of 
myocardial injury were interrogated for the diagnostic accuracy. The troponin rise in 
the sham procedure group compromised the validity of this control. Therefore, 
miRNA results from the baseline cohort were used as the control population. MiR-1, 
-133a, -145, -22, 30d, 30a and -499 significantly diagnose myocardial injury 2 hours 
after onset, with an ROC-AUC greater than 0.8 (Table 3.5). 6 hours following injury, 
miR-100, -133a, -145, -23a, -30d, -499 and -99b similarly diagnose myocardial 
ischaemia. Notably, miR-1, -133a, -145, -30a and -499 all performed well 2 hours 
following injury but at 6 hours miR-133a, 23a, 30d, and -499 had the greatest 
diagnostic accuracy (ROC-AUC >0.95). 
3.3.4. MiRNA profile changes in tissue following ischaemic injury 
The miRNAs of interest were quantified in tissue using the same experimental 
model of myocardial injury. The miRNA content of the left ventricle, right ventricle, 
renal cortex and liver were investigated at baseline and 2- and 6-hours following 
myocardial injury (n=5 in each group). Kidney and liver were studied as control 
organs but also with reference to future chapters that explore miRNA signalling.  
 
In the left ventricle, expression of miR-499 significantly decreased 6 hours following 
myocardial injury but there was no significant change at the 2 hour post-injury time 
point (Figure 3.4b). There were no significant changes noted in the miR-499 content 
of the right ventricle or in expression of the other miRNAs of interest (data not 
shown). Downstream from the myocardium, miR-499 expression was noted to 
increase in the renal cortex 6 hours following CAL (Figure 3.4a). No other significant 
changes were noted in the other miRNAs interrogated. No change was noted in the 
miRNA content of the liver, with regard to our miRNAs of interest. Functional 
prediction of miR-499 was ascertained using miRpath v.3 and predicted pathways 








2-hour time point  6-hour time point 
ROC-AUC (95% CI) P- Value  ROC-AUC (95% CI) P- Value 
miR-1 0.96 (0.84 to 1.077) 0.02  0.84 (0.58 to 1.101) ns 
miR-100 0.84 (0.58 to 1.101) ns  0.92 (0.74 to 1.102) 0.03 
miR-133a 1.00(1.00 to 1.000) 0.02  0.96 (0.84 to 1.077) 0.02 
miR-140 0.80 (0.51 to 1.089) ns  0.64 (0.26 to 1.016) ns 
miR-145 0.96 (0.84 to 1.077) 0.02  0.8 (0.662 to 1.098) 0.05 
miR-22 1.00(1.00 to 1.000) 0.0090  0.80 (0.45 to 1.151) ns 
miR-23a 0.800 (0.49 to 1.106) ns  1.00(1.00 to 1.000) 0.01 
miR-30d 0.92 (0.74 to 1.102) 0.03  1.00(1.00 to 1.000) 0.01 
miR-30a 0.96 (0.84 to 1.077) 0.02  0.76 (0.41 to 1.113) ns 
miR-499 1.00(1.00 to 1.000) 0.01  1.00(1.00 to 1.000) 0.01 
miR-99b 0.840 (0.58 to 1.101) ns  0.920 (0.74 to 1.102) 0.03 
 
Table 3.5: ROC curves analyses of circulating miRNAs of interest. 
Blood samples taken from mice, and mice 2- or 6-hours post-CAL (n=5 each group). Plasma samples were analysed miRNA of interest 
(normalised to external control ce-miR-39 using the ΔCt method) and compared using the ROC curve.  
 








Figure 3.4: Tissue expression of miRNAs of interest change following 
myocardial injury. 
Tissue samples taken from healthy mice (baseline), and mice 2- or 6-hours post-
CAL (n=5 each group). Samples were analysed for miRNA of interest (normalised to 
internal control U6 using the Ct method). Data are shown as Tukey boxplot. 
Statistical significance was determined by unpaired 2-tailed t-test. Figure 3.4a: MiR-
499: within the renal cortex increase 6 hours following myocardial injury (p=0.03). 
Figure 3.4b: Conversely, levels of miR-499 fall in the left ventricle following 
myocardial injury (p=0.01). Data for other miRNAs and tissues are not shown as no 
significant difference was noted.  
















































a) Renal Cortex: miR-499
b) Left ventricle: miR-499










Symbol Gene description 
Cell cycle (hsa04110) 
 

















E2F Transcription Factor 5 
S-Phase Kinase Associated 
Protein 2 
MYC Proto-Oncogene, BHLH 
Transcription Factor 
Cell Division Cycle 27 



















Forkhead Box O4 
S-Phase Kinase Associated 
Protein 2 
Protein Kinase AMP-Activated 
Catalytic Subunit Alpha 1 
MDM2 Proto-Oncogene 













Apoptotic Peptidase Activating 
Factor 1 
Phorbol-12-Myristate-13-Acetate-
Induced Protein 1 




Table 3.6: MiR-499 KEGG pathway targets 
  







3.4.1. Main findings 
The main findings of chapter 3 were:  
• Circulating miR-499 significantly increases 2 hours following myocardial 
injury in mice in comparison to control. 6 hours following myocardial injury, 
miR-499a, miR-1 and miR-30d significantly increased in mice in comparison 
to control 
• 2 hours following murine myocardial injury, circulating miR-499 correlates to 
TnI. 6 hours following injury, miR-499, miR-1, miR-133a all correlate to TnI. 
• In a mouse model of myocardial injury, TnI significantly increases in sham 
procedure 6 hours following intervention. 
• MiR-499 expression levels decrease within the LV 6 hours following murine 
myocardial injury. MiR-499 increases within the renal cortex at this time 
point. 
3.4.2. Circulatory miRNAs are biomarkers of myocardial injury that can 
translate across species 
The main objectives of this chapter were to translate the changes in circulatory 
miRNA expression described in Chapter 2 into a mouse model of myocardial injury. 
Furthermore, circulatory miRNA changes were to be compared with miR-expression 
changes in murine tissue.  
 
Chapter 3 confirms that some cardiac miRNA translate across species and can 
predict cardiac injury. In the animal model of myocardial injury, circulating miR-499 
was significantly higher than in the sham cohort 2 hours following intervention 
(Table 3.4). 6 hours following CAL, miR-1, miR-30d and miR-499 were all 
significantly higher within the circulation, suggesting miRNAs are released into the 
circulation as a result of myocardial injury (Table 3.4). These results are similar that 
that of previously published work, using a rat model of CAL [53]. ROC analysis 
suggested that all of these miRNAs could be useful biomarkers of myocardial injury 
versus healthy controls (Table 3.5). The present study adds to the published 
literature by correlating circulating miR-499 and TnI, 2 hours following myocardial 





injury, suggesting miR-499 may be a suitable biomarker to predict degree of 
myocardial damage. MiR-499 concentration has previously been correlated to TnI 6 
hours following onset on injury[25], but no published work has investigated this at an 
earlier time point. 
3.4.3. Myocardial injury affects the miRNA content of the myocardium 
and renal cortex 
Reduced expression of miR-499 was demonstrated 6 hours following myocardial 
ischaemia (Figure 3.4) This instinctively seems correct, if the hypothesis of tissue 
miRNAs released into the circulation following injury is true. Reduced expression of 
miR-499 in the injured myocardium would correspond to increased concentration in 
circulation. Reduced miR-499 in the myocardium has previous been noted in a 
myocardial IRI canine model, in which miR-499 was significantly lower 2.5 hours 
following injury onset [224], but this observation has not been investigated in murine 
or human models. MiR-499-5p is an intronic miRNA encoded within MyH7p, a 
myosin gene, and therefore it is enriched within the cardiomyocytes and skeletal 
muscle [7, 204].The decrease in myocardial miR-499 expression could be as a 
consequence of tissue necrosis and loss of viable tissue but it has been 
hypothesised that it may be a therapeutic target for myocardial protection[224]. 
Predicted KEGG pathway targets implicate miR-499 in several pathways implicated 
in cell cycle regulation and apoptosis (FoxO pathway and p53; Table 3.6). 
Experimentally, miR-499 has been shown to inhibit cardiomyocyte apoptosis 
through its suppression of calcineurin-mediated dephosphorylation of dynamin-
related protein-1 (Drp1), reducing myocardial infarction size induced by 
ischaemia[225]. Furthermore, loss of myocardial miR-499 inhibits ischaemic post-
conditioning via the programmed cell death 4 (PDCD4)[226] and elevated levels 
have conversely been shown to protect cardiomyocytes from ischaemia via the 
same pathway[227]. MiR-499 has also been implicated in the pathogenesis of 
myocardial hypertrophy and cardiomyopathy[228]. These findings raise the 
intriguing possibility that loss of miR-499 may have a deleterious effect post 
infarction and, if it is subsequently taken up by surrounding viable cardiac myocytes, 
it may have a beneficial effect on the ischaemic penumbra. This hypothesis has 





already been taken forward experimentally, showing miR-499 plays a role in the 
maturation of cardiac fibroblasts to cardiomyocytes in vivo and in vitro 
[229].   
 
Interestingly, the observation of increased concentration of miR-499 in renal tissue 
in a model of myocardial injury has not previously been described (Figure 3.4). Cell-
free circulating miRNAs have been reported to be biologically stable, referring to 
their resilience to breakdown in an RNase rich environment, a function attributed to 
their association with protein complexes and EVs [5]. This led to the hypothesis that 
paracrine miRNA cell-cell signalling could be mediated by EVs [21], an observation 
now reported in a large variety of tissues and disease processes [76-78]. At the time 
of writing, there are no indications that miRNA-protein complexes are implicated in 
miRNA cell-cell signalling. No group has described miRNA cell transfer to distal 
organs in a model of single organ injury. With regard to the role miR-499 may play in 
the kidney, it is possible miR-499 may play a role in cell viability. Predicted miR-499  
KEGG pathway targets  include cell cycle regulation and apoptosis (FoxO pathway 
and p53; Table 3.6); potentially affecting cell viability as demonstrated in 
cardiomyocytes. While no experimental work has been conducted at the proximal 
tubule with regard to miR-499, calcineurin inhibitors are widely used in the treatment 
of minimal change disease, a renal disease process driven by podocytes. MiR-499 
overexpression has been shown to ameliorate podocyte injury by targeting 
Calcineurin Aα and Calcineurin Aβ in a minimal change disease mouse model [230],  
 
Whether the observed increase in miR-499 in renal tissue is due to downstream 
miRNA transfer from heart to kidney or endogenous transcription in the renal tissue 
is yet to be elucidated. Correct interpretation of miRNA source is challenging, since 
the majority of miRNAs are not tissue specific and there are scarce reports of 
prevalence in diseased tissue. Further work regarding, EV uptake /release 
mechanisms affecting the renal tubule and the transcriptomic consequences of 
miRNA transfer will be further investigated in Chapters 4-6. 






The current gold-standard biomarker of myocardial injury, troponin I, is known to 
correlate to both degree of myocardial injury and predict mortality [231, 232]. This 
study therefore compares biomarker performance to a surrogate endpoint and does 
not provide information on prognosis. Myocardial infarction has been noted to cause 
a significant rise in TnI 4-6 hours following injury[233]. Following advent of high 
sensitivity TnI, this biomarker can now diagnose myocardial infarction with 1 hour of 
symptom onset[234]. The observation that TnI levels were elevated 2 hours 
following CAL was therefore unsurprising and the significant TnI rise in the sham 
cohort represented a unique challenge in this study (Figure 3.2). A rise in cardiac 
miRNAs has previously been described in the sham rat model of coronary ligation 
(thoracotomy only)[53], raising concerns regarding the sham cohort as the control 
population. Unfortunately, the presence of miR-133a and miR-1 in skeletal muscle 
ensures muscle injury cannot be accounted if using healthy controls[208], thus 
limiting the use of this CAL model for biomarker kinetic studies. Alternative models 
of myocyte injury have been described in the literature, for example genetically 
manipulating myocardial tissue via vectors to induce targeted myocyte injury. Such 
models include adeno-associated virus serotypes AAV-1, -6 and -8[235]. While 
these models are effective at specifically targeting myocytes, gene expression 
becomes affected 1 week post-transduction, limiting the use of this model for 
biomarker of early myocardial injury[236]. The work presented in Chapter 2 and 3 
confirm the normalisation of the circulating miRNA signature 24 hours after injury 
and therefore a model requiring several days to establish injury is unlikely to be 
suitable. 
3.4.5. Summary 
Circulating miRNAs can predict myocardial injury, translate across human and 
mouse experimental models and may have utility as early diagnostic biomarkers. 
These early diagnostic biomarkers may help to improve specificity of the current 
gold standard biomarker TnI for myocardial infarction, through the development of a 
biomarker panel manipulating the different kinetics affecting these biomarkers of 
interest. MiRNA profiles change in organs distal to the single-organ injury but it is 





not clear if this is as a result of cell-cell miRNA signalling or of endogenous origin. 
This will be investigated in subsequent chapters.  
  










Chapter 4: EV uptake and release from the proximal tubule 
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Urine, the excreted filtrate of the kidney, is unique in providing a non-invasive 
snapshot of the kidney’s function. This filtrate is composed of ions, inorganic and 
organic compounds (including proteins, hormones and metabolites) suspended in 
water. Investigation of the protein fraction of urine has demonstrated the presence 
of integral membrane proteins within EVs [131]. Several subtypes of vesicles have 
been identified in urine, including exosomes and microvesicles [35, 101], containing 
both proteins [102, 135]and nucleic acids [237].  
 
EVs can be identified by transcriptomic and proteomic markers specific to the cell of 
origin [35, 117]. Rigorous characterisation of the EVs protein and RNA content has 
identified molecules unique to all regions of the nephron and products of genes 
associated with renal disease processes and systemic illness [35, 36]. A number of 
studies have demonstrated circulatory EV uptake by tubular epithelial kidney cells 
[238, 239] and identified EVs in urine [139, 240]. The ability of circulatory EVs to 
cross the glomerulus and enter the nephron is not fully understood, raising the 
possibility of repackaging of EV contents as EVs transit across membranes. Within 
the kidney, evidence suggests that EVs may be able to transit intact between cells, 
and through the basement membrane, until the intracellular release of its contents 
[241].  
 
Inter-cellular communication depends upon the ability of EVs to influence a recipient 
cell, either by receptor-mediated interaction, endocytosis of the EV, or fusion of the 
vesicle membrane to the plasma membrane (Figure 1.2). This latter signalling 
mechanism results in delivery of an EV’s contents directly into the cellular 
cytoplasm; including transfer of transcription factors, miRNA, mature RNA and 
infective particles [21, 95, 132, 133]. EV mediated inter-cellular signalling has been 
postulated to explain why PT proteins are present in downstream nephron segments 
[134-136], but this has not yet been conclusively demonstrated in vivo [135]. 
Hypothetically, EVs native to the kidney or derived from the circulation could affect 
the proteome, and therefore function, of a downstream recipient cell within the 





nephron [137]. Therefore, understanding the signalling processes which drive EV 
release and uptake along the nephron is crucial to the translation of EVs as 
therapeutic targets in renal disease. Several mechanisms have been proposed to 
increase EV release from non-renal cells, all largely driven by cellular activation. 
Pro-inflammatory stimuli [242-244], toxins[245], viruses, [241, 246], low sheer 
stress[247], hypoxia[248] and senescence[249] have all been implicated in 
stimulating EV release. Interestingly, purinergic receptor activation has also been 
implicated[95, 250, 251]. While these drivers may affect EV release, it has yet to be 
elucidated what affects EV release by tubular cells.  
 
Factors affecting EV uptake within the nephron are slightly better understood. 
Notably, the exosomal fraction of AQP2 increases in response to desmopressin and 
transfer of EVs from desmopressin-treated cells to untreated cells results in an 
increase of functional AQP2 expression in the recipient cell [129, 138]. Cortical 
collecting duct cells stimulated with vasopressin take up ECVs, in vitro and in vivo, a 
process which can be manipulated to deliver miRNA to collecting duct cells, 
resulting in downregulation of target transcripts [139]. This study demonstrated that 
EV signalling is a physiologically regulated process, which can be manipulated to 
deliver miRNA downstream along the nephron, thus affecting physiological tubular 
function[135, 252]. Interaction of EVs with recipient cells may involve specific 
interaction with primary cilia, as reported with polycystic disease-positive vesicles 
using transmission electron microscopy images [140, 141]. This observation is 
supported by data from a biliary model that demonstrate exosome signalling affects 
ERK signalling, miRNA expression and cell proliferation, with abolishment of this 
signal following removal of cilia [142]. Furthermore, EVs may be transported within 
uromodulin polymers , modulating the interaction between EVs and their target cells 
along renal tubular lumen [135]. 
 
As suggested by Chapter 3, miRNAs may transfer from the circulation to the renal 
tubule. An understanding of the regulatory aspects of EV uptake and release by the 
PT in health is a critical first step in investigating this novel signalling pathway, which 
can be built on to explore the effect of circulating EVs on kidney cells. Several 
physiological agonists of the PT were chosen for this study. These agonists were 





selected as they have well-defined physiological activity at the proximal tubule and 
targeting pathways that may be related to EV uptake and release. Notably, EV 
release has been noted as a consequence of purinergic stimulation in platelets [95], 
dendritic cells [250], and glial cells [251]. EV release at the PT as a consequence of 
purinergic stimulation has not been described.  
 
4.1.2. Objectives 
• Establish an appropriate PT cell model for the study of EV release and 
uptake 
• Identify factors which affect EV release from the PT  
• Identify factors which affect EV uptake by the PT 
  






4.2.1. Cell culture 
4.2.1.1. Previously established cell lines 
Two PT cell lines were used in the following experiments; the HK2 cell line, a HPV-
16 transformed human PT cell line, and the LLC-PK1, a porcine PT cell. 
 
The HK2 cell line was a kind gift from Dr Kenneth Simpson (University of Edinburgh, 
United Kingdom) and grown following previously published methods [253]. Briefly, 
cells were grown in culture medium containing K-SFM (Gibco, CA, USA) 
supplemented with 0.05 mg/ml bovine pituitary extract (BPE) and 5 ng/ml human 
recombinant epidermal growth factor (EGF). The cells were incubated at 37°C and 
maintained in a humidified 5% CO2 atmosphere. The media was changed every 48-
72 hours. 
 
The LLC-PK1 cell line was a kind gift from Dr Karen Chapman (University of 
Edinburgh, United Kingdom) and grown following previously published 
methods.[254] Briefly, cells were grown in culture medium containing Medium 199 
(Gibco, CA, USA) containing 1.5 g/L to 2.2 g/L sodium bicarbonate and 3% 
exosome depleted foetal bovine serum (FBS; System Biosciences, CA, USA). The 
cells were incubated at 37°C and maintained in a humidified 5% CO2 atmosphere. 
The media was changed every 48-72 hours. 
 
Subcultivation processing was similar for both cell lines. Cells were passaged at 
80% confluency, at a subcultivation ratio of 1:4. Passaging was achieved by two x 5 
minute washes with 1 mM EDTA in Dulbecco's phosphate-buffered saline (DPBS) 
followed by incubation in 0.05% (w/v) Trypsin- 0.53 mM EDTA solution (Lonza, 
Basel, Switzerland). Complete growth medium was added, to terminate the reaction, 
and cells were pelleted at 150 x g for 5 minutes. Subsequently, the supernatant was 
removed and cells were resuspended in complete growth medium. Aliquots 
containing 95% culture medium and 5% DMSO were stored in liquid nitrogen. 





4.2.1.2. Primary cell culture 
Primary cell culture method was modified from Richardson et al.[255] [256-258]. 
Briefly, male rats were euthanised using cervical dislocation. Their kidneys were 
removed immediately under aseptic conditions and placed in DMEM/Ham’s F12 
medium with Glutamax (Gibco, CA, US) containing 10% wt/vol FBS (Gibco, CA, 
US), 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco, CA, US) (hereafter 
referred to as isolation medium). After the peri-renal fat was removed, the kidneys 
were decapsulated and the cortex macroscopically dissected. The cortex was 
minced and incubated in serum-free isolation medium containing 1mg/ml 
collagenase I and IV (Sigma Aldrich, Dorset, UK) for 45 minutes in a shaking 
waterbath at 37 °C. The reaction was terminated by washing 3 times in isolation 
medium. The resultant solution was ground in Wheaton mortar and pestle and 
serially sieved to a final filter size of 40µm. The filtered solution was centrifuged at 
27 000 x g through a 48% Percoll gradient (Sigma Aldrich, Dorset, UK) and each of 
the 4 distinct bands (F1-F4; top-bottom) were carefully removed.  
 
Cells contained within the lowermost band (F4) were washed in isolation medium to 
remove residual Percoll and passed through a 40 µm sieve. The cells were 
resuspended in DMEM/Hams’s F12 media with glutamax containing: 5 μg/ml insulin, 
50 nM hydrocortisone, 10 ng/ml EGF, 5 μg/ml transferrin, 50 nM sodium selenite, 10 
nM triiodothyronine, 100 U/ml penicillin, 100 μg/ml streptomycin and 1% (wt/vol) 
exosome depleted FBS (System Biosciences, CA, US) (hereafter referred to as 
culture medium). The suspension was plated onto collagen-coated 35-mm tissue 
culture dishes (Corning, NY, US) and maintained in an incubator under humidified 
5% CO2 atmosphere at 37 °C. The culture media was replaced after 48 hours and 
every 48 hours thereafter. 
4.2.2. Validation of primary cell culture 
4.2.2.1. Alkaline phosphatase activity 
After the Percoll gradient stage of the primary cell culture method, cells from each of 
the 4 bands were washed in isolation medium and cultured in culture medium for 48 
hours. Cells were subsequently washed 3 times in DPBS, lysed in 500 µL assay 
buffer (Abcam, Cambridge, UK) and incubated at 4 °C for 10 minutes. The 





solubilised sample was subsequently centrifuged at 12,000 x g at 4 °C for 3 minutes 
to remove any insoluble material. A small aliquot of each sample was taken for 
protein quantification, using bicinchoninic acid assay (BCA) protein assay kit as per 
the manufacturer’s instructions (Thermo Scientific, Perth, UK). Samples were 
subsequently normalised to protein concentration and immediately processed using 
an alkaline phosphatase colorimetric assay kit (Abcam, Cambridge, UK), as per the 
manufacturer’s instructions.  
4.2.2.2. Western blotting 
4.2.2.2.1. Protein extraction from cells 
Cells from each band were resuspended in ice-cold  
Radioimmunoprecipitation assay (RIPA) buffer (Sigma Aldrich, Dorset, UK) 
containing protease inhibitor (Roche, 1 tablet per 10ml). Cells were lysed by 
repeated passage through a 21 G needle and then incubated on ice for 15 minutes. 
Lysates were centrifuged at 16,000 x g for 15 minutes at 4 °C and then the 
supernatant was stored at -80 °C. The protein concentration of each sample was 
determined in duplicate using the BCA Protein Assay Kit (Thermo Scientific, Perth, 
UK).  
4.2.2.2.2. Gel electrophoresis and electrophoretic transfer 
Protein samples were mixed 1:1 with 2 × Laemmli buffer (giving the following final 
concentrations: 62.5 mM Tris-Cl pH 6.8, 2 % sodium dodecyl sulfate (SDS), 10 % 
vol / vol glycerol, 0.1 mg/ml bromophenol blue, 100 mM dithiothreitol (DTT)), heated 
to 100 °C for 2 - 10 minutes and then loaded immediately into the wells of the 12% 
Tris-HEPES gel (Precise, ThermoScientific, Perth, UK). Samples were 
electrophoresed at 100 V for 45 minutes. After equilibrating the gel and an 
Amersham Hybond polyvinylidene difluoride (PDVF) membrane (GE Healthcare, 
Buckinghamshire, UK) in Towbin transfer buffer (25 mM Tris, 192 mM glycine, 0.1 % 
SDS and 20 % v/v methanol), samples were transferred to the membrane using a 
BioRad Trans-Blot semi-dry electrophoretic transfer cell (at 10 V for 30 minutes).  
4.2.2.2.3. Western Blotting 
Membranes were incubated with blocking buffer (5 % w/v non-fat dry milk powder / 
0.2 % v/v Tween-20 in PBS) on a rolling shaker at room temperature for 1 hour and 





then incubated with primary antibody overnight at 4 °C. After three five-minute 
washes with wash buffer (0.2 % v/v Tween-20 in PBS) the membrane was 
incubated with an HRP-conjugated secondary antibody for 1 – 2 hours at room 
temperature and then washed again (three x ten minute washes). Peroxidase 
activity was revealed using SuperSignal ® West Pico Chemiluminescent Substrate 
(Thermo Scientific, Perth, UK) as per the manufacturer’s instructions and 
membranes were exposed to photographic film for 1 – 30 minutes.  
 
Gels and films were placed on a light-box and photographed using a digital SLR 
camera (Nikon D40), with the exposure set to maximize dynamic range without 
significant pixel saturation. Antibodies used are demonstrated in Table 4.1. 
  















NHE3 Rabbit Abcam AB95299 1000 mg/ml 1:1000 
Secondary Antibodies 




 1:2000  
 
 
Table 4.1: Primary and secondary antibodies used for Western blotting. 
 All antibodies were polyclonal.  
  





4.2.2.2.4. Coomassie blue staining 
Gels were incubated on an orbital shaker with Coomassie blue staining solution 
(250 mg/L Coomassie Brilliant blue R in de-staining solution I; Bio-Rad, CA, US) for 
4 hours. The bulk of the stain was removed by incubating with de-staining solution I 
(40 % methanol / 7 % acetic acid) for 30 minutes. The gel was then placed in de-
staining solution II (5 % methanol / 7 % acetic acid), which was changed every 12 
hours until a clear background was obtained (typically after 24 hours).  
4.2.2.3. Confocal microscopy 
Primary proximal tubule (PPT) cells were grown on a cover slip. Cells were fixed 
with 4% PFA for 15 minutes at room temperature, washed in PBS, and 
subsequently permeabilised with 0.3% triton for 10 minutes. Cells were incubated 
with 20% goat serum for 1 hour then co-incubated with 15µg/ml KIM-1 goat-antibody 
(AF3689, R&D Systems, MN, USA) for 16 hours at 4 °C. The following day, the cells 
were co-incubated with the 0.2% v/v donkey anti-goat antibody conjugated with 
Alexa 488 (A11055, Thermo Fisher, UK) and/or 0.1% v/v phalloidin conjugated to 
Alexa 594 (A12381, Thermo Fisher, UK) at room temperature for 20 minutes. 
Immediately prior to imaging, cells were stained with 0.1% v/v 4',6-diamidino-2-
phenylindole (DAPI) for 10 minutes and washed with PBS. 
 
Images were captured using a confocal laser scanning microscope (LSM 710, 
Zeiss, Cambridge, UK). Images were collected with a 60x oil immersion objective 
lens and acquired using ZenPro Software (Zeiss, Cambridge, UK). Image analysis 
was performed using Image J software. Each picture was acquired with laser 
intensities and amplifier gains adjusted to avoid pixel saturation and analysed using 
Image J 2016 (National Institutes of Health, Maryland, US).  
4.2.3. PT cell stimulation with physiological agonists 
Agonists were added to fresh cell media for up to 48 hours (as specified for each 
experiment). For EV uptake experimentation, agonists and QDot loaded EVs were 
added simultaneously to the cell media. Methodology for QDot loading described in 
Section 4.2.6.1. The doses used were informed by previously published PT cell 
studies investigating signalling provoked by MeSADP [259], angiotensin II [260], 
fenoldopam[261] and forskolin[262].  

















Purinergic receptors P2Y1, 
P2Y12 and P2Y13 












Ionophore (positive control) Ca2+ 1 μM 
Fenoldopam Sigma 
SML0198 
Dopamine receptor D1  
 
cAMP 1 μM 
Forskolin Sigma 
F6886 
Directly activates eukaryotic 
adenylyl cyclase (positive 
control) 
cAMP 10 μM 







Purinergic receptor P2Y1  1 nM 
Table 4.2: Agonists and antagonist used in cell culture 
  





4.2.4. Assessing response of proximal tubule cells to physiological 
agonists 
4.2.4.1. cAMP concentration 
Cells were grown to 70% confluency, washed twice in PBS and replaced with fresh 
culture media (warmed to 37°C). Cells were stimulated with agonists for 10 minutes 
and immediately washed in ice-cold PBS. Samples were processed according to 
manufacturer’s instructions using ParameterTM cAMP colorimetric assay (R&D 
Systems, MN, USA). All biological samples were processed in triplicate. 
4.2.4.2. Calcium flux  
Cells were washed twice in room temperature DPBS followed by incubation in 
0.05% (w/v) Trypsin- 0.53 mM EDTA solution (Lonza, Basel, Switzerland). Complete 
growth medium was added, to terminate the reaction, and cells were pelleted at 150 
x g for 5 minutes. Subsequently, the supernatant was removed and cells were 
resuspended in cell loading media (CLM; 1 mM calcium chloride, 1 mM KCl, 1 mM 
MgSO4 and 0.5% v/v BSA; pH 7.35). Cells were incubated with 2 µM Indo-1 AM 
(Invitrogen, CA, US) for 30 minutes at 37°C. Cells were then pelleted at 400 x g for 
5 minutes and resuspended in CLM. Total cell fluorescence was measured by flow 
cytometry on a 5LSR Fortessa cytometer (BD Biosciences, Oxford, UK). Cells were 
excited with a violet laser (405 nm) and their emission was detected using 530/30 
(Indo-1 blue) and 440/40 (Indo-1 violet) band pass filters, respectively. Gates were 
set using unstained cells, 1,000,000 events were recorded for each sample and flow 
rate was set at 200 events/second. For each experiment, 10,000 events were 
recorded prior to introduction of agonist. 2 mM ethylene glycol-bis(β-aminoethyl 
ether)-N,N,N',N'-tetraacetic acid (EGTA) and 1µM ionomycin (Sigma Aldrich, Dorset, 
UK) were used as negative and positive controls, respectively. 
 
Flow cytometry data were analysed with FlowJo LLC software version 8 (FlowJo 
LLC, Oregon, USA). The population of interest identified using FSC/SSC parameter 
and samples analysed as time vs mean fluorescence (Indo 1 (violet)/Indo-1 (blue)). 
The results are presented as the percentage of total fluorescent cells. Results are 
demonstrated as percentage change in peak fluorescence from baseline. 





4.2.5. EV release in response to physiological agonists 
4.2.5.1. Particle size and concentration distribution measurement 
with NTA 
At the appropriate time point, media was removed from the cells and centrifuged at 
300 x g for 5 minutes to remove cell debris. The supernatant was isolated and 
stored at -80°C, if not processed immediately. Nanoparticles within the supernatant 
were analysed using the NanoSight LM 10 instrument (NanoSight Ltd, Amesbury, 
UK) allowing simultaneous estimation of size, size distribution and concentration of 
dilute suspensions of nanoparticles. Using a 532 nm (green) diode laser beam a 60 
second video was taken with a frame rate of 30 frames/second and particle 
movements were analysed by NTA software. Each experiment was carried out in 
triplicate. All experiments were carried out at a 1:100 dilution, yielding particle 
concentrations in the region of 1x108 particles/ml in accordance with the 
manufacturer’s recommendations. All samples were analysed in triplicate. In each 
run, fresh samples were injected three times and measurements were performed 
following each injection. Standard deviations were determined from concentrations 
obtained from replicate runs.  
 
NTA software provides the number of particles of each size between 10-1000 nm. 
The AUC for the size range of interest was calculated using the trapezoidal rule, 
with values increasing incrementally on the x-axis, and expressed as the sum of the 
individual trapezoids. 
 
4.2.6. EV uptake in response to physiological agonists 
4.2.6.1. Isolation and dye loading of EVs 
As described previously[129], culture media from PPT cells was vigorously vortexed 
then centrifuged at 15,000 x g for 10 minutes to pellet any cells, large membrane 
fragments and other debris. The supernatant was then centrifuged at 200,000 x g 
for 60 minutes to pellet the EV fraction. The pellet was washed with PBS and then 
re- centrifuged at 200,000 x g for 60 minutes before final resuspension in PBS. 
Pelleted EVs were conjugated with Cell Tracker 655 (Invitrogen, CA, US) following 





the manufacturer’s protocol. Briefly, pelleted EVs were incubated with the Cell 
Tracker 655 conjugate in 200μl fresh culture media for 1 hour at 37°C. The EV pellet 
suspension was washed twice with fresh media before being put back on confluent 
cells.  
 
EV size distribution was confirmed by NTA of a 1:1000 dilution of Cell Tracker 655 
conjugate. Dye loaded EVs were co-incubated with cells at a concentration of 250 x 
108/ml media. 
4.2.6.2. Flow cytometry for total cell fluorescence 
Following trypsinisation, cells were resuspended in PBS and briefly stained with 
1μM DAPI nucleus stain (Sigma Aldrich, Dorset, UK). Total cell fluorescence was 
measured by flow cytometry on a 5LSR Fortessa cytometer (BD Biosciences, 
Oxford, UK). Particles were excited with a violet laser (405 nm) and emission 
detected using 450/50 and 630/70 band pass filters, respectively. Gates were set 
using unstained cells and cells stained with DAPI alone. Flow cytometry data were 
analysed with FlowJo LLC software version 8 (FlowJo LLC, Oregon, USA) and the 
results are presented as the percentage of total fluorescent cells and mean cell 
fluorescence. 
4.2.7. Data evaluation and statistical analysis 
Where possible data were presented as Tukey box plots. Tukey box plots consist of 
4 parameters; box ends at the quartiles Q1 and Q3, median as a horizontal line in 
the box, ‘whiskers’ to the farthest points that are not outliers (i.e. within 3/2 times 
the interquartile range of Q1 and Q3) and dot plot of outliers. Data were analysed 
using GraphPad PRISM (version 6.03 for Windows, GraphPad Software, San 
Diego, USA) and a P-value < 0.05 was considered statistically significant. When 
testing for a difference in the means of more than two datasets (e.g. EV release in 
response to physiological agonists) a one-way ANOVA and post-hoc comparison 
using Tukey’s multiple comparison test was used. When datasets were influenced 
by more than one factor (i.e. EV uptake as affected by time and agonist) a two-way 
ANOVA with Tukey’s multiple comparison test was utilised. 
  






4.3.1. Validation of primary proximal tubule cells 
In order to investigate the PPT cells, cell monolayers from each Percoll fraction 
were investigated for archetypal morphological, enzymatic and proteomic features. 
After 48 hours in culture, cultured cells from F4 exhibited the cobblestone-like 
phenotype characteristic of epithelial cells (Figure 4.1d) more prominently than cell 
monolayers from the other fractions (Figure 4.1a-c). The enzymatic activity 
associated with each fraction is depicted in Figure 4.2. Cells cultured from the F4 
Percoll fraction demonstrated significantly higher alkaline phosphatase activity in 
comparison to cells from the 3 other Percoll fractions (alkaline phosphatase activity 
within cell lysate was normalized to total protein to take into account differences in 
total cell number). Furthermore, NHE3 was associated with cells isolated from 
Percoll bands F3–F4 (Figure 4.3), a protein marker specific to the PT and thick 
ascending limb[263]. Due to animal numbers needed for each experiment, this 
experiment was run once, inhibiting quantitative statistical analysis.  
 
Cells cultured from F4 retained morphological, enzymatic and proteomic features of 
PT cells and were therefore taken forward as representative of PPT cells. To 
conclude cell validation, confocal microscopy was conducted on the PPT cells. 
Figure 4.4 depicts cobble-stoned cells, articulating with actin, containing KIM-1 
(another archetypal proteomic marker of the PT). 
  













Figure 4.1: Bright-field micrograph of primary renal cell preparations in 
culture. 
Cells isolated from Percoll fractions were grown in culture medium for 48 hours. 
Bright-field microscopy of cell monolayers from F1 (a), F2 (b), F3 (c) and F4 (d). 
Each image is representative of 3 samples from each fraction. 
  






Figure 4.2: Cultured primary renal cells retain alkaline phosphatase activity. 
Alkaline phosphatase activity was retained in cultured cells, isolated from Percoll 
bands F1-4. Cultured cells within F4 had significantly higher alkaline phosphatase 
activity than the 3 other bands, when normalized to total protein. Data are shown as 
Tukey boxplots, n=4. Statistical significance was determined by one- way AVOVA 
with Tukey’s multiple comparison test. 
  

























Figure 4.3: Western blots to estimate the abundance of NHE3 in primary renal 
cells.  
Cells were isolated from each Percoll fraction and homogenized. 12 µg of protein 
was loaded per lane. Gels were in duplicate allowing for a Coomassie blot to 
provide loading controls. A) Western blot to detect total NHE3 (NHE3 band detected 











































Figure 4.4: Confocal image of F4 cell monolayer confirms expression of 
archetypal proximal tubule proteins. 
Images a-c indicates actin, KIM-1 and nuclear (DAPI) staining, respectively. 
Amalgamated image (d) shows KIM-1 (green), nuclei stained with DAPI (blue) and 
actin within the cell membrane (red). Images are representative of 3 samples. Scale 
bars are 20 μm.  





4.3.2. Cultured cell response to physiological agonists 
Firstly, HK2, LLC-PK1 and PPT cells were interrogated for an appropriate response 
to known physiological agonists of the PT by assessment of their secondary 
messengers. Data pertaining to the effect of fenoldopam on cAMP concentration are 
presented in Figure 4.5a. The intracellular Ca2+ responses to MeSADP and 
angiotensin II (Dmean fluorescence) are presented in Figure 4.5b. 
 
No difference in cAMP concentration within HK2 cells could be detected following 
stimulation with fenoldopam or vehicle (Figure 4.5a). Likewise, HK2 intracellular 
Ca2+ concentrations remained unchanged when stimulated with MeSADP and 
angiotensin II (Figure 4.5b). In both experimental designs, cAMP and Ca2+ 
intracellular concentrations significantly increased in response to the relevant 
positive controls, forskolin and ionomycin, respectively.  
 
By contrast, the cAMP concentration within LLC-PK1 and PPT cells in the 
fenoldopam treated group significantly increased, in comparison to vehicle (Figure 
4.5a). Similarly, MeSADP and angiotensin II elicited an increase in intracellular Ca2+ 
in both the LLC-PK1 and PPT cell lines (Figure 4.5b). 
  






Figure 4.5: Effect of physiological agonists on cultured proximal tubule cells. 
Assessment of cellular secondary messenger response to known physiological 
agonists of the PT. Cultured cells were challenged with vehicle (PBS; blue), 
fenoldopam (1 µM; pink) or forskolin (10 µM; yellow) for 10 minutes, prior to 
assessment of cAMP concentration (Figure a; n=4, data expressed as absolute 
value (pmol)). Total cell calcium concentration was viewed in real time following 
introduction of vehicle (PBS; blue), MeADP (100 µM; pink), angiotensin II (50 nM; 
yellow) or ionomycin (1 µM; purple) (Figure b; Dmean fluorescence) (Tukey box 
plot). Statistical significance was determined by 1 way ANOVA with Tukey multiple 
comparison to vehicle within the same cell line (n=3).   









































































4.3.3. Effect on EV release by physiological agonists 
EVs were considered in 3 cohorts: total EV population (20-1000 nm diameter), 
exosome population (20-100 nm diameter) and microvesicle population (100-500 
nm), corresponding to i, ii and iii in the following figures. Example EV particle size 
range in cell culture supernatant is shown in Figure 4.6. EV release in response to 
agonist stimulation was examined in all 3 cell lines (Figure 4.7a-d) and the following 
findings observed: 
 
• Angiotensin II stimulation resulted in significantly fewer EVs to be released 
from LLC-PK1 and PPT cells 24 hours after stimulation (Figure 4.7a-i). This 
corresponded to changes seen in the exosome cohort (Figure 4.7a-ii). 
Notably, there was not a consistent temporal response, as no significant 
changes were seen 48 hours following stimulation.  
• MeSADP stimulation resulted in significant increase in EV release from LLC-
PK1 cells after 48 hours, and from PPT cells 24 and 48 hours following 
stimulation (Figure 4.7b-i). These changes were all described in the 
exosome cohort (Figure 4.7b-ii) and an increase in the microvesicle 
population was also observed in the LLC-PK1 group (Figure 4.7b-iii). 
• Significant changes were noted within the LLC-PK1 and PPT cell lines 
following stimulation with fenoldopam (Figure 4.7c). These changes were not 
consistent across cell lines, nor was there a temporal response.  
• Direct activation of adenylyl cyclase with forskolin, with corresponding 
intracellular cAMP increase, did not result in any significant change in EV 
release within HK2 and LLC-PK1 cell lines (Figure 4.7d).  
• No significant changes were noted in HK2 cell EV release within any of the 
cohorts in response to the physiological agonists(Figure 4.7a-d).  
• Interestingly, fewer microvesicle particles were released from PPT cells in 
comparison to HK2 and LLC-PK1 cell lines. This effect was seen across the 
experimental groups as defined by agonist (Figure 4.7a-c). 
  







Figure 4.6: Size distribution of EVs released from primary proximal tubule 
cells in culture 
Mean particle size range (nm) of EVs in cell culture supernatant following 48 hours 
in culture. N = 12 
  
















































Figure 4.7: EV release is under physiological control 
Cell culture media was collected at predefined time points following cell stimulation. 
0, 12, 24. 48 corresponds to number of hours following stimulation with vehicle (v) or 
agonist (A). Cultured cells were challenged with angiotensin II (50 nM; Figure 4.7a), 
MeADP (100 µM; Figure 4.7b), fenoldopam (1 µM; Figure 4.7c), or forskolin (10 µM; 
Figure 4.7d) (mean±SD). EVs were considered in 3 cohorts: total EV population (20-
1000 nm diameter), exosome population (20-100 nm diameter) and microvesicle 
population (100-500 nm), corresponding to i, ii and iii. The vehicle control for each 
time point is shown in light blue, red corresponds to HK2 cells, yellow to LLCPK1 
and dark blue to primary proximal tubule. Statistical significance was determined by 
1-way ANOVA with Tukey’s multiple comparisons test within each cell line (n=3).  



















































































































Figure 4.7 (cont.) 
  





















































































































Figure 4.7 (cont.) 
  





















































































































Figure 4.7 (cont.) 
  













































































































The EV release in response to MeSADP was further examined in the presence of 
the purinergic receptor P2Y1 antagonist, MRS. As expected, stimulation with 
MeSADP alone resulted in an increase in vesicles within the exosome cohort, an 
increase abolished in the presence of P2Y1 antagonist (Figure 4.8). Notably, 
stimulation with MRS alone did not have any effect on EV release within any of the 
cohort. 
  







Figure 4.8: P2Y1 antagonism inhibits purinergic driven EV release 
LLC-PK1 cells were stimulated with MeSADP and/or MRS for 48 hours, prior to 
isolation of the cell medium. EVs were considered in 3 cohorts: total EV population 
(20-1000 nm diameter), exosome population (20-100 nm diameter) and microvesicle 
population (100-500 nm), corresponding to i, ii and iii. Statistical analysis was 
conducted using 1-way ANOVA with Tukey’s multiple comparisons test (n=6). 
  




























































































4.3.4. Effect on EV uptake by physiological agonists 
Using confocal microscopy, PPT cells uptake dye-loaded EVs when co-cultured for 
48 hours (Figure 4.9). The mean particle size range of isolated EVs is demonstrated 
in Figure 4.10. 
 
To quantify temporal EV uptake, flow cytometry was utilised to describe EV uptake 
by PPT cells (Figure 4.11a&b; percentage cell uptake and mean cell fluorescence, 
respectively). Using the same methodology, EV uptake in response to PT agonists 
was also studied. 
 
Significantly more PPT cells take up EVs over time (12 hours vs 48 hours co-
incubation; mean percentage fluorescent cells of total 4.67 vs 14.25; 1 way ANOVA 
with Tukey multiple comparison p<0.01; Figure 4.11a), correspondingly affecting the 
average fluorescence of the PTT cells (12 hours vs 48 hours; mean fluorescence 
intensity 2393 vs 3604; 1 way ANOVA with Tukey multiple comparison p<0.05; 
Figure 4.11b).  
 
There were no significant differences in cell uptake of EVs by PTT cells between the 
experimental groups (i.e. vehicle vs angiotensin II vs MeSADP vs fenoldopam) as 
defined by percentage cell uptake or mean fluorescence intensity (Figure 4.11a&b).  













Figure 4.9: Confocal image of PPT cells confirm EV uptake. 
PPT cells were co-cultured with dye-loaded EVs for 48 hours prior to analysis. 
Images a-c indicates EV, KIM-1 and nuclear (DAPI) staining, respectively. 
Amalgamated image (d) shows ECV (red), nuclei stained with DAPI (blue) and KIM-
1 (green). Images are representative of 3 samples. Scale bars are 20 μm. 
  







Figure 4.10: Size distribution of primary proximal tubule EVs following 
ultracentrifugation 
Mean particle size range (nm) of EVs isolated from cell culture supernatant following 
ultracentrifugation protocol. N = 3 
  






























Figure 4.11: EV uptake is not under physiological control 
Cells were incubated with dye-loaded EVs and stimulated with the appropriate 
agonist for a predefined time period (angiotensin II, pink, 50 nM; MeSADP, yellow, 
100 µM; Fenoldopam, purple, 1 µM; and vehicle, PBS, blue). The raw data is 
presented above as %fluorescent cells of total population (Figure a) and mean 
fluorescent intensity (Figure b) (Tukey box plot). There are no significant differences 
between groups at each time point; 2-way ANOVA with Bonferroni’s multiple 
comparisons test (n=5). 
 
  





























































4.4.1. Main findings 
The main findings of Chapter 4 were: 
• Cultured PPT cells retain morphological, enzymatic, proteomic and 
physiological features consistent with PT cells. 
• Our HK2 cell line did not reliably model PT cells. 
• P2Y1 stimulation increases EV release from PT cells. 
• PT cells uptake more EVs over time, a process unaffected by physiological 
agonists.  
4.4.2. Established immortalised proximal tubule cell lines do not 
reliably model primary cells with regard to EV biology 
Improvement of our understanding of the drug transport mechanisms affecting the 
PT has been impaired by challenges in establishing reliable in vitro models. An 
immortalised PT cell line would be the ideal model; ensuring reproducibility, 
decreasing variance and reduce the number of animals required for primary cell 
culture. This issue is further complicated by species differences in expression levels 
of key PT receptors [264] and the drive towards establishing an immortalised human 
PT cell line is therefore understandable. The HK2 cell line has been extensively 
used since 1994 [253]. In this original paper, HK2 cells demonstrated a secondary 
messenger (protein kinase C) response to fenoldopam and angiotensin II, although 
similar results could not be reproduced in this chapter (Figure 4.5). Since their 
introduction, HK2 cells have been recommended and used extensively in 
cytotoxicity research [265], despite scarcity in receptor transport studies. Critically, 
with regard to future work in later chapters, PT cells do not express OCT2 mRNA, 
the receptor required for transport of cisplatin into the PT [266]. This published work, 
taken together with the findings in this chapter, would suggest that the HK2 cell line 
is of limited value in cytotoxicity studies. This may explain why LLC-PK1 cells 
continue to be used for research in drug transport studies. Established in 1976 
[267], the LLC-PK1 cells have been used extensively in PT drug transport 
investigation and have crucially been shown to retain functional OCT2 [268]. In 
addition to their appropriate secondary messenger response to known PT agonists 
(Figure 4.5). They also retain function of the endocytic-receptor megalin [269]. This 





is of particular interest, given the hypothesis of miRNA cell-cell transport is 
dependent upon the endocytosis of EVs. 
Despite the favourable findings with regard to the LLC-PK1 cell line, establishing a 
methodology to isolate PPT was critical for 2 reasons. Firstly, the mechanisms 
underpinning EV signalling at the PT have yet to be elucidated. It is therefore 
paramount the chosen model reflects a native PT cell as closely as possible. 
Secondly, the ultimate goal of investigating circulating EV uptake would derive EVs 
from mice models of single-organ injury. Using a murine PT model would be 
preferable, to overcome any potential species variation in EV targeting and uptake. 
Consequently, the demonstration that PPT cells retain morphological (Figure 4.1), 
enzymatic (Figure 4.2), proteomic (Figure 4.3) and physiological features (Figure 
4.5) consistent with PT  cells would suggest they are a suitable model for EV 
signalling. 
4.4.3. P2Y1 stimulation affects EV release 
MeSADP purinergic receptor stimulation increased EV release from both the LLC-
PK1 cell line and the PPT cells (Figure 4.7bi). This increase was in the exosome 
size range of vesicles in both cells lines when stimulated with MeSADP (Figure 
4.7ii). This finding is consistent with other work describing purinergic stimulation 
resulting in exosomes release from other tissues [95, 250, 251]. This is the first 
description of PT EV release being driven by purinergic stimulation, specifically 
P2Y1 activation (Figure 4.8).  
 
ATP-sensitive P2 receptors have been described in all mammalian nephron 
segments [270], specifically P2Y1 receptors have been described in the PT[271]. 
P2Y receptors are G-protein-coupled and are activated by adenosine and urodine 
nucleotides (ATP, UTP, ADP, UDP). Renal cells have been proposed to 
physiologically release ATP and UTP into the extracellular space via exocytosis 
[272] and pathologically, when released by lytic dying or injured cells. Purinergic 
stimulation of the PT has been implicated in inhibition of sodium transporters PT 
[273, 274]. How purinergic driven exosome-release contributes to PT physiology, as 
yet, remains unclear. None of the other agonists investigated consistently affected 
the rate of EV release by PT cells (Figure 4.7).  






Despite not being the focus of the investigation, fewer microvesicle particles were 
released from PPT cells in comparison to HK2 and LLC-PK1 cell lines. This effect 
was seen across all the experimental groups as defined by agonist (Figure 4.7a-c). 
Increased cell activation as a result of viruses has previously been described to 
increase EV release [241, 246]. Together with the work described in this chapter, 
these findings raise concerns about the validity of immortalised cell lines in the 
investigation of EV signalling.  
4.4.4. Limitations 
Isolation and identification of a pure exosome or microvesicle sub-population is 
notoriously challenging, largely because sub-populations are defined by their 
biogenesis and not an identifiable, physical characteristic. Using size discrimination 
methodologies, for example NTA, will result in some misclassification of vesicle 
origin, in part because of the size overlap between the vesicle sub-populations. This 
problem is a challenge in EV research and due to lack in consistency in isolation 
and identification techniques, there is often great difficulty in discerning which 
vesicle subpopulation is being discussed in published work. The International 
Society of Extracellular Vesicles has proposed the minimal experimental 
requirements required to define a exosome subpopulation [103] The requirements 
state that firstly, exosomes must be purified from extracellular fluid in manner 
limiting disruption to cells; secondly, at least three proteins expected and not 
expected of exosomes should be identified; and thirdly, indication of heterogeneity 
using 2 different methodologies must be used e.g. EM and NTA. Our previous 
validation of NTA provides confidence that the vesicles are exosomes but further 
validation would be required for certainty.  
4.4.5. Summary 
PPT cells retain features consistent with PT cells and are a valid study model for EV 
signalling. Conversely, the HK2 cell line is not an appropriate model for this context. 
In health, purinergic stimulation of PT cells via P2Y1 results in release of small 
vesicles, consistent with exosomes. No tested stimulant affected EV uptake by PT  
cells. Having investigated EV release in health, the next chapter investigated the 
response to injury.   











Chapter 5: Effect of proximal tubule cell injury on EV uptake 
and release 
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Despite decades of research, the prevalence of AKI remains high and this disease 
has no effective therapy [275]. The kidney is vulnerable to a plethora of injury 
modalities. High oxygen demand and low tissue oxygen tension in the renal 
parenchyma sensitise tubular cells to hypoxia and this can lead to acute and chronic 
kidney injury. Furthermore, tubular cells are vulnerable to the toxic effects of drugs 
because of the kidney’s role within the body. High intracellular drug concentrations 
are attributed to increasing intra-tubular concentrations as the filtrate moves along 
the nephron and the reuptake mechanisms for solutes (which are often renal 
segment specific). The presence of toxic metabolites is also implicated in the 
pathogenesis of AKI. Cisplatin is a chemotherapeutic agent used for the treatment 
of solid-organ tumours [276]. Despite its high success rate, its use is limited by the 
incidence of AKI [276]. In PT cells, low dose cisplatin causes mitochondrial 
dysfunction and activation of the extrinsic and intrinsic apoptotic pathway; at higher 
doses this mechanism is overwhelmed and necrosis becomes the principal cell 
death pathway[277]. Understanding of the underlying molecular signalling is 
important for prevention of toxicity and treating established kidney injury [130]. 
 
EV signalling between renal cells has been implicated in the pathogenesis of acute 
kidney injury (AKI). For example, EVs from injured tubular cells transfer TGF-b1 
mRNA into fibroblasts, resulting in cell activation [143]. In vitro, vesicles appear to 
be important in mediating vascular smooth muscle cell calcification, a potential 
mechanism for accelerated vascular calcification in end stage renal disease [144]. 
Dominguez, et.al have recently described the potential for renal tubule-derived EVs 
to protect against ischaemic PT injury in vivo. [239]. EVs administered intravenously 
after the onset of renal ischemia improved multiple parameters of renal structure, 
function, and the cellular transcriptome profile. This effect was more pronounced 
with EVs derived from ischaemic-preconditioned cells, in comparison to control EVs 
from healthy cells. 
 





EVs have been implicated in other pathophysiological processes affecting the 
kidney. Renal brush border-derived exosomes can induce calcium oxalate 
crystallization in nephrolithiasis and may have a role in renal stone disease, a 
mechanism yet to be demonstrated in vivo [163]. EVs may also act as antibacterial 
immune effectors, mediating the host response to urinary tract infection by inhibiting 
growth of pathogenic and commensal Escherichia coli and inducing bacterial lysis 
[161]. This highlights the multimodality capacity of EVs in therapeutics, specifically 
their potential as novel antibiotics for urinary tract infections, a common illness 
affecting 150 million patients annually [162].  
 
Despite the observation that EVs propagate pathophysiological processes, 
mechanisms underpinning EV-cell interaction and EV internalisation remain unclear. 
Interestingly, EVs may have natural targeting capacity, presumably by receptor-
ligand binding [164-166]. Recent work, conducted by Hoshino et al. [167] 
demonstrated that tissue-specific uptake of EVs is mediated by distinct integrins via 
their interaction with the extracellular matrix of the target tissue. Manipulation of this 
mechanism, through therapeutic targeting of these integrins, reduced EV uptake 
and impeded metastatic spread of cancer. This ability to predict the metastatic 
course of cancer raises the exciting possibility of prediction and redirection of 
tumour progression. EV signal manipulation in vivo, to target exogenous vesicles to 
the tissue of interest through delivery of miRNA and siRNA, has already been 
demonstrated, ultimately affecting downstream gene expression [169, 170]. A 
similar mechanism could also be responsible for EV signalling along the nephron 
and the observation of proximal tubular specific proteins in distal segments raises 
the possibility this process occurs in vivo. Following EV-cell interaction, there are 
several proposed mechanisms for EV internalisation, including: direct delivery of the 
EV cargo to the cellular cytosol by fusion with the recipient cell membrane or 
through phagocytosis, macropinocytosis or clathrin-mediated endocytosis [278-281] 
(Figure 1.2). Notably, EV phagocytosis has been described as dependent upon the 
actin cytoskeleton and phosphatidylinositol 3-kinase [279]. KIM-1 is a 
phosphadylserine receptor, expressed on the apical surface of the PT, and is 
robustly induced in injury [282] . This receptor confers a phagocytic phenotype to PT 





cells [283] and may responsible for the engulfment of apoptotic cells [284] and 
albumin [285], consequently posing an attractive target for EV internalisation. 
5.1.2. Objectives 
• Identify effect of nephrotoxic injury on EV release from the PT 
• Identify effect of nephrotoxic injury on EV uptake by the PT 
• Investigate the role of KIM-1 on PT EV uptake   






5.2.1. Cell culture 
Murine PPT cells were isolated and cultured as detailed in section 4.2.1.2.  
5.2.2. Cell viability, necrosis and apoptosis analysis 
Cells were seeded on a 96-well plate at a cell density of 5x103 cells/well in 100 μL 
serum-free medium for 48 hours. These cells were washed 3 times in PBS and the 
100 μL serum-free medium was replaced. Temporal- and dose-response evaluation 
of cisplatin (Cambridge Bioscience, Cambridge, UK) to PPT cells was performed at 
37 °C. Cisplatin was re-constituted from powder using PBS and stored at -20 °C for 
a maximum of 1 week. The following protocols were used to ascertain cell viability, 
necrosis and apoptosis. 
5.2.2.1. Luciferase cell viability assay 
The plate and its contents were equilibrated at room temperature for ~30 minutes. 
100 μL of the CellTiter-Glo® Reagent (Promega, Wisconsen, USA) was added to 
each well, mixed on an orbital shaker for 2 minutes and then allowed to incubate at 
room temperature for 10 minutes. Luminescence was recorded with an integration 
time of 0.5 seconds per well using the Infinite® M1000 PRO (Tecan, Männedorf, 
Switzerland) microplate reader. 
5.2.2.2. MTS cell viability assay 
CellTiter 96® Aqueous Assay Reagents solution (20μL)( Promega, Wisconsen, 
USA) was added to each well and incubated for 60 minutes at 37 °C. The 
absorbance at 490 nm was recorded using a colorimetric plate reader. 
5.2.2.3. Caspase 3/7 apoptosis assay 
Apo-ONE® Homogeneous Caspase-3/7 Reagent (100 μL) (Promega, Wisconsen, 
USA) was added to each well. The contents were gently mixed using a plate shaker 
for 30 seconds and the content incubated for 60 minutes at room temperature. 
Using the T Infinite® M1000 PRO (Tecan, Männedorf, Switzerland) microplate 
reader, fluorescence was measured in each well (499±10 nmEx/521±10 nmEm). 





5.2.3. EV release in response to cisplatin 
5.2.3.1. Particle size and concentration distribution measurement  
Particle size and EV concentration of media was ascertained using NTA technology 
as defined in Section 4.2.5.1. 
5.2.4. EV uptake in reponse to cisplatin 
5.2.4.1. EV isolation and dye loading of EVs 
EV isolation and dye loading of PPT EVs was conducted as described in Section 
4.2.6.1. 
5.2.4.2. Flow cytometry for total cell fluorescence 
Section 4.2.6.2 describes the methodology employed for quantifying total cell 
fluorescence using flow cytometry. 
5.2.5. KIM-1 inhibition and effect on EV uptake 
5.2.5.1. KIM-1 expression analysis 
Following co-incubation with cisplatin, cell culture supernatant was centrifuged at 
300 x g at 4 °C for 3 minutes to remove any cell debris. Samples were immediately 
processed using an KIM-1/HAVCR Quantikine ELISA Kit (R&D Systems, MN, USA) 
as per the manufacturer’s instructions. KIM-1 expression was normalised to total 
protein, as quantified from cell lysate, using the BCA Protein Assay Kit (Thermo 
Scientific, Perth, UK). 
5.2.5.2. Inhibition of KIM-1 
KIM-1 inhibition was undertaken as previously described [285]. Briefly, experiments 
were performed at 37 °C in a humidified atmosphere of 5% CO2 in air. PPT cells 
were grown in 35-mm dishes and cultured to 90% confluence in culture medium. For 
inhibition experiments, the incubation medium also included anti-mKIM-1 antibody 
(AF3689, goat IgG, 10 µg/ml; R&D Systems, MN, USA) for 60 minutes before the 
addition of dye loaded EVs. EV uptake was quantified using flow cytometry (as 
described above). 
 





5.2.6. Data evaluation and statistical analysis 
Where possible data were presented as Tukey box plots. Tukey box plots consist of 
4 parameters; box ends at the quartiles Q1 and Q3, median as a horizontal line in 
the box, ‘whiskers’ to the farthest points that are not outliers (i.e. within 3/2 times 
the interquartile range of Q1 and Q3) and dot plot of outliers. Data were analysed 
using GraphPad PRISM (version 6.03 for Windows, GraphPad Software, San 
Diego, USA) and a P-value < 0.05 was considered statistically significant. When 
testing for a difference in the means of more than two datasets (e.g. EV release in 
response to cisplatin injury) a one-way ANOVA and post-hoc comparison using 
Tukey’s multiple comparison test was used. When datasets were influenced by 
more than one factor (i.e. EV uptake as affected by time and cisplatin injury) a two-
way ANOVA with Bonferroni’s multiple comparison test was utilised. Unpaired t-test 
were used to compare the mean difference in EV uptake following KIM-1 inhibition. 
  






5.3.1. Validation of cell viability assays 
The reliability of the cell assays was confirmed by seeding PPT cells to 96 well 
plates in multiple 1:2 serial dilutions. Readouts were conducted as detailed and 
linear regression analysis of the data indicated the R2 values were as follows: MTS 
cell viability assay, 0.967; and, luciferase cell viability assay, 0.972. 
5.3.2. Cellular effect of PT cells to cisplatin 
The model confirmed a temporal- and dose-dependent change in PPT viability 
(Figure 5.1a & b). At 48 hours, the ED50 for ATP concentration and NADPH activity 
were 8.64 and 9.36 µM, respectively (Figure 5.1a & b). The dose response graphs 
for 1, 12 and 24 hours did not reach maximal effect and therefore ED50 cannot be 
calculated. However, there was a temporal effect as evidenced in Figure 5.1a & b. A 
concentration of 10 µM was selected for further experimental study as 
representative of the ED50 on cell viability 
 
With regard to caspase 3/7 activity, the maximal apoptotic activity was present with 
5 µM cisplatin after 48 hours incubation. Notably at our selected ED50 dose at 48 
hours, 10 µM, there was maximum variability in the result (Coefficient of variation: 5 
µM, 10 µM and 25 µM; 7.55%, 17.08% and 5.66%, respectively; Figure 5.1c).  
 
 







Figure 5.1: In vitro dose-response relationship of PPT cells to cisplatin 
exposure  
PPT cells were exposed to cisplatin for 1 hour (blue), 12 hours (pink), 24 hours 
(yellow) or 48 hours (purple) prior to assessment of cell viability. NADPH activity 
(Figure a) and cellular ATP concentration (Figure b) decreased with increasing 
cisplatin concentration and exposure time. Caspase 3/7 concentration is affected by 
cisplatin concentration in a negatively skewed distribution (Figure c). Each point 
represents the mean±SD (n = 4)  































































































5.3.3. Effect of cisplatin on EV release from proximal tubule cells 
As in section 4.3.3, EVs were considered in 3 cohorts: total EV population (20-1000 
nm diameter), exosome population (20-100 nm diameter) and microvesicle 
population (100-500 nm). The effect of cisplatin on EV release is presented in 
Figure 5.2. The following patterns of EV release were noted: 
• Across all time points, total EV concentration correlated to increasing 
cisplatin concentration in a negatively skewed distribution, with maximal EV 
release corresponding to 75 µM cisplatin (Figure 5.2). 
• Changes in the MV population reflected changes noted in the total EV 
population, with maximal release corresponding to 75 µM cisplatin (Figure 
5.2). 
• Greater variation was seen in the exosome population than MV population. 
1- and 12- hours following injury, exosome release corresponded to 
increased cisplatin concentration in a negatively skewed distribution, with 
maximal release seen at 25 and 50 µM cisplatin, respectively (Figure 5.2). 
24- and 48 hours following nephrotoxic injury, there was a positive 
correlation between exosome release and cisplatin concentration with 
maximal exosome release being noted at 100 µM (Figure 5.2). 
 
   
 
150
Figure 5.2: EV release increases 
following nephrotoxic injury 
Cell culture media was collected at 
predefined time points following 
nephrotoxic injury with cisplatin 
Cultured cells were exposed to 
cisplatin for 1 hour (i; blue),12 hours 
(pink; ii), 24 hours (yellow; iii), or 48 
hours (purple; iv). EVs were 
considered in 3 cohorts: total EV 
population (20-1000nm diameter; 
Figure a), exosome population (20-
100nm diameter; Figure b) and 
microvesicle population (100-500nm; 
Figure c). Each point on the graphs 
represent the mean±SD. Statistical 
significance was determined by 1-way 
ANOVA with Tukey’s multiple 
comparisons to vehicle population 
(n=3). 























































































































































































































































































































































5.3.4. Effect of cisplatin on EV uptake by proximal tubule cells 
To quantify EV uptake, flow cytometry was utilised to describe EV uptake by PPT 
cells following injury with cisplatin (Figure 5.3a&b; percentage cell uptake and mean 
cell fluorescence, respectively). Significantly fewer PPT cells take up EVs after 
exposure to increasing cisplatin concentrations (Figure 5.3a). A similar trend 
correspondingly affected the average fluorescence of the PTT cells - 48 hours 
following cisplatin exposure mean cell fluorescence was lower in cells treated with 
10µM cisplatin in comparison to vehicle (Figure 5.3b). 
  







Figure 5.3: EV uptake by PPT cells negatively correlates to cisplatin injury 
Cells were incubated with dye-loaded EVs and concurrently exposed to cisplatin 
cisplatin (vehicle (PBS), blue, 1 µM, pink; 10 µM, yellow) The raw data are 
presented above as %fluorescent cells of total population (Figure a) and mean 
fluorescent intensity (Figure b) (Tukey box plot). Significance was ascertained by 2-































































5.3.5. Effect of cisplatin on proximal tubule cell KIM-1 expression  
KIM-1 protein expression within cell supernatant was quantified following PPT 
exposure to cisplatin. This experiment was conducted to confirm the archetypal 
proteomic injury response exhibited by PT cells. In PPT cell media, KIM-1 
concentration significantly increased at all time points following injury with 25- and 
50- µM cisplatin (Figure 5.4). 
  







Figure 5.4: KIM-1 expression increases following nephrotoxic injury 
Cell culture media was isolated following cisplatin injury of PPT cells after a pre-
defined time point. KIM-1 expression follows a negatively skewed distribution to 
increasing cisplatin concentrations at 12-, 24- and 48-hours following injury (graphs 
a), b), and c), respectively; mean±SD). Significance ascertained using 1-way 
ANOVA and Tukey multiple comparison to vehicle (n=3). 
  





























































































5.3.6. Effect of KIM-1 inhibition on proximal tubule cells EV uptake 
In order to ascertain if KIM-1 mediated endocytosis was implicated in PT EV uptake, 
PT cells were incubated with anti-KIM1 antibody for 1 hour prior to co-incubation 
with dye-loaded EVs. PT cells were analysed 48 hours later using flow cytometry to 
describe changes in PT cell fluorescence. No significant differences were observed 
between percentage PT cell uptake or mean cell fluorescence (Figure 5.5a&b, 
respectively).  
  







Figure 5.5: KIM-1 inhibition does not affect EV uptake by PPT cells 
Incubation medium also included anti-mKIM-1 antibody for 1 hour prior to the 
addition of dye loaded EVs. The raw data is presented above as %fluorescent cells 
of total population (Figure a) and mean fluorescent intensity (Figure b) (Tukey box 

























































5.4.1. Main findings 
The main findings of Chapter 5 were: 
• Cisplatin causes PT cell death in a temporal- and dose-dependent manner. 
• Cisplatin at low dose results in EV release but causes no significant. 
difference at higher doses. This is consistent with changes in the 
microvesicle sub-population. 
• Cisplatin inhibits EV uptake by PT cells in a dose-dependent manner. 
• PPT cells release KIM-1 into the cell supernatant with increasing cisplatin-
induced injury. 
• KIM-1 inhibition does not affect EV uptake by PT cells. 
5.4.2. Cisplatin affects EV release by proximal tubule cells 
As previously discussed, mechanisms driven by cell activation have been implicated 
in increasing EV release in non-renal cells; namely, toxins [245], hypoxia [248] and 
senescence [249]. In vivo PT cells have been described to release EVs in response 
to pro-inflammatory stimuli and hypoxia. These EVs contain miRNA and protein 
specific signatures that have known CKD association [286]. The studies presented 
in Chapter 5 add to this body of work, by demonstrating EV release in a dose-
dependent manner in response to low dose cisplatin injury. Interestingly, EV release 
does not seem to be affected by high dose cisplatin, presumably because at higher 
doses necrosis becomes the principal cell death pathway (Figure 5.1) [277]. 
 
This pattern of EV release corresponds to changes noted in the microvesicle 
subpopulation, as differentiated by size. Given the pattern of MV release closely 
follows that of caspase 3/7 activity, this pattern of release may be related to 
apoptosis, as well as cell stress. Microvesicles are characteristically 100 - 1000nm 
in size)[97] and are shed directly from the plasma membrane in response to cell 
stress [94]. Apoptotic bodies are extensively liberated from the plasma membrane in 
the later stages of apoptosis. Although apoptotic bodies are generally considered to 
be larger in size than other vesicles (500-4000nm), a smaller subpopulation has 
been proposed, 50-500nm [79, 99]. Without further investigation and validation, 





these 2 vesicle subpopulations cannot be differentiated and either could be 
responsible for the noted EV release pattern. 
5.4.3. Cisplatin reduces EV uptake and KIM-1 expression is not 
correlated to EV uptake by proximal tubule cells 
EV uptake by PT cells reduces in a dose-response manner with cisplatin injury 
(Figure 5.3). The reduction in the passive process of uptake (as demonstrated in 
Chapter 4) likely reflects reduced cell viability (Figure 5.1). The hypothesis that EV 
uptake may be dependent upon KIM-1 medicated endocytosis could not be proven. 
KIM-1 inhibition had no demonstrable effect on EV uptake (Figure 5.5). KIM-1 has 
previously been implicated in engulfment of apoptotic cells[284] and albumin[285], 
and is one of a number of cells which confer a phagocytic phenotype to PT 
cells[283]. It is worth considering a possible flaw in the study methodology; there is 
no positive control to KIM-1 has been effectively inhibited. Although this 
methodology was informed by a previous study[285], it is the only published 
research that utilises commercially available antibodies to inhibit the phagocytic 
effect of KIM-1. Other studies largely rely upon transfected cell lines[287] suggesting 
antibody inhibition may not be a reliable model. 
5.4.4. Limitations 
KIM-1 is highly expressed within the cell media of PPT cells (Figure 5.4). While KIM-
1 concentration increased as expected in a dose dependent manner in response to 
cisplatin injury, the high levels of KIM-1 at baseline do not reflect KIM-1 expression 
in vitro. KIM-1 is not detectable in either healthy human or murine tissue but is 
increased more than other proteins in renal injury[288]. Elevated KIM-1 
concentration has also been described in dedifferentiated epithelial cells in a model 
of renal carcinoma[289], and therefore may represent a marker of dedifferentiation 
in PT cells. Elevated KIM-1 concentration in PPT cell lysate and cell media has 
previously been described [290], but whether this is as a result of cell injury or 
dedifferentiation has yet to be elucidated. 
5.4.5. Summary 
In a cytotoxic model of PT injury, low dose cisplatin injury causes EV release from 
PT cells, an effect lost at higher doses of the nephrotoxin. This may reflect the 





change from apoptotic to necrotic cell death, seen at higher dose of cisplatin. EV 
uptake is inhibited by increasing cisplatin and unaffected by the inhibition of the 
KIM-1. The following chapter will integrate the experimental work described thus far 
and determine whether EVs (and their miRNA cargo) released from the injured heart 
have an effect on our PPT cell model.  
  











Chapter 6: Effect of EVs from injured distant organs on 
proximal tubule cells  
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The proposed role for EV signalling in health and disease highlights their potential 
as vectors to deliver therapeutic interventions. There are a number of on-going 
phase I and II clinical trials harnessing EV-based therapeutics (registered at 
https://clinicaltrials.gov). Although we remain in the early phase of such studies, 
theoretical clinical utility could be mediated by the manipulation of EVs as targeted 
therapeutic vectors. 
 
EVs are candidate drug delivery systems because they are stable within the 
circulation, have a wide biodistribution and previous work has suggested EV 
signalling is likely related to RNA interference [152-156]. EVs can be selectively 
loaded and can deliver functional RNA into cells [139, 170]. The integrity of RNA 
isolated from vesicles is similar to that of tissue, as the membrane protects the RNA 
cargo from RNase degradation [36, 88]. As discussed previously, EVs have natural 
targeting capacity, presumably by receptor-ligand binding [164-166]. Recent work, 
conducted by Hoshino et al. [167] demonstrated tissue-specific uptake of EVs is 
mediated by distinct integrins via their interaction with the extracellular matrix of the 
target tissue. Manipulation of this mechanism, through therapeutic targeting of these 
integrins, reduced EV uptake and impeded metastatic spread of cancer. This ability 
to modify the metastatic course of cancer raises the exciting possibility of prediction 
and redirection of tumour progression.  
 
Similar mechanisms could also be responsible for EV signalling along the nephron 
with the potential for EV to come from either an exogenous or proximal endogenous 
source. Initial observations of this potential were first reported in the field of 
mesenchymal stem cell (MSC) research. MSCs have been described to accelerate 
recovery and repair tissue following AKI; an effect demonstrated using diverse injury 
modalities [146-150]. Interestingly, the observation that the MSC supernatant 
conferred a beneficial effect, equal to that of MSCs themselves, opened the field to 
EV research [151]. Seminal work by Bruno et al. supported the claim that this 
positive result was largely due to EV transfer, likely related to RNA interference 





[152-156], with further work suggesting EV miRNA has a significant role in this MSC 
effect on kidney cell injury [157].  
 
This possible role of EV signalling in the delivery of functional miRNA and 
pathogenesis of AKI highlights their potential as a therapeutic intervention. 
Abnormal levels of miRNA could be one of the mechanisms explaining dysregulated 
protein expression during kidney disease progression and interference with this 
process represents a potential therapeutic target [160]. MiRNAs have been 
implicated in propagating inflammation, apoptosis and fibrosis within the kidney, 
while others have been described to have a beneficial effect on these pathological 
processes [291]. The first evidence of miRNAs having pathological roles in AKI was 
reported by Wei et al. who described resistance to injury in an ischemia reperfusion 
injury (IRI) model of AKI in DICER knockout mice [292]. These mice exhibit a global 
down-regulation of microRNAs in the renal cortex, demonstrating significantly better 
renal function, less tissue damage, and better survival than their wild-type 
counterparts [291, 292]. Within the field of EV research, miRNAs associated with EV 
endothelial progenitor cells have been noted to reduce apoptosis and promote cell 
regeneration in IRI, an effect lost with depletion of RNA, notably, miR-126 and miR-
296 [153, 158, 159]. Similarly, EV mediated horizontal transfer of IGF-1R mRNA 
from bone marrow MSC to tubular cells potentiates cell proliferation in cisplatin 
injury and may play a significant role in renoprotection [293]. 
 
Cisplatin injury of the PT has been associated with several networks of 
transcriptomic changes. Cisplatin injury facilitates binding of FOXO3 and p53, 
critical for induction of the apoptosis pathway [130]. MiR-122 and miR-34a have 
been implicated as important regulatory factors in this process. MiR-122 has been 
reported to reduce cisplatin-induced tubular injury through inhibition of FOXO3, 
[130] and miR-34a antagonism had been implicated in increased cell death, 
although the latter finding has not been consistently described [130, 294]. In similar 
studies, miR-125b has also been implicated in inhibiting p53 activation, thus 
protecting the kidney from acute injury [295]. Together with the emerging evidence 
of miRNA cellular communication via ECV shuttling, this work highlights the 





potential for miRNA, delivered via EVs, to confer protective properties to PT cells in 
nephrotoxic injury.  
 
The role miR-122 may play in cisplatin induced nephrotoxic injury is of particular 
interest. MiR-122 is enriched in the liver of humans [74, 296] - a finding translated 
across several species [70-72] - accounting for 72% of a hepatocytes total miRNA 
[69]. It plays an important role in modulation of several critical pathways including 
fatty acid metabolism, stress response and gluconeogenesis [73]. Emerging reports 
have suggest that miR-122 may also have the ability to be trafficked between cells 
by EVs, lending to the theory of EV dependent cell-to-cell communication [23]. MiR-
122 has gained prominence in recent years a biomarker at the point of 
implementation into routine clinical care. MiR-122 accurately predicts DILI [297], 
demonstrating a 100-fold increase in the circulation of patients with paracetamol-
induced DILI and exhibits a greater sensitivity and specificity than the current 
biomarker ALT [74]. At the time of writing, little work has been conducted 
investigating the role of miR-122 signalling at the PT though. In support of the 
hypothesis of miR-122 interference at the PT, the paracrine effect of liver stem cells 
has been shown to aid regeneration of renal tubular injury via release of EVs [145], 
a process which may be related to EV transfer of miR-122.  
 
6.1.2. Objectives 
This chapter integrates the preceding experimental chapters. 
• Establish if EVs isolated from the circulation can be taken up by PT cells in vitro 
• Describe the role the circulatory EVs from cardiac injury mice may play in PT cell 
viability  
• Ascertain if EVs from mice with liver injury transfer miR-122 to PT cells in vitro 
and describe the downstream targets which may be affected 
• Describe in vivo miR-122 changes in the renal tissue during DILI  







6.2.1.1. Breeding and maintenance of mice 
Mouse studies were in accordance with the Animals (Scientific Procedures) Act 
1986 and approved by the local Animal Ethics Committee. 10-14 week old 
C57BL/6NCrl mice were used for this study (purchased from Charles River 
Laboratory, Wilmington, MA). Animals were housed in standard sterile conditions 
with free access to chow and water. No adverse effects were encountered.  
6.2.1.2. Cardiac ischaemia model 
CAL was performed as described previously [220, 221] and detailed in Section 
3.2.2.1 
6.2.1.3. Paracetamol toxicity model 
The mouse model of DILI was conducted as described previously[298]. Briefly, 
animals were fasted for 14 hours prior to paracetamol dosing. Groups of randomly 
selected animals were administered 300 mg/kg of paracetamol (DILI; Sigma Aldrich, 
Dorset, UK) or 0.9% saline (control) with a single i.p. injection. Paracetamol was 
dissolved in sterile 0.9% saline, warmed to 42 °C and allowed to cool prior to 
administration. Injection volumes ranged from 0.6-1 ml. Animals received normal 
diet and water thereafter. 
6.2.2. Study protocol 
6.2.2.1. Blood and tissue sampling sampling 
6 hours following onset of organ injury, blood was collected by cardiac puncture, 
under terminal inhaled anaesthesia (isoflurane). Immediately following this, the mice 
were humanely culled using a Schedule 1 method. This time point was selected 
from previous work investigating the temporal expression changes of circulatory 
miRNAs following onset of hepatotoxicity [298]. This demonstrated that the maximal 
miRNA increase was 6 hours following paracetamol dosing. Blood samples were 
centrifuged twice at 4000 x g for 5 minutes, and the subsequent supernatant 
isolated and stored at −80 °C.  
 





After cervical dislocation, tissue was collected for further sample processing. Prior to 
tissue removal the descending aorta was isolated (proximal to the distal bifurcation, 
and flushed with PBS for 30 seconds). Murine tissue was then macroscopically 
dissected, as necessary, using anatomical landmarks. Tissue samples for RNA 
interrogation were placed in RNAlater (Qiagen, MD, United States) and stored at 
−80 °C. 
6.2.3. Isolation and dye loading of EVs 
As described previously [5], mouse serum was vigorously vortexed then centrifuged 
at 12,500 x g for 30 minutes to pellet any large membrane fragments and other 
debris. The supernatant was then centrifuged at 120,000 x g for 70 minutes to pellet 
the EV fraction. The pellet was washed with PBS and then re- centrifuged at 
120,000 x g for 70 minutes before final resuspension in PBS.  
 
Pelleted EVs were conjugated with Cell Tracker 655 (Invitrogen, CA, US) following 
the manufacturer’s protocol. Briefly, pelleted EVs were incubated with the Cell 
Tracker 655 conjugate in 200 μl fresh culture media for 1 hour at 37 °C. The EV 
pellet suspension was ultracentrifuged twice with fresh media before being put back 
on confluent cells. EV size distribution was confirmed by NTA of a 1:1000 dilution of 
Cell Tracker 655 conjugate. Dye loaded EVs were co-incubated with cells at a 
concentration of 250 x108/ml media. 
6.2.4. Particle size and concentration distribution measurement with 
NTA 
Particle size and EV concentration of serum was ascertained using NTA technology 
as defined in Section 4.2.5.1.  
6.2.5. Cell culture 
6.2.5.1. Primary PT cell culture 
PPT cells were grown and cultured as per described method in section 4.2.1.2. PPT 
cells were seeded on a 96-well plate at a cell density of 5x103 cells/well in 100 μL 
serum-free medium for 48 hours. The circulatory EV uptake experiments were 
conducted as per Figure 6.1. Cells were washed 3 times in PBS and the 100 μL 
serum-free medium was replaced. Circulatory EVs were co-incubated with cells at a 





concentration of 250 x108/ml media, 48 hours prior to induction of injury. PPT cells 
were again washed 3 times in PBS and the 100 μL serum-free medium was 
replaced. Nephrotoxic injury was induced by the addition of 10 µM cisplatin 
(Cambridge Bioscience) to PPT cells for 48 hours. Cisplatin was re-constituted from 
powder using PBS and stored at -20°C for a maximum of 1 week. Experiments were 
conducted in technical triplicate (3 wells) and biological quintuplicate (EVs isolated 






Figure 6.1: Methodology for circulatory EV loading of PPT cells
48 
hours Cell viability readout
PPT cells AND 
circulatory EVs 
250x108/ml
PPT cells AND 













6.2.6. Cell viability, necrosis and apoptosis analysis 
The following protocols were used to ascertain cell viability: 
6.2.6.1. Luciferase cell viability assay 
Luciferase cell viability assay was conducted as detailed in section 5.2.2.1. 
6.2.6.2. MTS cell viability assay 
MTS cell viability was conducted as detailed in section 5.2.2.2. 
6.2.7. Flow cytometry for total cell fluorescence 
Section 4.2.6.2 describes the methodology employed for quantifying total cell 
fluorescence using flow cytometry. 
6.2.8. PCR validation 
6.2.8.1. RNA extraction 
RNA extraction from serum and tissue (including cells) was conducted as described 
in section 3.2.4.1. 
6.2.8.2. Quantitative real time analysis  
Reverse transcription of miRNAs was conducted as previous described (section 
2.2.3.3). To generate cDNA the miScript II Reverse Transcription Kit (Qiagen, MD, 
United States) was used according to manufacturer instructions. 6 µl of treated RNA 
was added to a master mix consisting of 4 µl of 5x HiFlex buffer, 2 µl of 10x Nucleics 
mix, 6 µl RNA free H2O and 2 µl of reverse transcriptase mix. Samples were 
incubated for 1 hour at 37 °C followed by 5 minutes at 95°C. All cDNA syntheses 
were diluted 10-fold and stored at -80 °C. 
 
Quantitative real time analysis was conducted as described in section 2.2.3.4. 
MiRNA Ct values were normalized in serum samples by using the mean Ct obtained 
from the spiked-in external control (cel-miR-39). U6 was used as the internal control 
for tissue samples and was validated in our sample cohort. For normalisation of 
precursor miRNA, 18s ribosomal RNA was ultimately used based on pilot data (data 
not shown). 























Table 6.1: MiScript Primer Assays used during real-time PCR validation of miRNA expression changes in murine model of 
hepatotoxicity






6.2.9. Data evaluation and statistical analysis 
Where possible data were presented as Tukey box plots. Tukey box plots consist of 
4 parameters; box ends at the quartiles Q1 and Q3, median as a horizontal line in 
the box, ‘whiskers’ to the farthest points that are not outliers (i.e. within 3/2 times 
the interquartile range of Q1 and Q3) and dot plot of outliers. Data were analysed 
using GraphPad PRISM (version 6.03 for Windows, GraphPad Software, San 
Diego, USA) and a P-value < 0.05 was considered statistically significant. When 
testing for a difference in the means of more than two datasets (e.g. circulatory EV 
uptake by PPT cells, miR-122 concentration in mouse plasma in different models on 
injury) a one-way ANOVA and post-hoc comparison using Tukey’s multiple 
comparison test was used. When only 2 groups were being considered, unpaired t-










6.3.1. Uptake of circulatory derived EVs by PT cells 
To confirm that PPT cells take up EVs, PPT cells were co-incubated for 48 hours 
with dye-loaded circulatory EVs isolated from serum from mice undergoing DILI 
(liver EV), myocardial injury (cardiac EV) or healthy mice (control EV) (Figure 6.3). 
The distribution of vesicle size isolated from murine plasma is demonstrated in 
Figure 6.2. To quantify EV uptake, flow cytometry was utilised to quantify circulatory 
EV uptake by PPT cells. Circulatory EV uptake was unaffected by the injury model 
of origin, as defined by the percentage of PPT cells and mean cell fluorescence, 
(Figure 6.3a&b)  
  







Figure 6.2: Size distribution 
Mean particle size range (nm) of EVs in cell culture supernatant following 48 hours 
in culture. N = 12 
 
  





























Figure 6.3: Circulatory EV uptake by PPT cells is unaffected by EV injury 
model 
Cells were incubated with dye-loaded circulatory EVs isolated from healthy mice 
(control; blue) or mice 6 hours following DILI (300mg/kg paracetamol; Liver EV; 
pink) or myocardial injury (CAL; Cardiac EV, yellow). Flow cytometry was used to 
describe uptake of EVs. The raw data are presented above as %fluorescent cells of 
total population (Figure a) and mean fluorescent intensity (Figure b) (Tukey box 
plot). Significance was ascertained by 1-way ANOVA with Tukey’s multiple 
comparison to vehicle (n=3).   







































































































6.3.2. Circulating vesicles prevent in vitro PT cell injury 
Informed by the EV uptake study and PT cell dose response described in Chapter 4 
and 5, respectively, PPT cells were co-incubated with circulatory EVs for 48 hours, 
washed with PBS and subsequently injured with 10 µM cisplatin (as described in 
Figure 6.1). 48 hours following cisplatin injury, readouts of cell viability were 
obtained (Figure 6.4). PPT cells that were co-incubated with DILI circulatory EVs 
(liver EV) had more NADPH activity following cisplatin injury when compared with 
cells co-incubated with EVs from a healthy control (control EV) (Figure 6.4a). EVs 
isolated from mice post-myocardial injury do not affect NADPH activity in 
comparison to the control population. The same pattern of cell viability was present 
when ATP concentration was measured (Figure 6.4b). 
  






Figure 6.4: DILI EVs protect PTT cells from subsequent nephrotoxic injury. 
PTT cells were co-incubated with circulatory EVs for 48 hours and subsequently 
injured with 10 µM cisplatin. Circulatory EVs were derived from healthy mice (control 
EV; blue), DILI mice (300mg/kg paracetamol IP; liver EV; pink) or myocardial injury 
(CAL; cardiac EV; yellow). Cells that were not injured with cisplatin and had no 
additional EVs added as represented by no injury (purple). All results were 
normalised to results from PTT cells injured with 10 µM cisplatin with no additional 
EVs (baseline). Data represents NADPH activity (Figure a) and ATP concentration 
(Figure b) as percentage change from injured cells without additional EVs. Statistical 
significance was ascertained using 1-way ANOVA with Tukey’s multiple comparison 
to control EV (n=5).  
  




































































6.3.3. Transcriptomic differences in plasma and circulating EVs  
Previous work has suggested EV signalling is likely related to RNA interference 
[152-156]. Some miRNAs have organ enrichment[68]. Notably, miR- 122, is 
enriched in the liver of humans [38], a finding translated across several species 
(including: mice [38], zebrafish [299]), and accounts for >70% of the liver 
transcriptome[300]. Consequently, murine serum and EVs were interrogated for 
miR-122. Figure 6.5 demonstrates miR-122 concentration within whole serum and 
EVs, as defined by injury cohort. Serum and circulating EVs isolated from mice 6 
hours post-DILI (liver group) had significantly higher miR-122 levels than both CAL- 
(cardiac) and vehicle cohorts.  
  






Figure 6.5: miR-122 concentration is increased in murine serum and 
circulating EVs following DILI 
Serum and circulating EV miR-122 in healthy (control; blue), DILI (liver; pink) and 
myocardial injury (cardiac; yellow) mice. Values represent 2−ΔCt normalised by miR-
39. Statistical significance was ascertained using 1-way ANOVA with Tukey’s 







































6.3.4. In vitro transcriptomic differences in PPT cells coincubated with 
circulatory EVs 
To investigate the premise of EV delivery of miRNA, PPT cell expression of miR-122 
were investigated following co-incubation with DILI- and healthy circulatory EVs. 
PPT cells co-incubated with circulatory EVs from the DILI cohort had increased 
expression of miR-122, in comparison to PPT cells incubated with EVs from healthy 
controls (Figure 6.6). When PPT cells were injured with cisplatin for 48 hours, this 
significant difference in miR-122 expression remained. Notably, the trend in reduced 
miR-122 following cisplatin injury was not seen in the PTT cells co-incubated with 
DILI EVs.  
 
To complement the miR-122 uptake data and confirm functional delivery of miRNA, 
cellular target mRNA suppression was investigated as a read out of functional EV 
uptake. Target genes influenced by miR-122 were identified: mRNA expression of 
ALDOA, ADAM10 and FOXO3 were measured. In the absence of cisplatin injury 
there was no significant difference in any of the 3 target mRNAs (Figure 6.7a-c). 
However, following cisplatin injury, FOXO3 was significantly lower in the PTT cell 
population co-incubated with DILI EV in comparison to control EVs (Figure 6.7c) 
  






Figure 6.6: miR-122 expression levels are increased in PPT cells co-incubated 
with DILI EVs 
miR-122 concentration in PPT cells exposed to circulating EVs from healthy 
(control; blue) and DILI (liver; pink) mice. The figure represents miR-122 expression 
with cisplatin injury (cisplatin) and in healthy control (vehicle). Values represent 
2−ΔCtnormalised by U6. Statistical significance was ascertained using unpaired, 2-




































Figure 6.7: Downstream gene targets of miR-122 within PPT cells were affected by co-incubation with DILI EV 
mRNA expression in PPT cells exposed to circulating EVs from healthy (control EV; blue) and DILI (liver EV; pink) mice. Each igure 
presents mRNA expression following cell exposure to vehicle or cisplatin A) ADAM10 B) ALDOA and C) FOXO3 expression as 
























































a) ADAM10 b) ALDOA C) FOXO3




6.3.5. In vivo transcriptomic changes in tissue following DILI 
To investigate the role of miR-122 signalling from the liver to the kidney in vivo, mice 
were injected with 300mg/kg paracetamol i.p. An age-matched cohort was injected with 
PBS to act as the control group. 6 hours following i.p. injection, renal and liver tissue 
was perfused post-mortem and the collected tissue was subsequently interrogated for 
miR-122. Mice in the DILI cohort had significantly higher miR-122 in the renal medulla 
and cortex, in comparison to the vehicle population (Figure 6.8a). There was a non-
significant downwards trend in miR-122 expression in liver tissue following DILI.  
  





Figure 6.8: miR-122 expression was increased in renal tissue following DILI 
MiR-122 expression in murine tissues following i.p injection of saline (control; blue) or 
300mg/kg paracetamol (paracetamol; pink). Data are presented as a Tukey plot. 
Values represent 2−ΔCt normalised by U6. Statistical significance was ascertained using 




















































6.4.1. Main findings 
The main findings in Chapter 6 were: 
• Circulating EVs from mice with injury to different organs are taken by PPT cells in 
vitro. 
• Circulatory EVs in DILI reduce subsequent nephrotoxic PT injury in vitro. 
• In DILI, miR-122 concentration increases in both the serum and circulatory EVs. 
• EVs transfer miR-122 to PT cells in vitro, subsequently affecting FOXO3, a 
downstream target of miR-122. 
• In vivo miR-122 expression increases within the renal cortex and medulla in murine 
DILI.  
6.4.2. Circulatory EVs isolated in DILI protect the PT from nephrotoxic 
injury in vitro 
Dynamic changes in the miRNA signature of PT cells have been implicated to have 
both a positive and negative effects in AKI [291]. As previously discussed, circulating 
miRNAs are stabilised in the circulation by forming miRNA-protein complexes or 
associating with EVs; to date there is no evidence of miRNA-protein complex uptake by 
recipient cells in mammals. There have, however, been multiple descriptions of 
functional delivery of miRNAs via EVs. A number of in vivo studies have demonstrated 
exogenous EV uptake from the circulation by PT cells and delivery of mRNA transcripts 
[238, 239]. In Chapter 3, miR-499 was released from the myocardium and pick up in 
the renal cortex, which may represent inter-organ signalling. While the ability of 
circulatory EVs to cross the glomerulus is poorly understood, evidence suggests that 
EVs may be able to transit across the basement membrane, until the intracellular 
release of their contents [241] or excretion in urine [139, 240]. There remains the 
possibility of basolateral vesicle transit, from the peritubular capillaries and interstitium 
to the proximal tubule, but as yet there is no evidence to support this hypothesis in 
vivo. In vitro, our group has demonstrated that EVs can enter polarised collecting duct 
cells both apically and basolaterally under the regulation of vasopressin. In principle 
this demonstrates basolateral uptake is possible but in vivo evidence is lacking. This 
chapter contains the first description of endogenous circulatory EVs being taken up by 




PT cells in vitro (Figure 6.3) and subsequent delivery of their miRNA cargo (Figure 6.5 
& Figure 6.6a).  
 
The cellular consequence of circulatory EV delivery was demonstrated in a proof-of-
concept in vitro study; DILI circulatory EVs protected PT cells from subsequent 
nephrotoxic injury (Figure 6.4). Increased cell viability (NADPH activity and ATP 
concentration) was higher in cells primed with DILI EVs comparison to EVs from both 
healthy mice and those with myocardial injury. The proposal that this may be as a 
consequence of miR-122 delivery is supported by the following observations. Firstly, 
EVs and serum isolated from DILI mice have significantly higher miR-122 
concentration than both the 2 control cohorts, healthy and CAL mice (Figure 6.5). 
Secondly, miR-122 is a liver enriched miRNA and accounts for 72% of the liver miRNA 
transcriptome [69] and is the most likely candidate miRNA to be responsible functional 
changes secondary to miRNA in DILI. Thirdly, miR-122 has been shown to be 
trafficked between cells by EVs [23]. And lastly, manipulation of miR-122 has been 
reported to reduce cisplatin-induced PT injury through inhibition of FOXO3 [130], a 
transcriptomic response reproduced in this chapter (Figure 6.6 & Figure 6.7).  
6.4.3. Limitations 
No transcriptomic response to increased miR-122 was demonstrated in healthy PT 
cells and the only significant consequence noted in cisplatin injury was reduction in 
FOXO3. At the time of writing, no work has been conducted investigating the role of 
miR-122 signalling in healthy PT cells, and consequently the downstream mRNAs 
investigated were chosen from targets in other tissues or disease models of the PT 
injury. We reproduced the only published work pertaining to the PT, in which miR-122 
reduced FOXO3 in nephrotoxic injury [130]. In order to investigate this further, network 
analysis of the all miRNA and mRNA consequences of DILI EV signalling would have 
to be conducted.  
 
The presented work focuses on NADPH and ATP activity, both established models of 
cell viability[301, 302]. Further in vitro work should ascertain which cell death pathways 
are affected by EVs containing miR-122. In addition to the proposed network analysis, 
models should attempt to differentiate between apoptosis, necrosis and autophagy. 




Apoptosis assays could include quantification of caspases and analysis of 
mitochondrial membrane depolarisation, in addition to investigation of leakage of 
mitochondrial proteins into the cell cytosol i.e. cytochrome c. Investigation of autophagy 
could include electron microscopy to quantify autophagosomes and necrosis could be 
investigated by quantifying leakage of cyclophilin A and high-mobility group box 1. 
These proposed assays could be further complemented by annexin V/propodium 
iodide cell staining evaluated by flow cytometry or fluorescent microscopy to grossly 
evaluate apoptosis and necrosis, respectively.  
 
The hypothesis that miR-122 signals to the PT via EV-cell signalling is novel and would 
change our view on circulating miRNA changes in illness. At present, this chapter 
includes proof of concept studies cementing this hypothesis in vitro. The in vivo 
observation of miR-122 increasing in the renal medulla and cortex may be as a 
consequence of native PT expression in DILI rather than EV delivery of the miRNA 
transcript. Several in vivo studies would be required to demonstrate miR-122 signalling 
to the PT from the injured liver. If manipulation of the changing miRNA signature can 
be shown to be of biological relevance, clearly manipulation of circulatory miRNAs may 
be of interest as a potential therapeutic. Caution must be exercised, however, as 
miRNA’s ubiquitous expression makes undesirable systemic effects unpredictable.  
6.4.4. Summary 
EVs isolated from DILI mice protect PT cells from subsequent nephrotoxic damage. 
Circulating EVs in DILI can delivery miR-122 to PT cells in vitro and affect downstream 
mRNA implicated in a key apoptotic pathway.  
 
  










Chapter 7: Concluding remarks 
  




7.1. GENERAL CONCLUSIONS 
The studies presented in this thesis aimed to better understand the role miRNAs may 
play as markers of organ injury and mediators of inter-organ signalling. The original 
hypothesis proposed that miRNAs that are released into the circulation, as a 
consequence of organ injury, can be taken up by the renal tubule via EV mediated 
transfer. The key research aims identified to address this hypothesis included: 
description of the miRNA concentration changes in the circulation following myocardial 
injury in human and mouse models of illness, development of a PT model of EV uptake 
and release in order to identify physiological and pathophysiological regulators, and 
comparison of the effect of circulating EVs from injured heart and liver in vitro. 
Consequently, the findings within this thesis confirm that miRNAs are released into the 
circulation as a result of myocardial injury and can be taken up by renal PTT cells. EV 
uptake by PT cells is not under physiological regulation, at least in vitro, but can affect 
the PT transcriptome and function in a model of cytotoxic injury, a mechanism 
proposed to be underpinned by miRNA transfer. Table 7.1 summarises the key 
objectives and findings contained within this thesis. 
 
To date, circulatory miRNAs have not been demonstrated to have significant 
consequences at distal organs in systemic illness, and the work in this thesis 
represents a novel signalling pathway amenable to therapeutic intervention. The 
transfer of miR-122 via EVs to distal organs is the ideal model for investigation of this 
concept. MiR-122 is unique in the miRNA population for its tissue specificity; miR-122 
is a liver enriched miRNA and accounts for 72% of the liver miRNA transcriptome [69]. 
It has not been described in healthy tissue elsewhere in the body. Other miRNAs are 
ubiquitous in their expression and therefore identification of their tissue of origin is 
severely limited [6]. Furthermore, investigation of hepato-renal signalling is of critical 
clinical importance. AKI commonly complicates a spectrum of clinical illnesses and 
remains an important independent predictor of morbidity and mortality [303]. 
Specifically, AKI is of prognostic importance in patients with liver injury [304, 305], 
including DILI. AKI has been described as a complication resulting in prolonged 
hospital admission in paracetamol poisoning [306] and has been reported to occur in 
the absence of significant liver dysfunction [307]. Investigation of hepato-renal miRNA 
signalling therefore has potential as a research model and is of clinical importance. 





There is great potential for EV bound miRNAs as therapeutic interventions, yet we 
remain some way from realising this potential and improving patient outcomes. If 
manipulation of the changing miRNA signature can be shown to be of biological 
relevance, clearly manipulation of circulatory miRNAs may be of interest as a potential 
therapeutic. Caution must be exercised, however, as the ubiquitous expression of most 





Chapter Objectives Key observations 
2 To describe the changes in circulatory 
miRNA expression associated with 
myocardial ischaemia at 2 and 6 hours 
following start of cardiac injury in 
humans. 
Circulating miR-30a significantly increases 2 hours following myocardial injury in 
humans. 
  
6 hours following myocardial injury, miR-499a, miR-1 and miR-30a significantly 
increased within human serum. 
 
Heparinase effectively removes heparin contamination from serum samples. 
 
3 To describe the changes in circulatory 
miRNA associated with myocardial 
ischaemia at 2 and 6 hours following 
cardiac injury in mice. 
 
To ascertain the presence of miRNA of 
interest within mouse myocardial 
tissue. 
 
To correlate circulating miRNA 
concentration to TnI, the gold-standard 
cardiac biomarker in current clinical 
care. 
Circulating miR-499 significantly increases 2 hours following myocardial injury in 
mice in comparison to control. 
 
6 hours following myocardial injury, miR-499a, miR-1 and miR-30d significantly 
increased in mice in comparison to control 
 
2 hours following murine myocardial injury, circulating miR-499 correlates to TnI. 6 
hours following injury, miR-499, miR-1, miR-133a all correlate to TnI. 
 
In a mouse model of myocardial injury, TnI significantly increases in sham procedure 
6 hours following intervention. 
 
MiR-499 expression levels decrease within the LV 6 hours following murine 
myocardial injury. MiR-499 increases within the renal cortex at this time point. 
 
4 Establish an appropriate PT cell model 
for the study of EV release and uptake 
 
Identify factors which affect EV release 
from the PT  
 
Identify factors which affect EV uptake 
by the PT 
 
Cultured PPT cells retain morphological, enzymatic, proteomic and physiological 
features consistent with PT cells. 
 
Our HK2 cell line did not reliably model PT cells. 
 
P2Y1 stimulation increases EV release from PT cells. 
 





5 Identify effect of nephrotoxic injury on 
EV release from the PT 
 
Identify effect of nephrotoxic injury on 
EV uptake by the PT 
Investigate the role of KIM-1 on PT EV 
uptake  
Cisplatin causes PT cell death in a temporal- and dose-dependent manner. 
 
Cisplatin at low dose results in EV release but causes no significant. difference at 
higher doses. This is consistent with changes in the microvesicle sub-population. 
 
Cisplatin inhibits EV uptake by PT cells in a dose-dependent manner. 
 
PPT cells release KIM-1 into the cell supernatant with increasing cisplatin-induced 
injury. 
 
KIM-1 inhibition does not affect EV uptake by PT cells. 
 
6 Establish if EVs isolated from the 
circulation can be taken up by PT cells 
in vitro 
 
Describe the role the circulatory EVs 
from cardiac injury mice may play in 
PT cell viability  
 
Ascertain if EVs from mice with liver 
injury transfer miR-122 to PT cells in 
vitro and describe the downstream 
targets which may be affected 
Describe in vivo miR-122 changes in 
the renal tissue during DILI 
 
Circulating EVs from mice with injury to different organs are taken by PPT cells in 
vitro. 
 
Circulatory EVs in DILI reduce subsequent nephrotoxic PT injury in vitro. 
 
In DILI, miR-122 concentration increases in both the serum and circulatory EVs. 
 
EVs transfer miR-122 to PT cells in vitro, subsequently affecting FOXO3, a 
downstream target of miR-122. 
 
In vivo miR-122 expression increases within the renal cortex and medulla in murine 
DILI.   
Table 7.1: Summary table of key observations by chapter  




7.2. Summary of key findings 
7.2.1. The circulating miRNA signature changes as a consequence of 
myocardial injury 
The studies in chapters 2 and 3 showed the investigation and validation of the dynamic 
circulatory miRNA expression changes following myocardial ischemia. Circulatory 
miRNA changes following CABG were investigated using second generation 
sequencing and compared to a control cohort. Candidate miRNAs, showing the largest 
temporal fold change, were validated using PCR methodology and subsequently 
translated into a mouse model of myocardial injury. The work highlighted the 
expression changes in circulating miRNA following organ injury and their translation 
across species. Several miRNAs were identified as potential biomarkers of myocardial 
injury, at an earlier time point than previous described. Furthermore, expression 
changes of the candidate miRNAs were investigated in murine tissue, demonstrating 
reduced expression in damaged myocardial tissue and increased expression in 
downstream renal tissue. To date, cell-cell miRNA signalling has been shown to be as 
a consequence of EV transfer, thus lending credence to the hypothesis of EVs 
facilitating miRNA transfer in inter-organ signalling.  
7.2.2. Physiological and pathophysiological states affect EV signalling at 
the PT 
The studies included in chapters 4 and 5 interrogated factors that may underpin EV 
release and uptake at the PT – key experiments built on in Chapter 6. Purinergic 
stimulation via P2Y1 was shown for the first time to be a regulator of EV release from 
the PT. Known agonists of the PT did not affect EV uptake. In a nephrotoxic model of 
PT injury, EV release was affected in a dose-dependent manner by cisplatin. This 
novel observation adds to the growing body of literature describing EV release as a 
consequence of cell activation and injury. Conversely, cisplatin injury reduced EV 
uptake in a dose dependent manner, presumably as a consequence of reduced cell 
viability. 




7.2.3. In DILI, circulatory EV uptake by the PT can reduce subsequent 
nephrotoxic injury  
Chapter 6 united the findings in the subsequent chapters through the investigation of 
the role circulatory miRNAs may play at the PT. This work includes the first description 
of endogenous circulatory EVs being taken up by PT cells in vitro and subsequent 
delivery of their miRNA cargo. Consequently, the functional implications of EV-PT 
signalling were investigated using an in vitro cisplatin model of nephrotoxic injury.  
 
Cell viability reduction as a consequence of cisplatin injury was affected by prior EV 
uptake and varied in accordance with the circulatory EV disease model. DILI circulatory 
EVs protect PT cells from subsequent nephrotoxic injury, in comparison to CAL and 
healthy control. Further studies investigated the hypothesis that the reno-protective 
effect was as a consequence of the liver-enriched miRNA, miR-122. EV-PT signalling 
transferred miR-122 and affected known downstream mRNA targets in the PT. Thus 
far, proof of this concept has been largely restricted to in vitro modelling. 
Transcriptomic analysis of the renal tissue in a murine model of DILI demonstrated 
increased expression of miR-122 within renal tissue, but whether this is as a 
consequence of renal tissue transcription or EV signalling as yet remains unclear. 
7.3. FUTURE EXPERIMENTS 
7.3.1. Development of cardiac miRNAs as biomarkers of myocardial 
injury 
To allow specific determination of the source of the proposed cardiac miRNAs, 
alternative murine models could be interrogated for trans-coronary and circulatory 
miRNA changes following induction of injury. Non-inducible models of DICER knockout 
in myocytes (inhibiting production of mature miRNAs within the cell) are lethal post-
natally as a consequence of dilated cardiomyopathy and heart failure [308]. However, 
an inducible mouse model system could be developed to allow deletion of DICER in 
selectively in cardiac myocytes. For example, cre recombinase could be driven under a 
heart specific promoter such as Troponin T or myosin 6 inducible by tamoxifen. When 
crossed with a DICER floxed mice this would allow researchers to ‘turn off’ mature 
microRNA production in the heart and explore the effect on distant organs. In Chapter 
3 it was demonstrated that miR-499 increased in the renal cortex following myocardial 




injury. A mouse model with inducible deletion of DICER (or miR-499 specifically) would 
allow researchers to determine whether the origin of renal miR-499 was the heart. It 
should be noted that the success of this approach could be limited if the extent of 
cardiac injury is significantly changed following microRNA deletion, for example, if the 
injury phenotype is more severe and mice dies prematurely following CAL.  
 
The biomarker development process has been described as 3 distant stages; 
biomarker discovery, validation of a markers predictive value within the context of use 
and implementation of a clinically approved assay [178, 179]. Within the discovery 
phase, candidate biomarkers are identified within a well-defined human study clinical 
population and subsequently translated across species – exemplified by the work 
conducted in chapters 2 and 3. The latter 2 stages therefore remain to be explored. 
The next step would be to move our candidate miRNAs into the validation phase, 
namely to determine the specificity and selectivity using a large, clinically well-defined, 
patient cohort. This would allow assessment of the potential for biomarkers to stratify 
patients presenting with chest pain by their final clinical diagnosis. Patients would be 
classified as having type 1 or type 2 myocardial infarction, or having myocardial injury 
according to the universal definition of myocardial infarction, or non-cardiac chest pain 
as per previous published work [45]. A panel of biomarkers: including candidate 
miRNAs described in this thesis and hsTnI would be measured in all patients and their 
positive and negative predictive values for the above conditions would be assessed.  
7.3.2. Vesicle release and uptake regulation at the PT  
In the proposed hypothesis of hepato-renal miRNA signalling it is crucial to investigate 
the mechanisms governing EV release and uptake by the PT - to ensure targeted 
therapeutics deliver content specifically to the renal tubule. We were able to show 
purinergic regulation of exosome release in the PT in vitro. While none of the factors 
investigated in chapter 4 or 5 affected EV uptake; previous studies have reported 
exosome uptake to be dependent on the protein signature of the vesicle coupled with 
the signalling status of receptors on the recipient cell [309]. Indeed, EV uptake by the 
renal collecting duct is driven by vasopressin in vitro and in vivo [139], a portion of the 
renal epithelium downstream from the proximal tubule.  Hormonal- or integrin-mediated 
EV uptake, discussed in Section 1.6, would suggest a segment or tissue specific 
uptake mechanism, KIM-1 confers a phagocytic phenotype to PT cells [283] and may 




be responsible for the engulfment of apoptotic cells [284] and albumin [285], 
consequently posing an attractive target for EV internalisation at the proximal tubule. 
KIM-1 inhibition had no demonstrable effect on EV uptake in Chapter 5. Further 
investigation could include KIM-1 transfection of LLC-PK1 cells. LLC‐PK1 cells 
expressing KIM‐1 and cells expressing empty vector could be co-incubated with dye-
loaded EVs and EV uptake quantified using flow cytometry, as per methodology in 
Chapter 4.  
7.3.3. In vivo study of miR-122 hepatorenal signalling 
The question as to whether in vivo renal miR-122 expression in DILI is transcribed 
within the tissue or transferred by circulatory EVs remains unresolved. To further clarify 
this issue, homozygous DICER-floxed mice could be challenged with AAV8-Cre 
recombinase to induce DICER knockdown within the hepatocyte only, as previously 
described [310]. In the proposed murine model, cleavage of all precursor miRNAs 
within liver tissue would be inhibited upon induction, including miR-122; miRNA 
biogenesis should be unaffected in other tissues. The use of a DICER knockdown 
model is preferential to the pre-existing liver specific miR-122 knockout model, MiR-
122 LKO, for 3 reasons. MiR-122 LKO, is a germline knockout mouse. Consequently, it 
is not inducible and carries an endogenous genetic aberration in which it is likely there 
are a variety of transcriptomic and proteomic compensatory changes in comparison to 
both wildtype and inducible animals [311]. Secondly, the hypothesis that the protective 
mediator is miR-122 is thus far speculative and using the DICER-floxed mouse would 
allow investigation for all liver-mediated changes to the circulating miRNA population. 
Finally, DICER deletion will leave the pre-miRs intact so provide specificity for testing 
whether the mature form is transferred between organs. 
 
The DICER KO model could be manipulated to explore whether circulatory EVs shuttle 
liver specific miRNA to the PT. If the hypothesis of EV trafficking of circulatory EVs 
holds true, DILI using this model should result in absent miR-122 within the circulation. 
If miR-122 is not elevated in renal tissue, it would confirm that miR-122 has been 
trafficked from the circulation trafficked via circulatory EVs in the wild-type experiment 
in Chapter 6. 
 




Unfortunately, further investigation of mortality, tissue injury/function would be difficult 
to interpret in this model. Previous studies have noted that mortality rates of liver-
specific miR-122 knockout mice were significantly higher than control mice when 
injected a paracetamol dose, not lethal to the wild-type control [312]. MiR-122 is a 
regulator of cytochrome P450 (CYP) enzymes, known to metabolise paracetamol into 
its toxic substrate N-acetyl-p-benzoquinone imine (NAPQI) [312]. In the absence of 
miR-122, CYP enzymes rapidly oxidize paracetamol to NAPQI, deplete glutathione, 
and causing oxidative stress; culminating hepatocyte death and liver toxicity. This 
increased hepatotoxicity will be difficult to control, given that depletion of miR-122 in 
the liver is the desired intervention. Therefore, any change in mortality or renal function 
could not be attributed to miR-122 concentration in the renal tissue. 
 
If miR-122 hepatorenal signalling was demonstrated in the DICER-floxed mice, EVs 
with high and low miR-122 cargo will be systemically injected into wildtype mice and 
downstream gene target expression measured in the kidney. MiRNA and mRNA 
expression changes will also be described following induction of DILI using 
paracetamol. In both models, the degree of kidney injury will be quantified using read-
outs of kidney injury, including: urinary neutrophil gelatinase-associated lipocalin 
(NGAL), KIM-1 and sodium excretion, blood urea, creatinine and kidney histology. 
 
7.3.4. Investigation of the mechanism underpinning the reno-protective 
effect of DILI circulatory EVs 
The model described above could be further utilised to investigate if the in vitro 
renoprotective effect of DILI EVs is as a consequence of miRNA transfer. Circulatory 
EV isolated from AAV8-Cre recombinase DICER-floxed mice (and EVs from their 
littermate controls) could be incubated with PPT cells. PPT cells would be 
subsequently injured with cisplatin and readouts of cell viability would be conducted, as 
previous described. If the renoprotective effect is lost as a consequence of DICER 
knockdown it could be concluded that this effect was as a result of miRNA transfer. 
Further in vitro studies could be conducted to investigate miR-122 as the specific signal 
in the proposed mechanism. LLC-PK1 cells could be transfected with miR-122 and 
injured with cisplatin as described in Chapter 5. Dose dependent changes in cell 




viability would be compared to several control cohorts including, LLC-PK1 cells loaded 
with negative control siRNA, mock transfected cells and un-transfected cells. 
 
7.4. Final conclusion 
This thesis interrogated the hypothesis of functional, circulatory miRNA signalling from 
injured distant organs to the renal PT via EVs. Circulatory EVs were shown to affect PT 
cell transcriptome and function in vitro, an effect dependent upon site of distal organ 
injury. If translated into an in vivo model, this would represent a novel signalling 
mechanism amenable to therapeutic intervention. The work presented in this thesis 
has highlighted the limitations and challenges related to EV research and should 
support future research within the field of EV signalling. 
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T2 0.000070030 0.000091500  T0 vs. T2 0.000066600 -0.0001706 to 0.0003038 ns 
T6 0.000218500 0.000414800  T0 vs. T6 -
0.000081840 
-0.0004432 to 0.0002795 ns 
T24 0.000090730 0.000153100  T0 vs. T24 0.000045900 -0.0001508 to 0.0002426 ns 
miR-23a T0 0.000684600 0.000976500          
T2 0.005804000 0.007533000  T0 vs. T2 -
0.005119000 





T6 0.002979000 0.003808000  T0 vs. T6 -
0.002294000 
-0.004823 to 0.0002345 ns 
T24 0.003334000 0.004531000  T0 vs. T24 -
0.002649000 
-0.005783 to 0.0004845 ns 
miR-199a T0 0.000806400 0.002988000          
T2 0.000302000 0.000356200  T0 vs. T2 0.000504500 -0.001491 to 0.002500 ns 
T6 0.000192500 0.000225600  T0 vs. T6 0.000614000 -0.001370 to 0.002598 ns 
T24 0.000206300 0.000251000  T0 vs. T24 0.000600100 -0.001254 to 0.002454 ns 
miR-125b T0 0.000084900 0.000305900          
T2 0.000042730 0.000079300  T0 vs. T2 0.000042170 -0.0001369 to 0.0002213 ns 
T6 0.000058090 0.000109800  T0 vs. T6 0.000026810 -0.0001626 to 0.0002163 ns 
T24 0.000064320 0.000188800  T0 vs. T24 0.000020580 -0.0001810 to 0.0002221 ns 
miR-145 T0 0.000340400 0.001228000          
T2 0.000112000 0.000103800  T0 vs. T2 0.000228400 -0.0004720 to 0.0009288 ns 
T6 0.000252600 0.000751700  T0 vs. T6 0.000087840 -0.0006929 to 0.0008686 ns 
T24 0.000080490 0.000165300  T0 vs. T24 0.000259900 -0.0004535 to 0.0009734 ns 
miR-140 T0 0.000019760 0.000033540          
T2 0.000045350 0.000075390  T0 vs. T2 -
0.000025600 










T24 0.000050390 0.000126900  T0 vs. T24 -
0.000030630 
-0.0001044 to 0.00004311 ns 
miR-208a T0 0.000008664 0.000017020          










T24 0.000039450 0.000128400  T0 vs. T24 -
0.000030790 
-0.0001018 to 0.00004027 ns 
miR-99a T0 0.000895900 0.001673000          
T2 0.000709800 0.000913800  T0 vs. T2 0.000186100 -0.0008146 to 0.001187 ns 
T6 0.002601000 0.004492000  T0 vs. T6 -
0.001705000 
-0.004581 to 0.001170 ns 
T24 0.011800000 0.044200000  T0 vs. T24 -
0.010910000 
-0.03531 to 0.01350 ns 
miR-769 T0 0.000385500 0.000915000          
T2 0.000670200 0.001097000  T0 vs. T2 -
0.000284700 





T6 0.001150000 0.002353000  T0 vs. T6 -
0.000764900 
-0.002184 to 0.0006539 ns 
T24 0.004240000 0.017840000  T0 vs. T24 -
0.003855000 
-0.01390 to 0.006190 ns 
miR-133a T0 0.000032370 0.000047510          
T2 0.000046520 0.000082020  T0 vs. T2 -
0.000014150 
-0.00006569 to 0.00003738 ns 
T6 0.000261000 0.000746200  T0 vs. T6 -
0.000228600 
-0.0006540 to 0.0001967 ns 
T24 0.000491700 0.001799000  T0 vs. T24 -
0.000459300 
-0.001484 to 0.0005654 ns 
Let-7e T0 0.000134000 0.000267000          
T2 0.000233000 0.000259800  T0 vs. T2 -
0.000099070 
-0.0002974 to 0.00009922 ns 
T6 0.000243800 0.000381800  T0 vs. T6 -
0.000109800 
-0.0003765 to 0.0001568 ns 
T24 0.000240700 0.000314400  T0 vs. T24 -
0.000106800 
-0.0003542 to 0.0001406 ns 
miR-30d T0 0.005874000 0.020540000          
T2 0.000273800 0.000355800  T0 vs. T2 0.005600000 -0.006090 to 0.01729 ns 





T24 0.001463000 0.004864000  T0 vs. T24 0.004411000 -0.007810 to 0.01663 ns 
miR-99b T0 0.001064000 0.004364000          
T2 0.000139100 0.000233900  T0 vs. T2 0.000925100 -0.001587 to 0.003437 ns 
T6 0.000198000 0.000336600  T0 vs. T6 0.000866100 -0.001568 to 0.003300 ns 
T24 0.000810700 0.002416000  T0 vs. T24 0.000253400 -0.002552 to 0.003059 ns 
miR-100 T0 0.000161100 0.000367200          
T2 0.000401700 0.000870600  T0 vs. T2 -
0.000240600 
-0.0007900 to 0.0003088 ns 
T6 0.000564000 0.000543500  T0 vs. T6 -
0.000402900 
-0.0007796 to -0.00002621 ns 
T24 0.017370000 0.076110000  T0 vs. T6 -
0.017210000 
-0.0007796 to -0.00002621 ns 
 
Appendix 1: rtPCR validation of plasma miRNA targets in human CABG cohort. 
Mean expression of miRNAs of interest vary following CABG injury. Comparison to baseline levels was conducted using paired 1-way 
ANOVA and Dunnet’s multiple comparison (significance 0.05, n=14). Plasma levels of miR-30a significantly increased at T2 in comparison 


















difference  95% CI of diff. Mean SD  P-value 
miR-499a T0 0.02232 0.07307          
T2 0.02933 0.1105  T0 vs. T2 -0.007012 -0.09086 to 0.07684 ns 
T6 0.1215 0.3454  T0 vs. T6 -0.09917 -0.3192 to 0.1208 ns 
miR-1 T0 0.005632 0.01355          
T2 0.04779 0.1838  T0 vs. T2 -0.04216 -0.1555 to 0.07116 ns 
T6 0.2987 0.8501  T0 vs. T6 -0.293 -0.8128 to 0.2267 ns 
miR-30a T0 0.04277 0.06734          
T2 1.317 5.087  T0 vs. T2 -1.274 -4.383 to 1.835 ns 
T6 4.755 13.5  T0 vs. T6 -4.713 -12.95 to 3.527 ns 
miR-22 T0 0.008462 0.0141          
T2 0.2229 0.8439  T0 vs. T2 -0.2145 -0.7304 to 0.3015 ns 
T6 1.259 4.58  T0 vs. T6 -1.251 -4.045 to 1.543 ns 
miR-378g T0 0.001104 0.003596          
T2 0.003028 0.0108  T0 vs. T2 -0.001924 -0.009042 to 0.005193 ns 
T6 0.01057 0.03495  T0 vs. T6 -0.009466 -0.03110 to 0.01217 ns 
miR-23a T0 0.06895 0.163          
T2 1.399 5.389  T0 vs. T2 -1.33 -4.628 to 1.968 ns 





miR-199a T0 0.0004069 0.01074          
T2 0.1557 0.3815  T0 vs. T2 -0.1553 -0.5295 to 0.2190 ns 
T6 0.04684 0.06786  T0 vs. T6 -0.04643 -0.1222 to 0.02938 ns 
miR-125b T0 0.000484 0.0009026          
T2 0.0008554 0.002455  T0 vs. T2 -0.0003714 -0.002011 to 0.001268 ns 
T6 0.008451 0.02243  T0 vs. T6 -0.007967 -0.02170 to 0.005761 ns 
miR-145 T0 0.001795 0.004365          
T2 0.1601 0.5722  T0 vs. T2 -0.1583 -0.5075 to 0.1909 ns 
T6 0.2535 0.7037  T0 vs. T6 -0.2517 -0.6811 to 0.1778 ns 
miR-140 T0 0.001789 0.005614          
T2 0.0169 0.04407  T0 vs. T2 -0.01511 -0.04261 to 0.01240 ns 
T6 0.05663 0.1595  T0 vs. T6 -0.05484 -0.1491 to 0.03941 ns 
miR-208a T0 0.0000421
4 
0.00007511          
T2 0.0005938 0.002119  T0 vs. T2 -0.0005517 -0.001849 to 0.0007459 ns 
T6 0.001128 0.003147  T0 vs. T6 -0.001086 -0.003011 to 0.0008392 ns 
miR-99a T0 0.001445 0.00219          
T2 0.06165 0.2359  T0 vs. T2 -0.0602 -0.2042 to 0.08382 ns 
T6 0.151 0.4108  T0 vs. T6 -0.1495 -0.4003 to 0.1012 ns 
miR-769 T0 0.0007042 0.001452          





T6 0.02391 0.06403  T0 vs. T6 -0.0232 -0.06240 to 0.01600 ns 
miR-133a T0 0.004379 0.01074          
T2 0.09958 0.3815  T0 vs. T2 -0.0952 -0.3285 to 0.1381 ns 
T6 0.01922 0.06786  T0 vs. T6 -0.01484 -0.05736 to 0.02768 ns 
Let-7e T0 0.0004526 0.0009721          
T2 0.06011 0.2261  T0 vs. T2 -0.05965 -0.1976 to 0.07829 ns 
T6 0.01533 0.04892  T0 vs. T6 -0.01487 -0.04472 to 0.01497 ns 
miR-30d T0 0.006267 0.009753          
T2 0.2184 0.8388  T0 vs. T2 -0.2122 -0.7246 to 0.3003 ns 
T6 0.3883 1.311  T0 vs. T6 -0.3821 -1.183 to 0.4184 ns 
miR-99b T0 0.000762 0.001324          
T2 0.00805 0.02737  T0 vs. T2 -0.007288 -0.02406 to 0.009481 ns 
T6 0.05429 0.1564  T0 vs. T6 -0.05353 -0.1490 to 0.04198 ns 
miR-100 T0 0.0004966 0.001007          
T2 0.01504 0.05721  T0 vs. T2 -0.01454 -0.04950 to 0.02042 ns 
T6 0.1131 0.3097  T0 vs. T6 -0.1126 -0.3016 to 0.07642 ns 
 
Appendix 2: rtPCR validation of plasma miRNA targets in human orthopaedic cohort 
Mean expression of miRNAs of interest do not vary significantly following orthopaedic injury. Comparison to baseline expression was 









Symbol Gene Description 
1 100 SOX6 SRY (sex determining region Y)-box 6 
2 100 EPM2AIP1 EPM2A (laforin) interacting protein 1 
3 99 VAV3 vav 3 guanine nucleotide exchange factor 
4 99 EML4 echinoderm microtubule associated protein like 4 
5 98 SOS2 son of sevenless homolog 2 (Drosophila) 
6 97 DDX1 DEAD (Asp-Glu-Ala-Asp) box helicase 1 
7 97 COL4A3BP collagen, type IV, alpha 3 (Goodpasture antigen) 
binding protein 
8 97 RCN2 reticulocalbin 2, EF-hand calcium binding domain 
9 97 KPNA3 karyopherin alpha 3 (importin alpha 4) 
10 96 ARGLU1 arginine and glutamate rich 1 
11 96 SLC30A4 solute carrier family 30 (zinc transporter), member 4 
12 96 REEP1 receptor accessory protein 1 
13 96 OSBPL1A oxysterol binding protein-like 1A 
14 96 FOXP2 forkhead box P2 
15 96 LRCH2 leucine-rich repeats and calponin homology (CH) 
domain containing 2 
16 96 SKIL SKI-like oncogene 
17 96 CCRN4L CCR4 carbon catabolite repression 4-like (S. 
cerevisiae) 
18 95 SOX5 SRY (sex determining region Y)-box 5 
19 95 RRAGB Ras-related GTP binding B 
20 95 C17orf75 chromosome 17 open reading frame 75 
21 94 MYEF2 myelin expression factor 2 
22 94 USP24 ubiquitin specific peptidase 24 
23 94 SMIM15 small integral membrane protein 15 
24 93 MAPK6 mitogen-activated protein kinase 6 
25 93 H2AFZ H2A histone family, member Z 
26 93 PTBP3 polypyrimidine tract binding protein 3 
27 93 HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) 
28 93 UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 
29 93 SLC12A2 solute carrier family 12 (sodium/potassium/chloride 
transporter), member 2 
30 92 REST RE1-silencing transcription factor 
31 92 PTBP2 polypyrimidine tract binding protein 2 
32 92 SDC2 syndecan 2 
33 92 KIAA1468 KIAA1468 
34 91 PHLDA2 pleckstrin homology-like domain, family A, member 2 
35 91 MARS2 methionyl-tRNA synthetase 2, mitochondrial 
36 90 SAMD8 sterile alpha motif domain containing 8 
37 90 RSBN1 round spermatid basic protein 1 




39 89 RCAN3 RCAN family member 3 
40 89 CNOT6L CCR4-NOT transcription complex, subunit 6-like 
41 88 GPC6 glypican 6 
42 88 DCP2 decapping mRNA 2 
43 88 TESK2 testis-specific kinase 2 
44 88 SYBU syntabulin (syntaxin-interacting) 
45 87 RALYL RALY RNA binding protein-like 
46 87 NDUFA5 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 5 
47 87 INPP5E inositol polyphosphate-5-phosphatase, 72 kDa 
48 86 LIN28B lin-28 homolog B (C. elegans) 
49 86 LCOR ligand dependent nuclear receptor corepressor 
50 86 LPXN leupaxin 
51 85 ASPH aspartate beta-hydroxylase 
52 85 FAM168A family with sequence similarity 168, member A 
53 85 KLHL42 kelch-like family member 42 
54 85 NOVA1 neuro-oncological ventral antigen 1 
55 85 TMEM100 transmembrane protein 100 
56 85 THBS2 thrombospondin 2 
57 85 RCOR3 REST corepressor 3 
58 84 RGS21 regulator of G-protein signaling 21 
59 84 NCBP2 nuclear cap binding protein subunit 2, 20kDa 
60 84 DNAJC25 DnaJ (Hsp40) homolog, subfamily C , member 25 
61 84 LRRC8B leucine rich repeat containing 8 family, member B 
62 83 PAPOLA poly(A) polymerase alpha 
63 83 LAMP3 lysosomal-associated membrane protein 3 
64 82 XRN1 5'-3' exoribonuclease 1 
65 82 LRP8 low density lipoprotein receptor-related protein 8, 
apolipoprotein e receptor 
66 81 TMBIM6 transmembrane BAX inhibitor motif containing 6 
67 81 CHM choroideremia (Rab escort protein 1) 
68 81 ZNF711 zinc finger protein 711 
69 81 SPTSSB serine palmitoyltransferase, small subunit B 
70 80 SEH1L SEH1-like (S. cerevisiae) 
71 80 ARID2 AT rich interactive domain 2 (ARID, RFX-like) 
72 79 FAM60A family with sequence similarity 60, member A 
73 79 TRUB1 TruB pseudouridine (psi) synthase family member 1 
74 78 RAB23 RAB23, member RAS oncogene family 
75 78 EPHA5 EPH receptor A5 
76 78 C3orf43 chromosome 3 open reading frame 43 
77 78 SMC6 structural maintenance of chromosomes 6 
78 78 COMT catechol-O-methyltransferase 




80 77 NOL9 nucleolar protein 9 
81 76 SLC9C1 solute carrier family 9, subfamily C (Na+-transporting 
carboxylic acid decarboxylase), member 1 
82 75 FGF9 fibroblast growth factor 9 
83 75 ATF2 activating transcription factor 2 
84 75 PREPL prolyl endopeptidase-like 
85 75 JPH1 junctophilin 1 
86 75 RICTOR RPTOR independent companion of MTOR, complex 2 
87 75 DSG2 desmoglein 2 
88 75 JADE1 jade family PHD finger 1 
89 74 PRKCE protein kinase C, epsilon 
90 74 RAB5C RAB5C, member RAS oncogene family 
91 74 DGCR8 DGCR8 microprocessor complex subunit 
92 74 IRF2BPL interferon regulatory factor 2 binding protein-like 
93 74 PCDHB13 protocadherin beta 13 
94 74 UBE2V1 ubiquitin-conjugating enzyme E2 variant 1 
95 73 CPNE4 copine IV 
96 73 RAD51 RAD51 recombinase 
97 73 SEC11A SEC11 homolog A (S. cerevisiae) 
98 73 RTKN2 rhotekin 2 
99 72 VPS13A vacuolar protein sorting 13 homolog A (S. cerevisiae) 
100 72 ZCCHC6 zinc finger, CCHC domain containing 6 
101 72 C12orf29 chromosome 12 open reading frame 29 
102 71 ZBTB10 zinc finger and BTB domain containing 10 
103 71 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 
104 71 P4HA1 prolyl 4-hydroxylase, alpha polypeptide I 
105 71 RMDN3 regulator of microtubule dynamics 3 
106 71 PNISR PNN-interacting serine/arginine-rich protein 
107 71 VCPIP1 valosin containing protein (p97)/p47 complex interacting 
protein 1 
108 70 SECISBP2L SECIS binding protein 2-like 
109 70 SLC1A3 solute carrier family 1 (glial high affinity glutamate 
transporter), member 3 
110 70 ANKRD40 ankyrin repeat domain 40 
111 70 ZIC3 Zic family member 3 
112 70 IKZF2 IKAROS family zinc finger 2 (Helios) 
113 69 ZEB2 zinc finger E-box binding homeobox 2 
114 68 ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 
115 68 FAM199X family with sequence similarity 199, X-linked 
116 68 SHISA6 shisa family member 6 
117 68 HEPHL1 hephaestin-like 1 
118 68 KCNA4 potassium voltage-gated channel, shaker-related 
subfamily, member 4 




120 68 CDC5L cell division cycle 5-like 
121 67 GTPBP4 GTP binding protein 4 
122 67 SCRN1 secernin 1 
123 67 DEPDC1B DEP domain containing 1B 
124 67 SIAH3 siah E3 ubiquitin protein ligase family member 3 
125 67 TMTC3 transmembrane and tetratricopeptide repeat containing 
3 
126 67 PHLPP2 PH domain and leucine rich repeat protein phosphatase 
2 
127 67 CLDN11 claudin 11 
128 66 RNF220 ring finger protein 220 
129 66 FAM117B family with sequence similarity 117, member B 
130 66 EDAR ectodysplasin A receptor 
131 66 DNM1L dynamin 1-like 
132 66 FBN1 fibrillin 1 
133 66 ZNF24 zinc finger protein 24 
134 66 ZSWIM7 zinc finger, SWIM-type containing 7 
135 66 UHRF1BP1 UHRF1 binding protein 1 
136 66 TRAM1 translocation associated membrane protein 1 
137 66 CDC27 cell division cycle 27 
138 65 ADAM10 ADAM metallopeptidase domain 10 
139 65 SMEK2 SMEK homolog 2, suppressor of mek1 (Dictyostelium) 
140 65 FNBP4 formin binding protein 4 
141 65 MEIS3 Meis homeobox 3 
142 65 DUSP11 dual specificity phosphatase 11 (RNA/RNP complex 1-
interacting) 
143 65 NRARP NOTCH-regulated ankyrin repeat protein 
144 64 TGFA transforming growth factor, alpha 
145 64 ERCC4 excision repair cross-complementation group 4 
146 64 FLRT2 fibronectin leucine rich transmembrane protein 2 
147 64 NAV2 neuron navigator 2 
148 64 ELMOD2 ELMO/CED-12 domain containing 2 
149 63 CNOT7 CCR4-NOT transcription complex, subunit 7 
150 63 GDF9 growth differentiation factor 9 
151 63 ATRN attractin 
152 63 PTP4A1 protein tyrosine phosphatase type IVA, member 1 
153 63 RALA v-ral simian leukemia viral oncogene homolog A (ras 
related) 
154 63 CHL1 cell adhesion molecule L1-like 
155 63 PRKAA1 protein kinase, AMP-activated, alpha 1 catalytic subunit 
156 63 LIMA1 LIM domain and actin binding 1 
157 62 UBE2E1 ubiquitin-conjugating enzyme E2E 1 
158 62 ATXN3 ataxin 3 




160 62 TMEM64 transmembrane protein 64 
161 62 SLC39A12 solute carrier family 39 (zinc transporter), member 12 
162 61 STAU2 staufen double-stranded RNA binding protein 2 
163 61 VPS13D vacuolar protein sorting 13 homolog D (S. cerevisiae) 
164 61 FAM172A family with sequence similarity 172, member A 
165 61 SKP1 S-phase kinase-associated protein 1 
166 61 ARHGAP12 Rho GTPase activating protein 12 
167 61 ZUFSP zinc finger with UFM1-specific peptidase domain 
168 60 C18orf54 chromosome 18 open reading frame 54 
169 60 PRKAR1A protein kinase, cAMP-dependent, regulatory, type I, 
alpha 
170 60 AEBP2 AE binding protein 2 
171 60 PLXNC1 plexin C1 
172 60 STEAP2 STEAP family member 2, metalloreductase 
173 60 YPEL1 yippee-like 1 (Drosophila) 
 












Symbol Gene Description 
1 100 LPPR4 lipid phosphate phosphatase-related protein type 4 
2 100 PTPLAD1 protein tyrosine phosphatase-like A domain containing 1 
3 100 GLCCI1 glucocorticoid induced transcript 1 
4 99 TPPP tubulin polymerization promoting protein 
5 99 ZMAT3 zinc finger, matrin-type 3 
6 99 SLC44A1 solute carrier family 44 (choline transporter), member 1 
7 99 CDK14 cyclin-dependent kinase 14 
8 98 SNX2 sorting nexin 2 
9 98 IP6K2 inositol hexakisphosphate kinase 2 
10 98 NRP1 neuropilin 1 
11 98 EIF4E eukaryotic translation initiation factor 4E 
12 98 FNDC3A fibronectin type III domain containing 3A 
13 98 EIF1AX eukaryotic translation initiation factor 1A, X-linked 
14 98 C2orf69 chromosome 2 open reading frame 69 
15 98 VAMP2 vesicle-associated membrane protein 2 (synaptobrevin 2) 
16 98 SOWAHC sosondowah ankyrin repeat domain family member C 
17 98 ANKIB1 ankyrin repeat and IBR domain containing 1 
18 97 DDX5 DEAD (Asp-Glu-Ala-Asp) box helicase 5 
19 97 KTN1 kinectin 1 (kinesin receptor) 
20 97 HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 
21 97 ZNF280D zinc finger protein 280D 
22 97 RIT2 Ras-like without CAAX 2 
23 97 CLCN3 chloride channel, voltage-sensitive 3 
24 97 WDR48 WD repeat domain 48 
25 97 AJUBA ajuba LIM protein 
26 97 HELZ2 helicase with zinc finger 2, transcriptional coactivator 
27 97 ARCN1 archain 1 
28 97 SMIM14 small integral membrane protein 14 
29 96 HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 
30 96 C5orf51 chromosome 5 open reading frame 51 
31 96 HNRNPU heterogeneous nuclear ribonucleoprotein U (scaffold 
attachment factor A) 
32 96 PHAX phosphorylated adaptor for RNA export 
33 96 NXT2 nuclear transport factor 2-like export factor 2 
34 95 TMCC1 transmembrane and coiled-coil domain family 1 
35 95 EDN1 endothelin 1 
36 95 SRSF1 serine/arginine-rich splicing factor 1 
37 95 CAAP1 caspase activity and apoptosis inhibitor 1 
38 95 RAD54B RAD54 homolog B (S. cerevisiae) 




40 95 CLTC clathrin, heavy chain (Hc) 
41 95 TAGLN2 transgelin 2 
42 95 TMEM178A transmembrane protein 178A 
43 95 ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 
1 
44 94 TMOD2 tropomodulin 2 (neuronal) 
45 94 GCH1 GTP cyclohydrolase 1 
46 94 TMEM243 transmembrane protein 243, mitochondrial 
47 94 SCAF11 SR-related CTD-associated factor 11 
48 94 ANKRD29 ankyrin repeat domain 29 
49 94 MAB21L1 mab-21-like 1 (C. elegans) 
50 94 API5 apoptosis inhibitor 5 
51 94 CNN3 calponin 3, acidic 
52 94 RARB retinoic acid receptor, beta 
53 94 SPRED1 sprouty-related, EVH1 domain containing 1 
54 94 CHSY1 chondroitin sulfate synthase 1 
55 94 NCL nucleolin 
56 94 CPEB1 cytoplasmic polyadenylation element binding protein 1 
57 93 THBS1 thrombospondin 1 
58 93 SLC28A3 solute carrier family 28 (concentrative nucleoside 
transporter), member 3 
59 93 TBC1D15 TBC1 domain family, member 15 
60 93 CPED1 cadherin-like and PC-esterase domain containing 1 
61 93 PDCD10 programmed cell death 10 
62 93 CEBPZ CCAAT/enhancer binding protein (C/EBP), zeta 
63 93 SULF1 sulfatase 1 
64 93 TNKS2 tankyrase, TRF1-interacting ankyrin-related ADP-ribose 
polymerase 2 
65 93 CLOCK clock circadian regulator 
66 92 BDNF brain-derived neurotrophic factor 
67 92 HSPD1 heat shock 60kDa protein 1 (chaperonin) 
68 92 C2CD5 C2 calcium-dependent domain containing 5 
69 92 TRAPPC3 trafficking protein particle complex 3 
70 92 HS3ST3B1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 
71 92 MMD2 monocyte to macrophage differentiation-associated 2 
72 92 PFDN1 prefoldin subunit 1 
73 91 YWHAQ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, theta 
74 91 NEDD9 neural precursor cell expressed, developmentally down-
regulated 9 
75 91 PBX1 pre-B-cell leukemia homeobox 1 
76 91 TSPAN4 tetraspanin 4 
77 90 GPR137C G protein-coupled receptor 137C 
78 90 ZNF24 zinc finger protein 24 




80 90 MXD1 MAX dimerization protein 1 
81 90 PAX3 paired box 3 
82 90 MEOX2 mesenchyme homeobox 2 
83 90 IMPACT impact RWD domain protein 
84 90 GNPDA2 glucosamine-6-phosphate deaminase 2 
85 90 ADPGK ADP-dependent glucokinase 
86 89 SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 
87 89 FAM91A1 family with sequence similarity 91, member A1 
88 89 ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 
89 89 USP33 ubiquitin specific peptidase 33 
90 89 SLC25A22 solute carrier family 25 (mitochondrial carrier: glutamate), 
member 22 
91 88 KIF2A kinesin heavy chain member 2A 
92 88 KANK4 KN motif and ankyrin repeat domains 4 
93 88 E2F5 E2F transcription factor 5, p130-binding 
94 88 UNC119B unc-119 homolog B (C. elegans) 
95 88 UST uronyl-2-sulfotransferase 
96 88 STEAP2 STEAP family member 2, metalloreductase 
97 88 BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 
98 88 ADAMTSL3 ADAMTS-like 3 
99 88 TRA2B transformer 2 beta homolog (Drosophila) 
100 88 UTRN utrophin 
101 88 KCNIP3 Kv channel interacting protein 3, calsenilin 
102 88 SRSF9 serine/arginine-rich splicing factor 9 
103 88 NDRG3 NDRG family member 3 
104 88 OSBPL7 oxysterol binding protein-like 7 
105 87 SFRP1 secreted frizzled-related protein 1 
106 87 PDIK1L PDLIM1 interacting kinase 1 like 
107 87 AP1G1 adaptor-related protein complex 1, gamma 1 subunit 
108 87 SLC10A7 solute carrier family 10, member 7 
109 87 ARFIP1 ADP-ribosylation factor interacting protein 1 
110 86 FAM63B family with sequence similarity 63, member B 
111 86 TKT transketolase 
112 86 NET1 neuroepithelial cell transforming 1 
113 86 MON2 MON2 homolog (S. cerevisiae) 
114 86 TRIM2 tripartite motif containing 2 
115 86 NBEA neurobeachin 
116 86 DGKE diacylglycerol kinase, epsilon 64kDa 
117 86 SLC8A1 solute carrier family 8 (sodium/calcium exchanger), 
member 1 
118 86 WWC1 WW and C2 domain containing 1 
119 85 MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 




120 85 FAM84A family with sequence similarity 84, member A 
121 85 PCDHB13 protocadherin beta 13 
122 85 Septin 6 septin 6 
123 85 SAMD8 sterile alpha motif domain containing 8 
124 85 GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 
125 85 FN1 fibronectin 1 
126 85 HMBOX1 homeobox containing 1 
127 85 IGF1 insulin-like growth factor 1 (somatomedin C) 
128 85 STC2 stanniocalcin 2 
129 85 AP3D1 adaptor-related protein complex 3, delta 1 subunit 
130 84 WBP1L WW domain binding protein 1-like 
131 84 PGM2 phosphoglucomutase 2 
132 84 AZIN1 antizyme inhibitor 1 
133 84 CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 
134 84 MAL2 mal, T-cell differentiation protein 2 (gene/pseudogene) 
135 83 SLC25A36 solute carrier family 25 (pyrimidine nucleotide carrier ), 
member 36 
136 83 MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A 
137 83 NFATC3 nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 3 
138 83 FBP1 fructose-1,6-bisphosphatase 1 
139 82 DRD1 dopamine receptor D1 
140 82 SDPR serum deprivation response 
141 82 MCHR1 melanin-concentrating hormone receptor 1 
142 82 PRKRIR protein-kinase, interferon-inducible double stranded RNA 
dependent inhibitor, repressor of (P58 repressor) 
143 82 LRRC8A leucine rich repeat containing 8 family, member A 
144 82 CREM cAMP responsive element modulator 
145 82 TBP TATA box binding protein 
146 81 METTL21A methyltransferase like 21A 
147 81 RICTOR RPTOR independent companion of MTOR, complex 2 
148 81 CTTNBP2NL CTTNBP2 N-terminal like 
149 81 SPATS2L spermatogenesis associated, serine-rich 2-like 
150 81 BHLHE22 basic helix-loop-helix family, member e22 
151 81 ATRNL1 attractin-like 1 
152 81 MMD monocyte to macrophage differentiation-associated 
153 81 FRS2 fibroblast growth factor receptor substrate 2 
154 80 CORO1C coronin, actin binding protein, 1C 
155 80 SEC22C SEC22 vesicle trafficking protein homolog C (S. 
cerevisiae) 
156 80 RNF165 ring finger protein 165 
157 80 PPIB peptidylprolyl isomerase B (cyclophilin B) 




159 80 LRCH1 leucine-rich repeats and calponin homology (CH) domain 
containing 1 
160 80 ANXA2 annexin A2 
161 79 CD2AP CD2-associated protein 
162 79 G6PD glucose-6-phosphate dehydrogenase 
163 79 BACH2 BTB and CNC homology 1, basic leucine zipper 
transcription factor 2 
164 79 PABPC1L2B poly(A) binding protein, cytoplasmic 1-like 2B 
165 79 ZNF800 zinc finger protein 800 
166 79 POGK pogo transposable element with KRAB domain 
167 78 JOSD1 Josephin domain containing 1 
168 78 HIAT1 hippocampus abundant transcript 1 
169 78 CXorf23 chromosome X open reading frame 23 
170 78 UBE4A ubiquitination factor E4A 
171 78 ARID2 AT rich interactive domain 2 (ARID, RFX-like) 
172 77 MIPOL1 mirror-image polydactyly 1 
173 77 C20orf112 chromosome 20 open reading frame 112 
174 77 C15orf57 chromosome 15 open reading frame 57 
175 76 VAMP4 vesicle-associated membrane protein 4 
176 76 KIAA2022 KIAA2022 
177 76 ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 
7 
178 76 ADAR adenosine deaminase, RNA-specific 
179 76 FBXL14 F-box and leucine-rich repeat protein 14 
180 76 RTN4IP1 reticulon 4 interacting protein 1 
181 76 C12orf49 chromosome 12 open reading frame 49 
182 76 CAV2 caveolin 2 
183 76 HOOK1 hook microtubule-tethering protein 1 
184 76 AKAP11 A kinase (PRKA) anchor protein 11 
185 75 ARF3 ADP-ribosylation factor 3 
186 75 BAG4 BCL2-associated athanogene 4 
187 75 EYA4 eyes absent homolog 4 (Drosophila) 
188 75 RSBN1 round spermatid basic protein 1 
189 75 EBPL emopamil binding protein-like 
190 75 KCTD10 potassium channel tetramerization domain containing 10 
191 75 UHMK1 U2AF homology motif (UHM) kinase 1 
192 75 JARID2 jumonji, AT rich interactive domain 2 
193 75 PRKCE protein kinase C, epsilon 
194 75 ASH2L ash2 (absent, small, or homeotic)-like (Drosophila) 
195 75 ABHD6 abhydrolase domain containing 6 
196 75 PAFAH1B1 platelet-activating factor acetylhydrolase 1b, regulatory 
subunit 1 (45kDa) 
197 75 HACE1 HECT domain and ankyrin repeat containing E3 ubiquitin 
protein ligase 1 




199 74 BET1 Bet1 golgi vesicular membrane trafficking protein 
200 74 SH3BGRL SH3 domain binding glutamate-rich protein like 
201 74 ZFP36L1 ZFP36 ring finger protein-like 1 
202 74 PPP1R3B protein phosphatase 1, regulatory subunit 3B 
203 74 SMEK2 SMEK homolog 2, suppressor of mek1 (Dictyostelium) 
204 74 WDR61 WD repeat domain 61 
205 73 CREBL2 cAMP responsive element binding protein-like 2 
206 73 EML3 echinoderm microtubule associated protein like 3 
207 73 ATF2 activating transcription factor 2 
208 73 ABI2 abl-interactor 2 
209 73 TWF1 twinfilin actin-binding protein 1 
210 73 MSANTD2 Myb/SANT-like DNA-binding domain containing 2 
211 73 RFWD3 ring finger and WD repeat domain 3 
212 73 TSPAN9 tetraspanin 9 
213 73 RAB5A RAB5A, member RAS oncogene family 
214 73 SNAP25 synaptosomal-associated protein, 25kDa 
215 73 SLC35F1 solute carrier family 35, member F1 
216 73 SUV420H1 suppressor of variegation 4-20 homolog 1 (Drosophila) 
217 73 PDE7A phosphodiesterase 7A 
218 73 SPATA13 spermatogenesis associated 13 
219 72 DDX55 DEAD (Asp-Glu-Ala-Asp) box polypeptide 55 
220 72 HIPK3 homeodomain interacting protein kinase 3 
221 72 TMSB4X thymosin beta 4, X-linked 
222 72 BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 
223 72 RNF145 ring finger protein 145 
224 72 LARP4 La ribonucleoprotein domain family, member 4 
225 72 ZDHHC21 zinc finger, DHHC-type containing 21 
226 71 PUM2 pumilio RNA-binding family member 2 
227 71 GPR125 G protein-coupled receptor 125 
228 71 SRI sorcin 
229 71 ZNF609 zinc finger protein 609 
230 71 MAP1A microtubule-associated protein 1A 
231 71 LASP1 LIM and SH3 protein 1 
232 71 PEAK1 pseudopodium-enriched atypical kinase 1 
233 71 SYN3 synapsin III 
234 70 RNF138 ring finger protein 138, E3 ubiquitin protein ligase 
235 70 MRO maestro 
236 70 TTC7B tetratricopeptide repeat domain 7B 
237 70 PTPRG protein tyrosine phosphatase, receptor type, G 
238 70 MATR3 matrin 3 




240 70 RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology 
domains 1 
241 70 EPHB1 EPH receptor B1 
242 69 PHF6 PHD finger protein 6 
243 69 MYOCD myocardin 
244 69 WEE1 WEE1 G2 checkpoint kinase 
245 69 SEC63 SEC63 homolog (S. cerevisiae) 
246 69 ZNF547 zinc finger protein 547 
247 69 PABPC4L poly(A) binding protein, cytoplasmic 4-like 
248 69 ARHGEF18 Rho/Rac guanine nucleotide exchange factor (GEF) 18 
249 68 ABHD2 abhydrolase domain containing 2 
250 68 DHX15 DEAH (Asp-Glu-Ala-His) box helicase 15 
251 68 HNRNPK heterogeneous nuclear ribonucleoprotein K 
252 68 FBXO33 F-box protein 33 
253 68 C2orf71 chromosome 2 open reading frame 71 
254 67 NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 
255 67 IFI44L interferon-induced protein 44-like 
256 67 ACER2 alkaline ceramidase 2 
257 67 CDC42SE1 CDC42 small effector 1 
258 67 OTX2 orthodenticle homeobox 2 
259 66 NAP1L5 nucleosome assembly protein 1-like 5 
260 66 ZBTB4 zinc finger and BTB domain containing 4 
261 66 YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta 
262 66 SLC25A17 solute carrier family 25 (mitochondrial carrier; 
peroxisomal membrane protein, 34kDa), member 17 
263 65 C3orf80 chromosome 3 open reading frame 80 
264 65 POLA1 polymerase (DNA directed), alpha 1, catalytic subunit 
265 65 CASK calcium/calmodulin-dependent serine protein kinase 
(MAGUK family) 
266 65 TMEM68 transmembrane protein 68 
267 65 AMOT angiomotin 
268 65 GRK6 G protein-coupled receptor kinase 6 
269 65 TBC1D9 TBC1 domain family, member 9 (with GRAM domain) 
270 65 BSCL2 Berardinelli-Seip congenital lipodystrophy 2 (seipin) 
271 64 NDFIP1 Nedd4 family interacting protein 1 
272 64 LOC102723422 uncharacterized LOC102723422 
273 64 HIGD1A HIG1 hypoxia inducible domain family, member 1A 
274 64 ZNF281 zinc finger protein 281 
275 64 COIL coilin 
276 64 TMEM232 transmembrane protein 232 
277 63 ZEB2 zinc finger E-box binding homeobox 2 
278 63 KMT2E lysine (K)-specific methyltransferase 2E 




280 63 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 
281 63 NFATC2 nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 2 
282 63 DLG4 discs, large homolog 4 (Drosophila) 
283 63 BCKDHB branched chain keto acid dehydrogenase E1, beta 
polypeptide 
284 63 WNT3 wingless-type MMTV integration site family, member 3 
285 62 PRR14L proline rich 14-like 
286 62 FUBP1 far upstream element (FUSE) binding protein 1 
287 62 SUSD1 sushi domain containing 1 
288 62 NUP50 nucleoporin 50kDa 
289 62 FAM72B family with sequence similarity 72, member B 
290 62 FAM72D family with sequence similarity 72, member D 
291 62 TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) 
292 62 SEMA6D sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D 
293 62 ARHGAP20 Rho GTPase activating protein 20 
294 62 PSIP1 PC4 and SFRS1 interacting protein 1 
295 62 FAM72A family with sequence similarity 72, member A 
296 62 FAM72C family with sequence similarity 72, member C 
297 62 TEX35 testis expressed 35 
298 61 TMED5 transmembrane emp24 protein transport domain 
containing 5 
299 61 CPLX2 complexin 2 
300 61 ANXA4 annexin A4 
301 61 TMEM55B transmembrane protein 55B 
302 61 CELF2 CUGBP, Elav-like family member 2 
303 61 FNDC3B fibronectin type III domain containing 3B 
304 61 STXBP4 syntaxin binding protein 4 
305 61 UNC50 unc-50 homolog (C. elegans) 
306 61 SLC38A3 solute carrier family 38, member 3 
307 61 RAB43 RAB43, member RAS oncogene family 
308 61 PI15 peptidase inhibitor 15 
309 61 ZNF148 zinc finger protein 148 
310 60 RYBP RING1 and YY1 binding protein 
311 60 CCL2 chemokine (C-C motif) ligand 2 
312 60 NOTCH2 notch 2 
313 60 ZNF516 zinc finger protein 516 
314 60 THAP5 THAP domain containing 5 
315 60 NADK NAD kinase 
316 60 TNPO1 transportin 1 
317 60 VSIG1 V-set and immunoglobulin domain containing 1 
318 60 SP2 Sp2 transcription factor 
 









Symbol Gene Description 
1 100 TNRC6A trinucleotide repeat containing 6A 
2 100 CELSR3 cadherin, EGF LAG seven-pass G-type receptor 3 
3 100 LHX8 LIM homeobox 8 
4 100 EED embryonic ectoderm development 
5 100 SCN2A sodium channel, voltage-gated, type II, alpha subunit 
6 100 ANKRA2 ankyrin repeat, family A (RFXANK-like), 2 
7 100 BRWD3 bromodomain and WD repeat domain containing 3 
8 100 PLEKHM3 
pleckstrin homology domain containing, family M, 
member 3 
9 100 NT5E 5'-nucleotidase, ecto (CD73) 
10 100 PHTF2 putative homeodomain transcription factor 2 
11 100 YAF2 YY1 associated factor 2 
12 100 WDR7 WD repeat domain 7 
13 100 RFX7 regulatory factor X, 7 
14 100 EEA1 early endosome antigen 1 
15 100 POLR3E 
polymerase (RNA) III (DNA directed) polypeptide E 
(80kD) 
16 100 KLHL20 kelch-like family member 20 
17 99 PPARGC1B 
peroxisome proliferator-activated receptor gamma, 
coactivator 1 beta 
18 99 ANKRD17 ankyrin repeat domain 17 
19 99 PCGF5 polycomb group ring finger 5 
20 99 STK39 serine threonine kinase 39 
21 99 STAC SH3 and cysteine rich domain 
22 99 PDE7A phosphodiesterase 7A 
23 99 PTP4A1 protein tyrosine phosphatase type IVA, member 1 
24 99 GMNC geminin coiled-coil domain containing 
25 99 SCN9A sodium channel, voltage-gated, type IX, alpha subunit 
26 99 CCDC43 coiled-coil domain containing 43 
27 99 EML4 echinoderm microtubule associated protein like 4 
28 99 RTKN2 rhotekin 2 
29 99 PIP4K2A phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 
30 99 KLF10 Kruppel-like factor 10 
31 99 DDAH1 dimethylarginine dimethylaminohydrolase 1 
32 99 RRAD Ras-related associated with diabetes 
33 99 LRRC40 leucine rich repeat containing 40 
34 99 MBNL3 muscleblind-like splicing regulator 3 
35 98 PIK3CD 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit delta 
36 98 EXTL2 exostosin-like glycosyltransferase 2 
37 98 CCNE2 cyclin E2 
38 98 ATG12 autophagy related 12 




40 98 COL13A1 collagen, type XIII, alpha 1 
41 98 LRRC17 leucine rich repeat containing 17 
42 98 SNX18 sorting nexin 18 
43 98 USP37 ubiquitin specific peptidase 37 
44 98 REEP3 receptor accessory protein 3 
45 98 CAMK2D calcium/calmodulin-dependent protein kinase II delta 
46 98 TMEM181 transmembrane protein 181 
47 98 UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 
48 98 KIAA2026 KIAA2026 
49 98 ZMYND8 zinc finger, MYND-type containing 8 
50 98 STOX2 storkhead box 2 
51 98 FOXG1 forkhead box G1 
52 98 ALG10 ALG10, alpha-1,2-glucosyltransferase 
53 98 FAM160B1 family with sequence similarity 160, member B1 
54 98 LCLAT1 lysocardiolipin acyltransferase 1 
55 98 PTGFRN prostaglandin F2 receptor inhibitor 
56 98 ADAMTS9 
ADAM metallopeptidase with thrombospondin type 1 
motif, 9 
57 98 NRIP1 nuclear receptor interacting protein 1 
58 98 PTPN13 
protein tyrosine phosphatase, non-receptor type 13 
(APO-1/CD95 (Fas)-associated phosphatase) 
59 98 CCDC97 coiled-coil domain containing 97 
60 98 PRDM1 PR domain containing 1, with ZNF domain 
61 98 FRZB frizzled-related protein 
62 98 PPP3R1 protein phosphatase 3, regulatory subunit B, alpha 
63 98 BRD1 bromodomain containing 1 
64 97 GRIA2 glutamate receptor, ionotropic, AMPA 2 
65 97 ZNRF1 zinc and ring finger 1, E3 ubiquitin protein ligase 
66 97 KLHL28 kelch-like family member 28 
67 97 TTLL7 tubulin tyrosine ligase-like family, member 7 
68 97 PPP4R4 protein phosphatase 4, regulatory subunit 4 
69 97 OTUD6B OTU domain containing 6B 
70 97 LRRK2 leucine-rich repeat kinase 2 
71 97 SLC12A6 
solute carrier family 12 (potassium/chloride transporter), 
member 6 
72 97 ZNF608 zinc finger protein 608 
73 97 YTHDF3 YTH domain family, member 3 
74 97 SCN1A sodium channel, voltage-gated, type I, alpha subunit 
75 97 ITGA6 integrin, alpha 6 
76 97 ABCC9 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 9 
77 97 SETD5 SET domain containing 5 
78 96 STX16 syntaxin 16 




80 96 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 
81 96 DESI2 desumoylating isopeptidase 2 
82 96 CLOCK clock circadian regulator 
83 96 GSKIP GSK3B interacting protein 
84 96 FLVCR2 
feline leukemia virus subgroup C cellular receptor family, 
member 2 
85 96 SLC35A3 
solute carrier family 35 (UDP-N-acetylglucosamine (UDP-
GlcNAc) transporter), member A3 
86 96 BDP1 
B double prime 1, subunit of RNA polymerase III 
transcription initiation factor IIIB 
87 96 LPPR4 lipid phosphate phosphatase-related protein type 4 
88 96 CALU calumenin 
89 96 PCDH17 protocadherin 17 
90 96 ANKHD1 ankyrin repeat and KH domain containing 1 
91 96 RIMBP2 RIMS binding protein 2 
92 96 DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha 
93 96 RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 
94 96 CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 
95 96 LIN28B lin-28 homolog B (C. elegans) 
96 96 PAPD4 PAP associated domain containing 4 
97 96 EDEM3 ER degradation enhancer, mannosidase alpha-like 3 
98 95 FAP fibroblast activation protein, alpha 
99 95 RARG retinoic acid receptor, gamma 
100 95 PAPOLA poly(A) polymerase alpha 
101 95 MAN1A2 mannosidase, alpha, class 1A, member 2 
102 95 MEX3B mex-3 RNA binding family member B 
103 95 CHL1 cell adhesion molecule L1-like 
104 95 CADPS Ca++-dependent secretion activator 
105 95 SRSF7 serine/arginine-rich splicing factor 7 
106 95 FYCO1 FYVE and coiled-coil domain containing 1 
107 95 MAML1 mastermind-like 1 (Drosophila) 
108 95 CBX2 chromobox homolog 2 
109 95 CARS cysteinyl-tRNA synthetase 
110 95 GRM3 glutamate receptor, metabotropic 3 
111 95 EML1 echinoderm microtubule associated protein like 1 
112 95 KDM3A lysine (K)-specific demethylase 3A 
113 95 CHST2 
carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 
2 
114 95 ZBTB39 zinc finger and BTB domain containing 39 
115 95 ARID4A AT rich interactive domain 4A (RBP1-like) 
116 95 FNDC3A fibronectin type III domain containing 3A 
117 95 MIER3 mesoderm induction early response 1, family member 3 
118 95 PNKD paroxysmal nonkinesigenic dyskinesia 




120 95 B3GNT5 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 
121 95 CBLB Cbl proto-oncogene B, E3 ubiquitin protein ligase 
122 94 BCOR BCL6 corepressor 
123 94 NAALADL2 N-acetylated alpha-linked acidic dipeptidase-like 2 
124 94 CALCR calcitonin receptor 
125 94 ADAM19 ADAM metallopeptidase domain 19 
126 94 ARF4 ADP-ribosylation factor 4 
127 94 MARF6 
membrane-associated ring finger (C3HC4) 6, E3 ubiquitin 
protein ligase 
128 94 DSG2 desmoglein 2 
129 94 PPAPDC2 
phosphatidic acid phosphatase type 2 domain containing 
2 
130 94 FAM210B family with sequence similarity 210, member B 
131 94 PIGA phosphatidylinositol glycan anchor biosynthesis, class A 
132 94 B4GALT6 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 6 
133 94 MMD monocyte to macrophage differentiation-associated 
134 94 DLL4 delta-like 4 (Drosophila) 
135 94 MBNL2 muscleblind-like splicing regulator 2 
136 94 PDSS1 prenyl (decaprenyl) diphosphate synthase, subunit 1 
137 94 FBXO45 F-box protein 45 
138 94 WIPF1 WAS/WASL interacting protein family, member 1 
139 94 KCNMB2 
potassium large conductance calcium-activated channel, 
subfamily M, beta member 2 
140 94 SLC38A2 solute carrier family 38, member 2 
141 94 MAST4 
microtubule associated serine/threonine kinase family 
member 4 
142 94 PCMTD2 
protein-L-isoaspartate (D-aspartate) O-methyltransferase 
domain containing 2 
143 94 RQCD1 
RCD1 required for cell differentiation1 homolog (S. 
pombe) 
144 94 PHACTR2 phosphatase and actin regulator 2 
145 94 RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 
146 94 LIMCH1 LIM and calponin homology domains 1 
147 94 SCN3A sodium channel, voltage-gated, type III, alpha subunit 
148 94 WDR44 WD repeat domain 44 
149 93 RUNX2 runt-related transcription factor 2 
150 93 NF1 neurofibromin 1 
151 93 UBE2J1 ubiquitin-conjugating enzyme E2, J1 
152 93 SHOC2 soc-2 suppressor of clear homolog (C. elegans) 
153 93 ACTR1A 
ARP1 actin-related protein 1 homolog A, centractin alpha 
(yeast) 
154 93 AFF4 AF4/FMR2 family, member 4 
155 93 RFX6 regulatory factor X, 6 
156 93 KIAA1804 mixed lineage kinase 4 




158 93 HCFC2 host cell factor C2 
159 93 ENOX2 ecto-NOX disulfide-thiol exchanger 2 
160 93 P4HA2 prolyl 4-hydroxylase, alpha polypeptide II 
161 93 GOLGA4 golgin A4 
162 93 SH3RF1 SH3 domain containing ring finger 1 
163 93 TAOK1 TAO kinase 1 
164 93 ACTC1 actin, alpha, cardiac muscle 1 
165 93 CHD1 chromodomain helicase DNA binding protein 1 
166 93 SH2B3 SH2B adaptor protein 3 
167 93 PICALM phosphatidylinositol binding clathrin assembly protein 
168 93 PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit 
169 93 RAD23B RAD23 homolog B (S. cerevisiae) 
170 93 ZDHHC17 zinc finger, DHHC-type containing 17 
171 92 R3HDM1 R3H domain containing 1 
172 92 NDEL1 nudE neurodevelopment protein 1-like 1 
173 92 CCNT2 cyclin T2 
174 92 ABI3BP ABI family, member 3 (NESH) binding protein 
175 92 SAMD4A sterile alpha motif domain containing 4A 
176 92 CCDC117 coiled-coil domain containing 117 
177 92 RAB23 RAB23, member RAS oncogene family 
178 92 GATM 
glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
179 92 ZNF280B zinc finger protein 280B 
180 92 SEC24A SEC24 family member A 
181 92 PSMD7 
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 7 
182 92 FNIP2 folliculin interacting protein 2 
183 92 FRMD6 FERM domain containing 6 
184 92 ARAF v-raf murine sarcoma 3611 viral oncogene homolog 
185 92 TRPM7 
transient receptor potential cation channel, subfamily M, 
member 7 
186 92 NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 
187 92 STIM2 stromal interaction molecule 2 
188 92 ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 
189 92 MFSD6 major facilitator superfamily domain containing 6 
190 92 KSR1 kinase suppressor of ras 1 
191 91 NECAP1 NECAP endocytosis associated 1 
192 91 CDK12 cyclin-dependent kinase 12 
193 91 HIVEP1 
human immunodeficiency virus type I enhancer binding 
protein 1 
194 91 PPID peptidylprolyl isomerase D 
195 91 ZNF521 zinc finger protein 521 
196 91 SCML1 sex comb on midleg-like 1 (Drosophila) 




198 91 ELL2 elongation factor, RNA polymerase II, 2 
199 91 FAM43A family with sequence similarity 43, member A 
200 91 FAM91A1 family with sequence similarity 91, member A1 
201 91 SORCS3 sortilin-related VPS10 domain containing receptor 3 
202 91 FZD3 frizzled class receptor 3 
203 91 PPP1R14C protein phosphatase 1, regulatory (inhibitor) subunit 14C 
204 91 CSNK1A1 casein kinase 1, alpha 1 
205 91 NEDD4 
neural precursor cell expressed, developmentally down-
regulated 4, E3 ubiquitin protein ligase 
206 90 FAHD1 fumarylacetoacetate hydrolase domain containing 1 
207 90 TWF1 twinfilin actin-binding protein 1 
208 90 ZBTB11 zinc finger and BTB domain containing 11 
209 90 FAM214A family with sequence similarity 214, member A 
210 90 DPY19L1 dpy-19-like 1 (C. elegans) 
211 90 DCTN4 dynactin 4 (p62) 
212 90 ENTHD2 ENTH domain containing 2 
213 90 MAP3K13 mitogen-activated protein kinase kinase kinase 13 
214 90 BNC1 basonuclin 1 
215 90 HOXA1 homeobox A1 
216 90 ZFAND5 zinc finger, AN1-type domain 5 
217 90 MROH9 maestro heat-like repeat family member 9 
218 90 YPEL5 yippee-like 5 (Drosophila) 
219 90 SLC4A7 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 7 
220 90 PDXDC1 pyridoxal-dependent decarboxylase domain containing 1 
221 90 FKBP3 FK506 binding protein 3, 25kDa 
222 90 LCORL ligand dependent nuclear receptor corepressor-like 
223 89 KMT2A lysine (K)-specific methyltransferase 2A 
224 89 DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 
225 89 CSNK1G1 casein kinase 1, gamma 1 
226 89 PON2 paraoxonase 2 
227 89 UBE2I ubiquitin-conjugating enzyme E2I 
228 89 CCNK cyclin K 
229 89 NFATC2 
nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 2 
230 89 SON SON DNA binding protein 
231 89 SEC22C 
SEC22 vesicle trafficking protein homolog C (S. 
cerevisiae) 
232 88 CPSF6 cleavage and polyadenylation specific factor 6, 68kDa 
233 88 MCF2L MCF.2 cell line derived transforming sequence-like 
234 88 MKRN3 makorin ring finger protein 3 
235 88 UBN1 ubinuclein 1 
236 88 BECN1 beclin 1, autophagy related 




238 88 CHKA choline kinase alpha 
239 88 RUNDC3B RUN domain containing 3B 
240 88 LRRC8D leucine rich repeat containing 8 family, member D 
241 88 ELMOD2 ELMO/CED-12 domain containing 2 
242 88 ACAP2 ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 
243 88 SOX9 SRY (sex determining region Y)-box 9 
244 88 TBC1D15 TBC1 domain family, member 15 
245 88 ATG5 autophagy related 5 
246 88 PPP1R12A protein phosphatase 1, regulatory subunit 12A 
247 88 DPYSL2 dihydropyrimidinase-like 2 
248 88 XPO1 exportin 1 
249 88 OXR1 oxidation resistance 1 
250 87 KMT2C lysine (K)-specific methyltransferase 2C 
251 87 ARID1A AT rich interactive domain 1A (SWI-like) 
252 87 AMOTL2 angiomotin like 2 
253 87 AVL9 AVL9 homolog (S. cerevisiase) 
254 87 HIC2 hypermethylated in cancer 2 
255 87 PAFAH1B2 
platelet-activating factor acetylhydrolase 1b, catalytic 
subunit 2 (30kDa) 
256 87 CPNE8 copine VIII 
257 87 CNOT6 CCR4-NOT transcription complex, subunit 6 
258 87 RORA RAR-related orphan receptor A 
259 87 AFAP1L2 actin filament associated protein 1-like 2 
260 87 SP4 Sp4 transcription factor 
261 87 SH3PXD2A SH3 and PX domains 2A 
262 87 LRP6 low density lipoprotein receptor-related protein 6 
263 86 KIF11 kinesin family member 11 
264 86 PAXBP1 PAX3 and PAX7 binding protein 1 
265 86 EXOC6 exocyst complex component 6 
266 86 BRAP BRCA1 associated protein 
267 86 PPFIA2 
protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 2 
268 86 KIAA0226L KIAA0226-like 
269 86 RASA1 RAS p21 protein activator (GTPase activating protein) 1 
270 86 FAM110B family with sequence similarity 110, member B 
271 86 PTPN2 protein tyrosine phosphatase, non-receptor type 2 
272 86 GLCE glucuronic acid epimerase 
273 86 GALNT7 polypeptide N-acetylgalactosaminyltransferase 7 
274 86 RPRD1A regulation of nuclear pre-mRNA domain containing 1A 
275 86 LYPLAL1 lysophospholipase-like 1 
276 86 SNX10 sorting nexin 10 
277 86 LARGE like-glycosyltransferase 




279 86 SRSF10 serine/arginine-rich splicing factor 10 
280 86 GOLGA1 golgin A1 
281 85 ZBTB18 zinc finger and BTB domain containing 18 
282 85 NADK NAD kinase 
283 85 NUS1 
nuclear undecaprenyl pyrophosphate synthase 1 
homolog (S. cerevisiae) 
284 85 SOCS3 suppressor of cytokine signaling 3 
285 85 DET1 de-etiolated homolog 1 (Arabidopsis) 
286 85 GALNT1 polypeptide N-acetylgalactosaminyltransferase 1 
287 85 RAB38 RAB38, member RAS oncogene family 
288 85 ADAMTS6 
ADAM metallopeptidase with thrombospondin type 1 
motif, 6 
289 85 MTDH metadherin 
290 85 HNRNPUL2 heterogeneous nuclear ribonucleoprotein U-like 2 
291 85 USP2 ubiquitin specific peptidase 2 
292 84 KPNA6 karyopherin alpha 6 (importin alpha 7) 
293 84 BCL10 B-cell CLL/lymphoma 10 
294 84 ME1 malic enzyme 1, NADP(+)-dependent, cytosolic 
295 84 RAB4B RAB4B, member RAS oncogene family 
296 84 KLF9 Kruppel-like factor 9 
297 84 SEC23A Sec23 homolog A (S. cerevisiae) 
298 84 DOLPP1 dolichyldiphosphatase 1 
299 84 PNN pinin, desmosome associated protein 
300 84 C9orf72 chromosome 9 open reading frame 72 
301 84 ATAD2B ATPase family, AAA domain containing 2B 
302 84 SDAD1 SDA1 domain containing 1 
303 83 MAPK8 mitogen-activated protein kinase 8 
304 83 ABCD2 ATP-binding cassette, sub-family D (ALD), member 2 
305 83 CSAD cysteine sulfinic acid decarboxylase 
306 83 EBF2 early B-cell factor 2 
307 83 NEURL1B neuralized E3 ubiquitin protein ligase 1B 
308 83 IL1RAPL2 interleukin 1 receptor accessory protein-like 2 
309 83 GFPT2 glutamine-fructose-6-phosphate transaminase 2 
310 83 NEDD4L 
neural precursor cell expressed, developmentally down-
regulated 4-like, E3 ubiquitin protein ligase 
311 83 NRG3 neuregulin 3 
312 83 CTNND2 catenin (cadherin-associated protein), delta 2 
313 83 LMBR1 limb development membrane protein 1 
314 83 CARF calcium responsive transcription factor 
315 83 DACT1 dishevelled-binding antagonist of beta-catenin 1 
316 83 ESCO1 
establishment of sister chromatid cohesion N-
acetyltransferase 1 
317 83 MBTPS2 membrane-bound transcription factor peptidase, site 2 
318 83 SKP2 





319 83 YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta 
320 83 MEIOB meiosis specific with OB domains 
321 83 SCN8A sodium channel, voltage gated, type VIII, alpha subunit 
322 82 RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 
323 82 JAK1 Janus kinase 1 
324 82 USP45 ubiquitin specific peptidase 45 
325 82 NHLH2 nescient helix loop helix 2 
326 82 SLC35D3 solute carrier family 35, member D3 
327 82 ACTR3C ARP3 actin-related protein 3 homolog C (yeast) 
328 82 PRLR prolactin receptor 
329 82 ZCCHC6 zinc finger, CCHC domain containing 6 
330 82 SNX33 sorting nexin 33 
331 82 CCDC6 coiled-coil domain containing 6 
332 82 ANO4 anoctamin 4 
333 82 NCAM1 neural cell adhesion molecule 1 
334 81 WDR64 WD repeat domain 64 
335 81 PIP4K2B phosphatidylinositol-5-phosphate 4-kinase, type II, beta 
336 81 SAMD8 sterile alpha motif domain containing 8 
337 81 PGP phosphoglycolate phosphatase 
338 81 UBE2D3 ubiquitin-conjugating enzyme E2D 3 
339 81 KIAA0408 KIAA0408 
340 81 USO1 USO1 vesicle transport factor 
341 81 OTUD4 OTU deubiquitinase 4 
342 81 SEMA6B 
sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6B 
343 81 SLC5A3 
solute carrier family 5 (sodium/myo-inositol 
cotransporter), member 3 
344 81 HDAC9 histone deacetylase 9 
345 81 PLXNC1 plexin C1 
346 80 FBXO32 F-box protein 32 
347 80 TULP4 tubby like protein 4 
348 80 VKORC1L1 vitamin K epoxide reductase complex, subunit 1-like 1 
349 80 LPGAT1 lysophosphatidylglycerol acyltransferase 1 
350 80 RMND5A 
required for meiotic nuclear division 5 homolog A (S. 
cerevisiae) 
351 80 PRUNE2 prune homolog 2 (Drosophila) 
352 80 DOK5 docking protein 5 
353 80 PGM1 phosphoglucomutase 1 
354 80 PAWR PRKC, apoptosis, WT1, regulator 
355 80 MYO1H myosin IH 
356 80 RAP2C RAP2C, member of RAS oncogene family 
357 80 NEUROD6 neuronal differentiation 6 




359 79 CDK19 cyclin-dependent kinase 19 
360 79 ADRA1D adrenoceptor alpha 1D 
361 79 GABRB1 gamma-aminobutyric acid (GABA) A receptor, beta 1 
362 79 SLC6A9 
solute carrier family 6 (neurotransmitter transporter, 
glycine), member 9 
363 79 TXNDC5 thioredoxin domain containing 5 (endoplasmic reticulum) 
364 79 PHIP pleckstrin homology domain interacting protein 
365 79 PLXNA2 plexin A2 
366 79 PPTC7 PTC7 protein phosphatase homolog (S. cerevisiae) 
367 79 KIF16B kinesin family member 16B 
368 79 FAM83F family with sequence similarity 83, member F 
369 78 ZNF518A zinc finger protein 518A 
370 78 DLGAP4 discs, large (Drosophila) homolog-associated protein 4 
371 78 SGCB 
sarcoglycan, beta (43kDa dystrophin-associated 
glycoprotein) 
372 78 VAT1L vesicle amine transport 1-like 
373 78 IP6K3 inositol hexakisphosphate kinase 3 
374 78 NEFL neurofilament, light polypeptide 
375 78 CBFB core-binding factor, beta subunit 
376 78 SLC35B4 
solute carrier family 35 (UDP-xylose/UDP-N-
acetylglucosamine transporter), member B4 
377 78 SLC25A36 
solute carrier family 25 (pyrimidine nucleotide carrier ), 
member 36 
378 78 SIX4 SIX homeobox 4 
379 78 VAT1 vesicle amine transport 1 
380 78 SOCS1 suppressor of cytokine signaling 1 
381 77 LGI1 leucine-rich, glioma inactivated 1 
382 77 CFL2 cofilin 2 (muscle) 
383 77 CCNA1 cyclin A1 
384 77 FGD6 FYVE, RhoGEF and PH domain containing 6 
385 77 LRCH2 
leucine-rich repeats and calponin homology (CH) domain 
containing 2 
386 77 GRHL1 grainyhead-like 1 (Drosophila) 
387 77 CUL2 cullin 2 
388 77 ZCCHC24 zinc finger, CCHC domain containing 24 
389 77 CDC37L1 cell division cycle 37-like 1 
390 77 GNG10 guanine nucleotide binding protein (G protein), gamma 10 
391 77 ACTBL2 actin, beta-like 2 
392 77 TMEM229A transmembrane protein 229A 
393 77 STRIP1 striatin interacting protein 1 
394 77 COL8A1 collagen, type VIII, alpha 1 
395 77 SPG20 spastic paraplegia 20 (Troyer syndrome) 
396 77 PPARGC1A 
peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha 




398 76 SYPL1 synaptophysin-like 1 
399 76 ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 
400 76 NRBP1 nuclear receptor binding protein 1 
401 76 AGO3 argonaute RISC catalytic component 3 
402 76 NAPG 
N-ethylmaleimide-sensitive factor attachment protein, 
gamma 
403 76 DTWD1 DTW domain containing 1 
404 76 ERLIN1 ER lipid raft associated 1 
405 76 RHD Rh blood group, D antigen 
406 76 YY2 YY2 transcription factor 
407 76 TBC1D10B TBC1 domain family, member 10B 
408 76 ZBTB6 zinc finger and BTB domain containing 6 
409 76 MSI2 musashi RNA-binding protein 2 
410 76 KIAA0355 KIAA0355 
411 76 PRICKLE1 prickle homolog 1 (Drosophila) 
412 76 ELOVL7 ELOVL fatty acid elongase 7 
413 76 LIN7C lin-7 homolog C (C. elegans) 
414 76 KLF12 Kruppel-like factor 12 
415 76 STK35 serine/threonine kinase 35 
416 76 RAB10 RAB10, member RAS oncogene family 
417 76 UBE2F ubiquitin-conjugating enzyme E2F (putative) 
418 76 ADO 2-aminoethanethiol (cysteamine) dioxygenase 
419 76 YIPF6 Yip1 domain family, member 6 
420 76 TMEM56 transmembrane protein 56 
421 75 NUP93 nucleoporin 93kDa 
422 75 XPR1 xenotropic and polytropic retrovirus receptor 1 
423 75 EPC2 enhancer of polycomb homolog 2 (Drosophila) 
424 75 TMEM121 transmembrane protein 121 
425 75 KIAA1715 KIAA1715 
426 75 SIX1 SIX homeobox 1 
427 75 COL4A3BP 
collagen, type IV, alpha 3 (Goodpasture antigen) binding 
protein 
428 75 FAM69A family with sequence similarity 69, member A 
429 75 SLC35F1 solute carrier family 35, member F1 
430 75 SAMHD1 SAM domain and HD domain 1 
431 75 RASD1 RAS, dexamethasone-induced 1 
432 75 FLVCR1 feline leukemia virus subgroup C cellular receptor 1 
433 75 CEP350 centrosomal protein 350kDa 
434 75 NARG2 NMDA receptor regulated 2 
435 75 DDHD2 DDHD domain containing 2 
436 75 PFN2 profilin 2 
437 74 GLDC glycine dehydrogenase (decarboxylating) 




439 74 CAMKK2 
calcium/calmodulin-dependent protein kinase kinase 2, 
beta 
440 74 ARL4A ADP-ribosylation factor-like 4A 
441 74 JAKMIP2 janus kinase and microtubule interacting protein 2 
442 74 RNF169 ring finger protein 169 
443 74 GNAI2 
guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 2 
444 74 TMEM47 transmembrane protein 47 
445 74 REV1 REV1, polymerase (DNA directed) 
446 74 FAM196A family with sequence similarity 196, member A 
447 74 CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 
448 74 VPS26B vacuolar protein sorting 26 homolog B (S. pombe) 
449 74 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
450 74 TMEM170B transmembrane protein 170B 
451 74 NKX2-2 NK2 homeobox 2 
452 74 NSG1 neuron specific gene family member 1 
453 73 ADAM22 ADAM metallopeptidase domain 22 
454 73 CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 
455 73 RAB32 RAB32, member RAS oncogene family 
456 73 CSMD3 CUB and Sushi multiple domains 3 
457 73 SCARA5 scavenger receptor class A, member 5 (putative) 
458 73 PDS5B 
PDS5, regulator of cohesion maintenance, homolog B (S. 
cerevisiae) 
459 73 EPDR1 ependymin related 1 
460 73 FRMPD1 FERM and PDZ domain containing 1 
461 73 GPCPD1 
glycerophosphocholine phosphodiesterase GDE1 
homolog (S. cerevisiae) 
462 73 IRS1 insulin receptor substrate 1 
463 73 SETD3 SET domain containing 3 
464 73 TP53INP1 tumor protein p53 inducible nuclear protein 1 
465 73 EIF5A2 eukaryotic translation initiation factor 5A2 
466 73 S100PBP S100P binding protein 
467 73 TTLL2 tubulin tyrosine ligase-like family, member 2 
468 73 NFATC3 
nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 3 
469 73 ATG2B autophagy related 2B 
470 73 LRRC8C leucine rich repeat containing 8 family, member C 
471 73 FAM13A family with sequence similarity 13, member A 
472 73 LYN 
v-yes-1 Yamaguchi sarcoma viral related oncogene 
homolog 
473 72 DDIT4 DNA-damage-inducible transcript 4 
474 72 SLC30A4 solute carrier family 30 (zinc transporter), member 4 
475 72 MAGI2 
membrane associated guanylate kinase, WW and PDZ 
domain containing 2 
476 72 GCSAM germinal center-associated, signaling and motility 




478 72 MZT1 mitotic spindle organizing protein 1 
479 72 GMEB2 glucocorticoid modulatory element binding protein 2 
480 72 MEIS2 Meis homeobox 2 
481 72 UBE2V1 ubiquitin-conjugating enzyme E2 variant 1 
482 72 PCDH20 protocadherin 20 
483 72 SLC36A4 
solute carrier family 36 (proton/amino acid symporter), 
member 4 
484 71 TNKS 
tankyrase, TRF1-interacting ankyrin-related ADP-ribose 
polymerase 
485 71 TENM3 teneurin transmembrane protein 3 
486 71 CCDC120 coiled-coil domain containing 120 
487 71 OCRL oculocerebrorenal syndrome of Lowe 
488 71 KCTD9 potassium channel tetramerization domain containing 9 
489 71 KPNA3 karyopherin alpha 3 (importin alpha 4) 
490 71 SLC35C1 
solute carrier family 35 (GDP-fucose transporter), 
member C1 
491 71 SYNGR3 synaptogyrin 3 
492 71 UBAC1 UBA domain containing 1 
493 71 REEP1 receptor accessory protein 1 
494 71 AKIRIN1 akirin 1 
495 71 IL1A interleukin 1, alpha 
496 71 GLI2 GLI family zinc finger 2 
497 71 JOSD1 Josephin domain containing 1 
498 71 CAPN5 calpain 5 
499 71 PPIL4 peptidylprolyl isomerase (cyclophilin)-like 4 
500 71 RAB11A RAB11A, member RAS oncogene family 
501 71 IFNAR2 interferon (alpha, beta and omega) receptor 2 
502 71 PAK7 p21 protein (Cdc42/Rac)-activated kinase 7 
503 71 FBXO34 F-box protein 34 
504 71 KXD1 KxDL motif containing 1 
505 71 MARK1 MAP/microtubule affinity-regulating kinase 1 
506 71 SSX2IP synovial sarcoma, X breakpoint 2 interacting protein 
507 71 BAHD1 bromo adjacent homology domain containing 1 
508 71 ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa 
509 70 CEP41 centrosomal protein 41kDa 
510 70 SPAST spastin 
511 70 LIN28A lin-28 homolog A (C. elegans) 
512 70 VPS13C vacuolar protein sorting 13 homolog C (S. cerevisiae) 
513 70 JPH4 junctophilin 4 
514 70 MAN1B1 mannosidase, alpha, class 1B, member 1 
515 70 MAP3K12 mitogen-activated protein kinase kinase kinase 12 
516 70 PITPNM2 
phosphatidylinositol transfer protein, membrane-
associated 2 




518 70 STC1 stanniocalcin 1 
519 70 WDR82 WD repeat domain 82 
520 70 NR5A2 nuclear receptor subfamily 5, group A, member 2 
521 70 OMG oligodendrocyte myelin glycoprotein 
522 70 C10orf25 chromosome 10 open reading frame 25 
523 70 RAB22A RAB22A, member RAS oncogene family 
524 70 CHMP2B charged multivesicular body protein 2B 
525 70 STX12 syntaxin 12 
526 70 MATR3 matrin 3 
527 70 SLC25A34 solute carrier family 25, member 34 
528 69 PTPRK protein tyrosine phosphatase, receptor type, K 
529 69 ACVR1 activin A receptor, type I 
530 69 TAF4B 
TAF4b RNA polymerase II, TATA box binding protein 
(TBP)-associated factor, 105kDa 
531 69 HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 
532 69 SLCO6A1 
solute carrier organic anion transporter family, member 
6A1 
533 69 PPIP5K2 diphosphoinositol pentakisphosphate kinase 2 
534 69 TFDP1 transcription factor Dp-1 
535 69 CELF3 CUGBP, Elav-like family member 3 
536 69 RNF165 ring finger protein 165 
537 69 LHFPL2 lipoma HMGIC fusion partner-like 2 
538 69 TDG thymine-DNA glycosylase 
539 69 IRF4 interferon regulatory factor 4 
540 69 MIB1 mindbomb E3 ubiquitin protein ligase 1 
541 69 ESPN espin 
542 69 TM4SF1 transmembrane 4 L six family member 1 
543 69 ZNF382 zinc finger protein 382 
544 69 SCYL3 SCY1-like 3 (S. cerevisiae) 
545 68 YPEL2 yippee-like 2 (Drosophila) 
546 68 LMBR1L limb development membrane protein 1-like 
547 68 NFIB nuclear factor I/B 
548 68 MICAL1 
microtubule associated monooxygenase, calponin and 
LIM domain containing 1 
549 68 RAB8A RAB8A, member RAS oncogene family 
550 68 TM4SF20 transmembrane 4 L six family member 20 
551 68 UGT2A3 UDP glucuronosyltransferase 2 family, polypeptide A3 
552 68 FAM46A family with sequence similarity 46, member A 
553 68 FAM49A family with sequence similarity 49, member A 
554 68 NAGPA 
N-acetylglucosamine-1-phosphodiester alpha-N-
acetylglucosaminidase 
555 68 SNX30 sorting nexin family member 30 
556 67 EAF1 ELL associated factor 1 




558 67 TMCC1 transmembrane and coiled-coil domain family 1 
559 67 CCDC178 coiled-coil domain containing 178 
560 67 ADAMTS3 
ADAM metallopeptidase with thrombospondin type 1 
motif, 3 
561 67 ERCC4 excision repair cross-complementation group 4 
562 67 HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) 
563 67 IL36RN interleukin 36 receptor antagonist 
564 67 A1CF APOBEC1 complementation factor 
565 67 ABHD10 abhydrolase domain containing 10 
566 67 ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 
567 66 NECAB1 N-terminal EF-hand calcium binding protein 1 
568 66 C4orf19 chromosome 4 open reading frame 19 
569 66 GJA1 gap junction protein, alpha 1, 43kDa 
570 66 ADRA2A adrenoceptor alpha 2A 
571 66 GPR125 G protein-coupled receptor 125 
572 66 LYRM7 LYR motif containing 7 
573 66 AP3S1 adaptor-related protein complex 3, sigma 1 subunit 
574 66 CHD7 chromodomain helicase DNA binding protein 7 
575 66 PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 
576 66 LOC101060521 DNA-directed RNA polymerase III subunit RPC5-like 
577 66 MCC mutated in colorectal cancers 
578 66 ASCC3 activating signal cointegrator 1 complex subunit 3 
579 66 ICK intestinal cell (MAK-like) kinase 
580 66 JARID2 jumonji, AT rich interactive domain 2 
581 66 SSH2 slingshot protein phosphatase 2 
582 66 SPTSSB serine palmitoyltransferase, small subunit B 
583 66 NDUFC2 
NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 2, 14.5kDa 
584 66 GALNT13 polypeptide N-acetylgalactosaminyltransferase 13 
585 66 TSEN15 TSEN15 tRNA splicing endonuclease subunit 
586 66 CECR6 cat eye syndrome chromosome region, candidate 6 
587 65 TASP1 taspase, threonine aspartase, 1 
588 65 FBXL17 F-box and leucine-rich repeat protein 17 
589 65 GZF1 GDNF-inducible zinc finger protein 1 
590 65 UBE3C ubiquitin protein ligase E3C 
591 65 SPOCK3 
sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan (testican) 3 
592 65 PAPOLB poly(A) polymerase beta (testis specific) 
593 65 CA10 carbonic anhydrase X 
594 65 CHIC1 cysteine-rich hydrophobic domain 1 
595 65 HERC2 
HECT and RLD domain containing E3 ubiquitin protein 
ligase 2 
596 65 CMTM4 CKLF-like MARVEL transmembrane domain containing 4 




598 65 KIAA1211 KIAA1211 
599 65 ZDHHC20 zinc finger, DHHC-type containing 20 
600 65 EMB embigin 
601 65 CAMK4 calcium/calmodulin-dependent protein kinase IV 
602 65 CCNY cyclin Y 
603 65 GNPDA1 glucosamine-6-phosphate deaminase 1 
604 65 PRDM13 PR domain containing 13 
605 65 MYBL2 
v-myb avian myeloblastosis viral oncogene homolog-like 
2 
606 64 NAP1L2 nucleosome assembly protein 1-like 2 
607 64 TRIM13 tripartite motif containing 13 
608 64 PPP1R1C protein phosphatase 1, regulatory (inhibitor) subunit 1C 
609 64 ERCC6 excision repair cross-complementation group 6 
610 64 STAG2 stromal antigen 2 
611 64 MESDC2 mesoderm development candidate 2 
612 64 UQCRB ubiquinol-cytochrome c reductase binding protein 
613 64 SALL4 spalt-like transcription factor 4 
614 64 BTBD10 BTB (POZ) domain containing 10 
615 64 DIP2B DIP2 disco-interacting protein 2 homolog B (Drosophila) 
616 64 PPP1R2 protein phosphatase 1, regulatory (inhibitor) subunit 2 
617 64 SMIM11 small integral membrane protein 11 
618 64 MAST3 microtubule associated serine/threonine kinase 3 
619 64 FOXD1 forkhead box D1 
620 63 DGKD diacylglycerol kinase, delta 130kDa 
621 63 USP48 ubiquitin specific peptidase 48 
622 63 TMOD2 tropomodulin 2 (neuronal) 
623 63 PDE4D phosphodiesterase 4D, cAMP-specific 
624 63 PLA2G12A phospholipase A2, group XIIA 
625 63 ZPBP2 zona pellucida binding protein 2 
626 63 KCTD20 potassium channel tetramerization domain containing 20 
627 63 MBOAT1 membrane bound O-acyltransferase domain containing 1 
628 63 UCP3 uncoupling protein 3 (mitochondrial, proton carrier) 
629 63 PER2 period circadian clock 2 
630 63 CEP76 centrosomal protein 76kDa 
631 63 HLF hepatic leukemia factor 
632 63 GALNT3 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3) 
633 63 SGMS2 sphingomyelin synthase 2 
634 63 PLEKHO2 
pleckstrin homology domain containing, family O member 
2 
635 62 C10orf76 chromosome 10 open reading frame 76 
636 62 TRMT10C tRNA methyltransferase 10 homolog C (S. cerevisiae) 




638 62 CRKL v-crk avian sarcoma virus CT10 oncogene homolog-like 
639 62 ALS2 amyotrophic lateral sclerosis 2 (juvenile) 
640 62 ZDBF2 zinc finger, DBF-type containing 2 
641 62 SEMA6D 
sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D 
642 62 RSF1 remodeling and spacing factor 1 
643 62 GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A 
644 62 KCTD8 potassium channel tetramerization domain containing 8 
645 62 ADAM12 ADAM metallopeptidase domain 12 
646 62 STXBP5 syntaxin binding protein 5 (tomosyn) 
647 62 DPY19L3 dpy-19-like 3 (C. elegans) 
648 62 NEFM neurofilament, medium polypeptide 
649 62 OR11A1 olfactory receptor, family 11, subfamily A, member 1 
650 62 PAPOLG poly(A) polymerase gamma 
651 62 TMEM35 transmembrane protein 35 
652 62 IKBIP IKBKB interacting protein 
653 62 HELZ helicase with zinc finger 
654 62 CREB1 cAMP responsive element binding protein 1 
655 61 STOML1 stomatin (EPB72)-like 1 
656 61 PROSER1 proline and serine rich 1 
657 61 DGKZ diacylglycerol kinase, zeta 
658 61 SLC7A5 
solute carrier family 7 (amino acid transporter light chain, 
L system), member 5 
659 61 DLGAP1 discs, large (Drosophila) homolog-associated protein 1 
660 61 SLC1A2 
solute carrier family 1 (glial high affinity glutamate 
transporter), member 2 
661 61 RBM12 RNA binding motif protein 12 
662 61 FAM208A family with sequence similarity 208, member A 
663 61 CTDSPL2 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase like 2 
664 61 ZNF644 zinc finger protein 644 
665 61 RAI14 retinoic acid induced 14 
666 61 SMIM14 small integral membrane protein 14 
667 61 ZNF148 zinc finger protein 148 
668 61 CTHRC1 collagen triple helix repeat containing 1 
669 61 SMAP1 small ArfGAP 1 
670 61 TSPYL5 TSPY-like 5 
671 61 AIDA axin interactor, dorsalization associated 
672 61 DGKH diacylglycerol kinase, eta 
673 61 ZFP36L2 ZFP36 ring finger protein-like 2 
674 61 SEC62 SEC62 homolog (S. cerevisiae) 
675 61 MGEA5 meningioma expressed antigen 5 (hyaluronidase) 
676 61 MTA1 metastasis associated 1 




678 60 EPB41 
erythrocyte membrane protein band 4.1 (elliptocytosis 1, 
RH-linked) 
679 60 GAREM GRB2 associated, regulator of MAPK1 
680 60 RAPH1 
Ras association (RalGDS/AF-6) and pleckstrin homology 
domains 1 
681 60 Septin 6 septin 6 
682 60 ARL13B ADP-ribosylation factor-like 13B 
683 60 ZNF746 zinc finger protein 746 
684 60 VOPP1 vesicular, overexpressed in cancer, prosurvival protein 1 
685 60 GTF2H1 general transcription factor IIH, polypeptide 1, 62kDa 
686 60 CLDND1 claudin domain containing 1 
687 60 GALR1 galanin receptor 1 
688 60 Septin 8 septin 8 
689 60 GALNT2 polypeptide N-acetylgalactosaminyltransferase 2 
690 60 SIKE1 suppressor of IKBKE 1 
691 60 CD2AP CD2-associated protein 
692 60 H6PD 
hexose-6-phosphate dehydrogenase (glucose 1-
dehydrogenase) 
693 60 CDCA7 cell division cycle associated 7 
694 60 NFYB nuclear transcription factor Y, beta 
695 60 NOV nephroblastoma overexpressed 
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